US SEC Filings Daily Market Digest — March 04, 2026

04-03-2026

Black Rock Coffee Bar, Inc. (BRCB) grew total stores to 181 from 149 with 32 net new openings, boosting total revenue 24.5% YoY to $200.3M and same-store sales growth to 10.1% from 6.3%, while average unit volume rose to $1.286M from $1.186M. However, income from operations plummeted 85.1% to $0.9M from $6.0M, and net loss widened 130.1% to $16.5M from $7.2M, driven by SG&A expenses surging 63.6% to $41.3M amid rising store operating costs.

• ·Store operating costs and expenses rose 22.2% YoY to $141.6M, with other store operating expenses up 28.4%.
• ·Pre-opening costs increased 28.2% to $4.3M.
• ·Interest expense, net improved 15.9% to $9.4M due to lower expense.
• ·Filing date: March 04, 2026 for year ended December 31, 2025.

04-03-2026

National Vision Holdings, Inc. reported FY2025 total net revenue of $1.99B, up 9.0% YoY from $1.82B, with comparable store sales growth accelerating to 5.9% from 1.9% driven by America's Best (+6.3%) and other owned segments. The company achieved net income from continuing operations of $29.6M, reversing a $27.2M loss, alongside Adjusted Operating Income of $102.5M (up 56% YoY) and Adjusted EBITDA of $193.0M (up 24%). However, new store openings slowed to 33 from 69, services and plans revenue grew slower at 6.3% versus 9.7% for products, and SG&A expenses rose 8.3% to $1.02B.

• ·Asset impairment declined to $2.0M from $39.9M YoY.
• ·Corporate and other revenue fell to $21.0M (1.0% of total) from $27.6M (1.5%).
• ·Adjusted Diluted EPS from continuing operations rose to $0.80 from $0.52.
• ·Stores in Fred Meyer segment reduced from 29 to 18.

04-03-2026

Horizon Technology Finance Corporation (HRZN) announced monthly cash distributions of $0.06 per share for April, May, and June 2026, totaling $0.18 per share, payable on April 15, May 15, and June 16, 2026, respectively. Since its 2010 IPO, Horizon has distributed a total of $360M to shareholders. The board's decision factors in results of operations, spillover income, and the anticipated merger with Monroe Capital Corporation (MRCC), with no declines or flat metrics reported.

• ·Ex-Dividend/Record Dates: March 16, 2026 ($0.06); April 16, 2026 ($0.06); May 18, 2026 ($0.06)
• ·Payment Dates: April 15, 2026; May 15, 2026; June 16, 2026
• ·Related SEC Registration Statement: File No. 333-290114
• ·HRZN Proxy Statement filed April 17, 2025 (amended May 15, 2025); MRCC Proxy Statement filed April 21, 2025

04-03-2026

Dakota Gold Corp. announced that its publicly traded warrants (DC.WS), each exercisable for one share of common stock at $2.08, will expire on March 15, 2026, with trading ceasing on or about March 13, 2026, ahead of NYSE American filing a Form 25 for delisting. The company's common stock (DC) will continue trading on NYSE American. This is a routine expiration event with no reported financial impact.

• ·Warrants terms referenced from Form of Common Stock Purchase Warrant in S-1/A filed May 6, 2022
• ·Company is an emerging growth company
• ·Principal executive offices: 106 Glendale Drive, Suite A, Lead, South Dakota 57754

04-03-2026

Kontoor Brands reported FY2025 net revenues of $3.15B, up 21% YoY from $2.61B, driven by the Helly Hansen acquisition ($476M), organic growth ($61M), and favorable FX ($8M); gross margin improved to 45.2% from 44.5%. However, operating income declined to $337M (10.7% margin) from $342M (13.1% margin) due to higher SG&A at 34.5% of revenues (vs 31.4%), with Wrangler up 6% in revenue but Lee down 5.1% with profit -23.1%. Helly Hansen contributed $460M revenue with 6.9% margin in its first year.

• ·Repurchased 369,955 shares under public program at weighted avg $67.58/share, $190M remaining authorization.
• ·SG&A expenses rose to 34.5% of revenues from 31.4%.
• ·Wrangler operating margin expanded to 23.0% from 20.3%.
• ·Other revenues surged 153% to $27.8M with margin turning positive at 13.7%.

04-03-2026

Morgan Stanley Bitcoin Trust filed Amendment No. 1 to its Form S-1 registration statement on March 4, 2026, registering an indeterminate amount of shares for a continuous offering intended to track the performance of bitcoin as measured by the CoinDesk Bitcoin Benchmark 4PM NY Settlement Rate, adjusted for expenses. The passive ETF, sponsored by Morgan Stanley Investment Management Inc., will hold bitcoin custodied by The Bank of New York Mellon and Coinbase Custody Trust Company, LLC, with shares anticipated to list on NYSE Arca, Inc. The offering may continue for up to three years from the original date, subject to Rule 415.

• ·Registrant classified as non-accelerated filer, smaller reporting company, and emerging growth company
• ·Continuous offering pursuant to Rule 415 under the Securities Act of 1933, not expected to terminate until three years from original offering date unless extended
• ·Trust not registered as investment company under 1940 Act, not a commodity pool under CEA
• ·Authorized Participants can create/redeem shares in cash or in-kind via Bitcoin Counterparties

04-03-2026

Ziff Davis, Inc. and its subsidiary Ziff Davis, LLC entered into a Securities Purchase Agreement dated March 2, 2026, to sell all outstanding equity interests in specified Transferred Entities (listed on Schedule I) and related Irish assets to Accenture Inc., subject to customary closing conditions and adjustments outlined in Section 2.2. The agreement includes ancillary documents such as an Irish Asset Purchase Agreement, Transition Services Agreement, Escrow Agreement, and employment agreements for Key Employees effective upon closing. No financial performance metrics or period-over-period comparisons are provided in the filing.

• ·Agreement executed on March 2, 2026; SEC 8-K filed March 4, 2026.
• ·Involves Irish Seller and Specified Irish Assets via separate Irish Asset Purchase Agreement (Exhibit A).
• ·Key Employees (listed in Purchaser Disclosure Schedule Section 1.1(a)) have executed employment agreements conditioned on closing.
• ·Closing subject to conditions in Article IX, including regulatory approvals and no material adverse changes.

04-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 4, 2026, announcing the issuance of a press release titled 'AITX's RAD Channel Partner Expands Detection to Guard Response Ecosystem,' attached as Exhibit 99.1. The filing discloses a positive development in channel partner expansion integrating detection capabilities into the Guard Response Ecosystem. No financial impacts or quantitative metrics were reported.

04-03-2026

CDT Environmental Technology Investment Holdings Ltd (CDTG) filed an F-1 registration statement on March 04, 2026, for a proposed IPO of Class A common stock. The filing includes financial statements for the six months ended June 30, 2025 (H1 FY2025) compared to H1 FY2024, and full-year FY2024 vs FY2023, focusing on sewage treatment systems and services through multiple Chinese subsidiaries. No specific financial metrics such as revenue or net income are detailed in the provided excerpt.

• ·Subsidiaries operate primarily in China across locations including Shenzhen, Beijing, Fujian, Tianjin, Chongqing, and others.
• ·Currencies referenced: CNY (Chinese Yuan), HKD (Hong Kong Dollar).
• ·Prior IPO activity noted around April 21-22, 2024.
• ·Balance sheet components include Common Stock, Additional Paid-in Capital, Retained Earnings (Statutory Reserves and Unrestricted), Accumulated Other Comprehensive Income, Noncontrolling Interest.
• ·Property categories: Buildings, Equipment (min/max depreciation), Furniture and Fixtures (min/max), Automobiles (min/max).

04-03-2026

U.S. Energy Corp. (USEG) sold an additional 6,525,843 shares of common stock to Roth Principal Investments for $7.3M pursuant to a $25M Common Stock Purchase Agreement originally entered on October 9, 2025, following a prior sale of 2M shares for $2M reported on February 10, 2026. This brings total shares outstanding to 44.3M, representing 19.1% of shares outstanding as of September 30, 2025 and causing significant dilution to existing shareholders. While the equity raise enhances liquidity, the private placement exceeds the 5% disclosure threshold under Item 3.02.

• ·Form S-1 Registration Statement for resale of shares declared effective December 1, 2025.
• ·Shares issued in reliance on Section 4(a)(2) exemption as private transaction to accredited investor.
• ·Original Purchase Agreement filed as Exhibit 10.1 to October 9, 2025 Form 8-K.

04-03-2026

Xponential Fitness reported system-wide sales growth of 13% YoY to $1.75B in 2025, with global studios increasing 7% to 3,097 and franchise revenue rising 10% to $193M, driving operating income of $20M versus a $54M loss in 2024. However, total revenue declined 2% YoY to $315M, same-store sales were flat at 0%, new studio openings dropped 20% to 341, and segments like equipment revenue (-35%) and merchandise (-12%) saw sharp declines, resulting in a net loss of $54M (improved from $99M but worse than 2023's $6M loss). AUV LTM edged up 2% to $695 but quarterly AUV declined 2% to $683.

• ·North America new studio openings net 2025: 160 (global net: 201)
• ·International franchise licenses sold new 2025: 112 (vs North America 67)
• ·Impairment of goodwill and other noncurrent assets 2025: $33M (down from $63M in 2024)
• ·Remaining studios obligated to open under MFAs EOY 2025: 767 (flat from 763 in 2024)

04-03-2026

Sky Acquisition Group filed an S-1/A registration statement on March 3, 2026, detailing its proposed IPO of 15,000,000 units, with no units outstanding prior to the offering. Post-offering, the company will have 20,000,000 ordinary shares outstanding (including conversion of 5,000,000 Class B founder shares) and 11,930,000 warrants, following the sponsor's purchase of 5,750,000 Class B founder shares on December 3, 2025, for $25,000. Warrants are exercisable at $11.50 per Class A ordinary share starting 30 days after the initial business combination, with no financial performance metrics or declines reported as this is a pre-operational SPAC.

• ·Separate trading of Class A ordinary shares and warrants prohibited until Form 8-K filed with audited balance sheet post-closing.
• ·Warrants expire 7 years after initial business combination or earlier upon redemption/liquidation.
• ·Up to 750,000 founder shares subject to forfeiture depending on underwriters’ over-allotment option exercise.
• ·Founder shares represent approximately 25% of outstanding shares post-offering on as-converted basis.

04-03-2026

On February 19, 2026, the disinterested members of the Board of Directors of Charles & Colvard, Ltd. approved reimbursement of $406,188.72 in expenses, including legal fees and solicitation costs, to Riverstyx Fund, LP—a shareholder affiliated with Board members Benjamin Franklin IV and Duc Pham—for its proxy solicitation related to the 2025 Annual Meeting of Shareholders. Interested Board members recused themselves from the decision. The reimbursement is deferred until the Company achieves a stronger financial position, reflecting considerations of governance improvements and majority shareholder support for the nominees.

• ·Approval contingent on conserving Company's cash position and deferred until stronger financial position.
• ·Board considered factors including shared benefits to Company and shareholders from Board reconstitution, majority shareholder vote for nominees, and common practice in proxy contest settlements.

04-03-2026

For FY ended October 31, 2025, MaxsMaking Inc. reported revenue growth of 36.33% YoY to $29.2M, primarily driven by Mainland China sales surging 54.13% to $26.6M. However, cost of sales rose 52.34% leading to a 34.11% decline in gross profit to $2.6M, while operating expenses increased 42.25% and income from operations fell 95.30% to $0.1M, resulting in net income plummeting 99.04% to $18K. Compared to FY2024 (which itself saw revenue decline 18.38% from FY2023), profitability deteriorated sharply despite top-line expansion.

• ·Asia (ex-Mainland China) sales declined 59.44% YoY to $0.8M (2.77% of total), Europe down 29.89% to $1.3M (4.34% of total)
• ·General and administrative expenses surged 132.97% YoY to $1.4M in FY2025
• ·Reliance on PRC subsidiaries for dividends poses cash transfer risks; unpatented technology vulnerable to imitation
• ·IPO consummated July 8, 2025

04-03-2026

FACT II Acquisition Corp. (FACT) filed a Form 425 on March 4, 2026, disclosing a LinkedIn post by Richard Nespola, Jr., sponsor team member, dated March 3, 2026, relating to the proposed business combination with Precision Aerospace & Defense Group, Inc. (PAD). The filing consists primarily of forward-looking statement disclaimers, extensive risk factors including regulatory hurdles, shareholder approvals, and potential redemptions, and directs investors to the pending Form S-4 Registration Statement for details. No financial metrics or performance data are provided.

• ·Commission File Number: 001-42421
• ·Registration Statement on Form S-4 filed with the SEC (not yet effective)

04-03-2026

Archimedes Tech SPAC Partners II Co. reported total assets of $241.3M as of December 31, 2025, primarily from $239.9M in its Trust Account following its February 12, 2025 IPO of 23M Units, with net income of $8.0M for the year driven by $8.7M in interest income. However, operating losses reached $0.8M from G&A expenses, shareholders' deficit expanded to $6.7M due to $24.6M accretion on redeemable shares, compared to a minor $54k deficit at year-end 2024 pre-IPO. The 2024 inception period showed a $79k net loss with negligible assets.

• ·IPO consummated on February 12, 2025, with full exercise of 3M over-allotment option; 750k sponsor shares no longer subject to forfeiture.
• ·Company inception date: June 7, 2024.
• ·Ordinary shares subject to redemption valued at $10.43 per share as of Dec 31, 2025.
• ·Promissory note to related party of $192k repaid by Dec 31, 2025.

04-03-2026

PetVivo Holdings, Inc. filed a Form 8-K on March 4, 2026, reporting an event dated March 3, 2026, to disclose an Investor Presentation (Exhibit 99.1) dated March 2026 under Item 7.01 Regulation FD for use in investor conferences and other forums. The presentation is furnished pursuant to Regulation FD and not deemed filed with the SEC. The filing was signed by CEO John Lai; no specific financial metrics or performance data are detailed in the filing itself.

• ·Registrant is an emerging growth company.
• ·Securities: Common Stock (PETV) on OTCQX; Warrants (PETVW) on OTCID.
• ·Principal executive offices: 5151 Edina Industrial Blvd. Suite 575, Edina, Minnesota 55439.

04-03-2026

Alliant Energy Corporation entered into a $400M Credit Agreement dated March 2, 2026, with U.S. Bank National Association as Administrative Agent and CoBank, ACB; Mizuho Bank, Ltd.; and TD Securities (USA) LLC as Joint Lead Arrangers and Joint Book Runners. The facility provides an Aggregate Commitment of $400M, with Applicable Margins of 0.00% for Base Rate Borrowings and 0.85% for Term SOFR Borrowings. No prior period comparisons are available as this is a new financing arrangement.

• ·Filing Date: March 04, 2026
• ·Agreement effective date: March 2, 2026
• ·Alternate Base Rate defined as highest of zero, Prime Rate, Federal Funds Effective Rate + 0.50%, or Term SOFR (1-month) + 1.00%

04-03-2026

Cricut, Inc. reported FY2025 total revenue of $709M, down 1% YoY from $713M due to a 5% decline in Products revenue to $381M, despite 5% growth in Platform revenue to $327M. Gross profit rose 11% to $390M with margin expansion to 55% (Platform at 89%, Products up to 26%), driving operating income up 26% to $96M and net income up 22% to $77M. However, sales and marketing expenses increased 11% to $159M while R&D rose 10% to $67M.

• ·Stock-based compensation expense declined to $35M in FY2025 from $45M in FY2024.
• ·Provision for income taxes increased 20% YoY to $31M in FY2025.
• ·Total revenue down 7% from FY2023 $765M peak.
• ·G&A expenses down 6% YoY to $68M but flat at 10% of revenue.

04-03-2026

News Corporation disclosed via 8-K information provided to the Australian Securities Exchange (ASX) regarding its ongoing $1B stock repurchase program authorizing purchases of Class A (NWSA) and Class B (NWS) common stock. The disclosures are attached as Exhibits 99.1 and 99.2, which include forward-looking statements on potential repurchases subject to market conditions and other factors. No specific repurchase transactions or amounts were detailed in the filing body.

• ·Event date: March 3, 2026
• ·Filing date: March 4, 2026
• ·Securities: Class A Common Stock (NWSA, par value $0.01), Class B Common Stock (NWS, par value $0.01) on Nasdaq Global Select Market

04-03-2026

NexGen Energy Ltd. filed its Form 40-F annual report for FY ended December 31, 2025, incorporating the Annual Information Form, MD&A, and audited IFRS financial statements for 2025 and 2024, with 659,960,072 common shares outstanding. Short-term compensation to key management personnel decreased 1.4% YoY to $5,950, while share-based payments increased 30.9% YoY to $32,397. Management confirmed effective disclosure controls and no material changes in internal controls over financial reporting.

• ·Audited by KPMG LLP (Auditor Firm ID: 85)
• ·Principal executive offices: Suite 3150, 1021 West Hastings Street, Vancouver, B.C., Canada V6E 0C3
• ·Agent for service in US: Puglisi & Associates, 850 Library Avenue, Suite 204, Newark, Delaware 19711
• ·No off-balance sheet arrangements material to investors
• ·No changes in internal control over financial reporting during FY2025

04-03-2026

Gran Tierra Energy Inc. reported 2025 average WI production of 45,709 BOEPD, up 32% YoY, with Q4 at 46,344 BOEPD (+13% YoY, +9% QoQ), and South American reserves replacement exceeding 100% for PDP and 2P, achieving before-tax 2P NAV of $1.8B. However, Adjusted EBITDA fell 23% YoY to $284M due to lower Brent prices, operating netback declined 37% to $20.18/boe, sales dropped 4% to $597M, and the company posted a net loss of $193M versus 2024 profit. Subsequent bond exchange reduced debt with 88% participation, extending maturities to 2031, and pro forma net debt of $533M, while entering Azerbaijan EDPSA.

• ·Canadian reserves replacement negative due to reclassification to contingent resources from lower gas prices; Canada represents 39% of 1P and 44% of 2P reserves.
• ·Operating expenses up 23% to $248.7M YoY; per boe down 6% to $15.17.
• ·Cash G&A costs up 37% to $56.9M; per boe up to $3.47.
• ·Bond buybacks: $21.3M face value at 20% discount.
• ·Azerbaijan EDPSA: 65% WI to Gran Tierra, 250 sq km 3D seismic, 2 wells in 36 months.
• ·Safety: TRIF 0.02 in 2025, top quartile; restored/protected 5,600 hectares.
• ·Future development costs: $888M (1P), $1,682M (2P).

04-03-2026

General Fusion's Chief Strategy Officer Megan Wilson highlighted the company's focus on practical fusion power and the January 21, 2026 Business Combination Agreement with Spring Valley Acquisition Corp. III (SVAC) during a fireside chat at the FusionX:Global Summit on March 3, 2026, noting that the deal provides capital for LM26 milestones. The transaction involves SVAC's continuation to British Columbia, amalgamation with General Fusion via NewCo, and renaming to General Fusion Group Ltd. However, the filing emphasizes significant risks including potential failure to complete the deal, regulatory hurdles, employee retention issues, and commercialization challenges for magnetized target fusion.

• ·Business Combination Agreement dated January 21, 2026
• ·Joint Registration Statement on Form F-4 filed with SEC, including preliminary proxy statement/prospectus
• ·SVAC Final Prospectus dated September 3, 2025, filed September 4, 2025
• ·Filing Date: March 04, 2026; Communication Date: March 3, 2026

04-03-2026

Procaccianti Hotel REIT, Inc. announced on March 2, 2026, that share repurchases for the quarter ended December 31, 2025, under its Amended and Restated Share Repurchase Program are prorated due to the funding limitation being reached, with insufficient DRIP proceeds to fulfill all requests. Deceased stockholders' shares will be repurchased in full, but remaining requests will only be honored at approximately 3.6% pro rata, with no requests from qualifying disabilities or small accounts (≤100 shares). This reflects constraints under the program's 5.0% annual share limit and funding caps, potentially delaying liquidity for other shareholders.

• ·Repurchase priorities: (1) deceased stockholders (full, pro rata if insufficient funds), (2) qualifying disabilities or involuntary exigent circumstances (e.g., bankruptcy) and small accounts ≤100 shares, (3) remaining requests pro rata.
• ·Unfulfilled repurchase requests automatically carry over to subsequent periods unless withdrawn 5 business days prior to next repurchase date.
• ·Death-related repurchases count toward 5.0% share limit but are exempt from percentage cap.

04-03-2026

Pelican Acquisition Corporation filed a DEFA14A on March 4, 2026, announcing a Prospectus Supplement dated March 3, 2026, to the S-4 prospectus, clarifying that warrants of Pelican Holdco, Inc. (PubCo) will not be listed or traded on Nasdaq or any exchange. This update relates to the pending business combination with Greenland Exploration Limited and March GL Company, with no other changes to the prospectus. The filing serves as soliciting material ahead of the Pelican Shareholder Meeting to approve the transaction.

• ·S-4 Registration Statement (No. 333-291171) declared effective February 17, 2026; original prospectus dated February 18, 2026.
• ·Pelican 10-Qs filed for quarters ended October 31, 2025 (Dec 19, 2025), July 31, 2025 (Sep 15, 2025), April 30, 2025 (Jun 27, 2025); S-1 effective May 22, 2025.
• ·Ordinary shares par value $0.0001 per share.

04-03-2026

MOVING iMAGE TECHNOLOGIES INC. (MITQ) issued a DEFA14A additional proxy statement for its Annual Meeting of Stockholders on March 12, 2024, at 10:00 a.m. local time. Proposals include electing five directors for a one-year term expiring at the 2025 annual meeting and ratifying Haskell & White LLP as independent auditors for the fiscal year ending June 30, 2024. The Board recommends voting 'FOR' both proposals.

• ·Meeting location: 17760 Newhope Street, Suite B, Fountain Valley, CA 92708
• ·Fiscal year reference for audit ratification: ending June 30, 2024
• ·Prior year reference: year ended June 30, 2023 (investor site link)

04-03-2026

Enhabit, Inc. entered into an Amended and Restated Credit Agreement dated February 26, 2026, which amends and restates the existing Credit Agreement dated June 1, 2022. Wells Fargo Bank, National Association serves as Administrative Agent, Collateral Agent, and Swingline Lender, with multiple banks including BofA Securities, Inc., Capital One, N.A., Regions Bank, JPMorgan Chase Bank, N.A., and Citizens Bank, N.A. acting as Joint Lead Arrangers and Joint Bookrunners. The agreement outlines standard terms for commitments, loans, borrowings, and covenants, with no specific facility sizes or rates detailed in the provided excerpt.

• ·Existing Credit Agreement originally dated June 1, 2022.
• ·SEC 8-K Filing Date: March 04, 2026.
• ·Items reported: 1.01 (Entry into Material Definitive Agreement), 2.03 (Creation of Direct Financial Obligation), 9.01 (Financial Statements and Exhibits).

04-03-2026

On March 3, 2026, the Board of Directors of Innovative Industrial Properties, Inc. approved a new share repurchase program authorizing the repurchase of up to $100 million of the Company's common stock, replacing the existing program scheduled to expire on March 17, 2026. Repurchases may occur through open market purchases, block trades, privately negotiated transactions, or via a Rule 10b5-1 plan, in compliance with Rule 10b-18 and subject to market conditions and management discretion. The program expires on March 4, 2027, and may be suspended, modified, or discontinued at any time.

• ·Securities registered: Common Stock (IIPR) and Series A Preferred Stock (IIPR-PA) on New York Stock Exchange
• ·Repurchases subject to Rule 10b-18 compliance and potential Rule 10b5-1 plan adoption

04-03-2026

Mitek Systems, Inc. held its annual stockholder meeting on March 3, 2026, with 38,435,860 shares represented out of 45,299,662 outstanding, where all five proposals were approved by stockholders. Eight directors were elected with strong support (For votes ranging from 27.2M to 30.1M), auditors BDO USA, P.C. were ratified (37.9M For), and the Amended ESPP was approved overwhelmingly (30.3M For). However, advisory approval of executive compensation received notable opposition (5.6M Against out of 30.5M voted) as did the Amended 2020 Incentive Plan (4.6M Against out of 30.5M voted).

• ·Director election withheld votes highest for Kimberly S. Stevenson (3,306,140)
• ·Proxy statement filed with SEC on January 26, 2026
• ·Fiscal year ends September 30, 2026

04-03-2026

Corvex, Inc. announced on March 3, 2026, the verified production deployment of confidential computing for AI on NVIDIA HGX B200 systems, featuring encrypted GPU-to-GPU communication and remote attestation for secure AI workloads with near-native performance. This achievement supports secure multi-tenant AI environments and is highlighted in the context of Corvex's definitive all-stock merger agreement with Movano Inc. (Nasdaq: MOVE), announced on November 10, 2025. No financial metrics or performance comparisons were disclosed.

• ·Definitive merger agreement (Merger Agreement) announced November 10, 2025
• ·Form S-4 registration statement File No. 333-292321 contains proxy statement/prospectus
• ·Merger is an all-stock transaction
• ·Movano Commission File No.: 001-40254
• ·Movano Annual Report on Form 10-K for year ended December 31, 2024

04-03-2026

This DEF 14A proxy statement solicits shareholder votes for the election of board members at the virtual annual meeting on April 16, 2026, for Nuveen Virginia Quality Municipal Income Fund (NPV) and 15 other Nuveen funds. For NPV, holders of Common and Preferred Shares vote together to elect four Class II Board Members, while Preferred Share holders vote separately to elect two Board Members. The record date is February 9, 2026, with no financial performance metrics disclosed.

• ·Annual Meeting: April 16, 2026, at 2:00 p.m. Central Time, virtual only via meetnow.global/M6VY4FD
• ·Record date: February 9, 2026
• ·Proxy materials mailed on or about March 6, 2026
• ·Quorum: Majority of shares for most votes; 33 1/3% of Preferred Shares for their separate election
• ·Registration for virtual attendance required 3 business days prior if held by intermediary

04-03-2026

Nuveen Variable Rate Preferred & Income Fund (NPFD), along with multiple other Nuveen funds, has issued a joint proxy statement for its virtual Annual Meeting of Shareholders on April 16, 2026, primarily to elect Board Members. For NPFD, this includes electing four Class II Board Members by holders of Common and Preferred Shares voting together as a single class, and two Board Members by Preferred Shares holders voting separately. The record date for shareholders entitled to vote is February 9, 2026, with no financial performance data or changes reported.

• ·Annual Meeting held virtually via live webcast at meetnow.global/M6VY4FD, 2:00 p.m. Central Time on April 16, 2026; no physical location.
• ·Quorum requires majority of shares entitled to vote, or 33 1/3% for Preferred Shares election of two Board Members.
• ·Proxy mailed on or about March 6, 2026; registration for intermediary-held shares required 3 business days prior.
• ·Shares located at 333 W. Wacker Drive, Chicago, IL 60606.

04-03-2026

This DEF 14A proxy statement for Nuveen Real Estate Income Fund (JRS) and 15 other Nuveen funds solicits shareholder votes for the virtual annual meeting on April 16, 2026, at 2:00 p.m. Central time to elect board members, including four Class II Board Members for JRS voted by common shareholders. No financial performance data or other metrics are disclosed; the filing is purely procedural for governance.

• ·Record date: February 9, 2026
• ·Proxy materials mailed on or about March 6, 2026
• ·Virtual meeting via meetnow.global/M6VY4FD; intermediaries must register 3 business days prior with legal proxy by 5:00 p.m. ET
• ·Quorum: majority of shares for most votes; 33 1/3% of Preferred Shares for certain elections
• ·SEC File Number: 811-10491; CIK: 0001158289

04-03-2026

This DEF 14A filing is a joint proxy statement for the annual shareholder meetings of multiple Nuveen closed-end funds, including Nuveen Real Asset Income & Growth Fund (JRI), scheduled virtually on April 16, 2026, at 2:00 p.m. Central time. Shareholders of record as of February 9, 2026, will vote to elect board members, with JRI seeking election of four Class II Board Members by common shareholders. No financial performance data or period comparisons are provided; the filing outlines voting procedures, quorum requirements, and virtual attendance details.

• ·Record date: February 9, 2026
• ·Proxy materials mailed on or about March 6, 2026
• ·Virtual meeting access: meetnow.global/M6VY4FD
• ·Registration for intermediary-held shares required 3 business days prior, by 5:00 p.m. ET
• ·Quorum: majority of shares entitled to vote; 33 1/3% for Preferred Shares elections in select funds

04-03-2026

Rise Gold Corp. entered a strategic 18-month development partnership with Morgan Hughes Energy to advance the Idaho-Maryland Mine as a gold and critical-minerals project, issuing 18 million warrants at $0.40 strike price and offering a potential $1.5M milestone payment upon securing capital commitments. Morgan Hughes will support planning, capital formation, and positioning within U.S. critical-minerals initiatives. However, the company faces ongoing regulatory hurdles, including a denied Use Permit by Nevada County Supervisors and a pending Writ of Mandamus with oral arguments on March 6, 2026.

• ·Warrants vest in tranches: 9M on critical-minerals framework advancement, 4.5M on development support, 4.5M on capital commitments.
• ·Morgan Hughes board seat upon qualifying milestone if maintaining 5% ownership.
• ·Alternative to reimbursement: 1.8M warrants for 12 months upon mutual agreement.
• ·I-M Mine historical grades: gold 0.50 oz/ton (17.1 g/t), no domestic U.S. tungsten mine since 2015.
• ·Writ of Mandamus filed May 2024 challenging denial of Use Permit and vested rights.

04-03-2026

Babcock & Wilcox reported Q4 2025 revenue of $161.0 million, essentially flat YoY compared to $161.8 million, but delivered strong profitability with operating income of $12.2 million (up from $2.6 million) and Adjusted EBITDA of $16.4 million (53% increase from $10.7 million). Full year 2025 revenue increased slightly by 1.2% to $587.7 million alongside a 107% surge in Adjusted EBITDA to $43.7 million, though the company still recorded a $32.8 million loss from continuing operations (improved from $104.3 million prior year). Key highlights include signing full notice to proceed on a $2.4 billion AI data center project with Base Electron, boosting continuing operations backlog to $2.8 billion (470% YoY increase) and reducing net debt to $119.7 million.

• ·Paid off outstanding bonds due February 2026 in December 2025; plans to pay off December 2026 bonds in 2026.
• ·Earnings conference call scheduled for March 16, 2026 at 5 p.m. ET.
• ·Extended maturity date of Axos facility.

04-03-2026

FactSet announced the appointments of Kate Stepp as Chief AI Officer and Bob Stolte as Chief Technology Officer, effective March 2, 2026, to accelerate enterprise AI and platform strategy, with both reporting to CEO Sanoke Viswanathan. Kate Stepp previously served as CTO since September 2022, focusing on client-centric technology and AI expansion. These leadership changes reinforce FactSet's commitment to AI innovation, serving more than 9,000 global clients and 239,000 users across 19 countries.

• ·Kate Stepp held the role of Chief Technology Officer since September 2022.
• ·Appointments announced on March 4, 2026.

04-03-2026

Somnigroup International Inc. (SGI) is hosting an Investor Day on March 4, 2026, with executive management presentations on the company's strategic vision, growth initiatives across business units, multi-year financial targets, and capital allocation strategy, followed by a Q&A session. The event is invitation-only in-person due to capacity limits but available via live webcast on the IR website at www.somnigroup.com starting at 8:00 a.m. ET, with replay and materials posted afterward. No financial results or performance metrics were disclosed in this announcement.

• ·Securities traded on New York Stock Exchange under ticker SGI (Common Stock, $0.01 par value)
• ·Principal executive offices: 100 Crescent Ct. Suite 700, Dallas, Texas 75201
• ·Information under Item 7.01 not deemed 'filed' under Section 18 of the Exchange Act

04-03-2026

Altisource Portfolio Solutions S.A. reported total revenue of $171M for the year ended December 31, 2025, up 7% YoY from $160M, driven by 16% growth in Origination service revenue to $35M and 5% increase in Servicer and Real Estate to $126M. However, gross profit declined 1% to $49M with margins contracting to 30% from 33%, income from operations fell 87% to $0.4M impacted by a $7.5M litigation settlement loss, and Marketplace revenue dropped 10% to $24M while Technology and SaaS Products declined 11% to $9M. The company achieved a net income attributable to Altisource of $1.6M, swinging from a $36M loss in 2024, supported by a 69% reduction in interest expense.

• ·REO Inventory - Customers other than Rithm increased 230% to 2.4 (in thousands) as of Feb 15, 2026 from 0.7.
• ·REO Inventory - Rithm remained flat at 1.0 (in thousands) as of Feb 15, 2026.
• ·Corporate and Others segment reported operating loss of $32.8M in 2025 vs $34.8M in 2024.
• ·SG&A expenses decreased 10% to $41M in 2025.
• ·Filing date: March 04, 2026 for year ended December 31, 2025.

04-03-2026

EyePoint Pharmaceuticals reported Q4 2025 net revenue of $0.6M, down 95% YoY from $11.6M, and full-year revenue of $31.4M, down 28% from $43.3M, primarily due to lower license and royalty revenue recognition from the YUTIQ agreement, while operating expenses rose 25% to $71.0M in Q4 and 45% to $274.8M for the year driven by Phase 3 trials. Net losses widened to $67.6M ($0.81/share) in Q4 and $232.0M ($3.17/share) for the year. However, cash and investments stood at $306M, providing runway into Q4 2027, with DURAVYU Phase 3 wet AMD trials (LUGANO/LUCIA) on track for mid-2026 topline data and first patients dosed in DME trials (COMO/CAPRI).

• ·U.S. patent issued in February 2026 extending DURAVYU insert formulation coverage into 2043.
• ·Manufacturing of registration batches for DURAVYU completed at Northbridge, MA facility for NDA CMC section.
• ·DSMC recommended continuation of Phase 3 wet AMD program with no modifications after second review.

04-03-2026

Trio Petroleum Corp amended its Prospectus Supplement under the January 9, 2026 ATM Agreement with Ladenburg Thalmann & Co. Inc., reflecting prior sales of 9,254,648 shares of Common Stock for $6.89M, increasing the maximum aggregate offering amount to $13.38M with $6.49M in shares now available for sale. Amendment No. 1 (March 3, 2026) updated availability to $3.29M after initial $3.60M sales of $3.60M (7.34M shares), while Amendment No. 2 (March 4, 2026) further adjusted figures. No performance metrics or financial impacts from proceeds are disclosed.

• ·Registration Statement on Form S-3 (File No 333-281813) effective September 10, 2024.
• ·January 9th 8-K filed reporting entry into ATM Agreement.
• ·ATM Agreement incorporated by reference as Exhibit 10.1 from January 9, 2026 8-K.

04-03-2026

H.B. Fuller Company filed definitive additional proxy materials (DEFA14A) on March 04, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee is required and is marked as definitive additional materials. No financial metrics, proposals, or other substantive details are provided in the excerpt.

04-03-2026

Dycom Industries reported record FY2026 contract revenues of $5.546B, up 17.9% YoY (6.5% organically), with Adjusted EBITDA rising 28.0% to $737.7M at 13.3% margin; Q4 revenues hit a record $1.458B, up 34.4% YoY (16.6% organically) and Adjusted EBITDA up 39.6% to $162.4M. However, Q4 GAAP net income declined 50.1% to $16.3M due to acquisition-related costs, despite annual net income growth of 20.5% to $281.2M. The company completed the acquisition of Power Solutions on Dec 23, 2025, adding entry into data centers, and provided FY2027 revenue outlook of $6.85B-$7.15B.

• ·Revised segment reporting to Communications and Building Systems effective Q4 FY2026.
• ·FY2027 outlook: Contract revenues $6.85B to $7.15B (Communications $5.70B-$5.90B, Building Systems $1.15B-$1.25B).
• ·Q1 FY2027 outlook: Revenues $1.64B-$1.71B, Adjusted EBITDA $202M-$218M, Adjusted Diluted EPS $2.57-$2.90.

04-03-2026

Applied Digital Corporation's subsidiary, APLD ComputeCo 2 LLC, priced an offering of $2.15 billion aggregate principal amount of 6.750% senior secured notes due 2031 at 98% of par, expected to close on or around March 10, 2026. Net proceeds will fund development and construction of 200 megawatts of critical IT load at the Polaris Forge 2 AI Factory campus in Harwood, North Dakota, which is leased to Oracle, along with project accounts and related fees. No prior period comparisons or performance metrics are provided in the filing.

• ·Notes to be sold to qualified institutional buyers under Rule 144A and non-U.S. persons under Regulation S.
• ·Campus located in Harwood, North Dakota.

04-03-2026

SSR Mining Inc. entered a binding memorandum of understanding to sell its 80% ownership in the Çöpler mine and related properties to Cengiz Holding A.S. for $1.5B in cash, payable at closing, with a $100M deposit and $50M reciprocal break fee. The transaction excludes the Hod Maden development project, is expected to close in Q3 2026 subject to Turkish regulatory approvals and limited due diligence, and is deemed fair by CIBC's fairness opinion. Proceeds will fund reinvestment, capital returns, and growth, repositioning the portfolio toward Americas operations including the Cripple Creek & Victor mine.

• ·Fairness opinion issued by CIBC World Markets Inc. on March 3, 2026
• ·Transaction not subject to financing contingency or operational permits
• ·Legal advisors: Allen Overy Shearman Sterling LLP
• ·Expected closure: third quarter of 2026
• ·SSR Mining retains 20% interest in Hod Maden project

04-03-2026

The Real Brokerage Inc. (REAX) filed its Form 40-F Annual Report for the fiscal year ended December 31, 2025, incorporating by reference its Annual Information Form, audited consolidated financial statements, and Management’s Discussion and Analysis. The company reported 210.5 million outstanding common shares as of December 31, 2025, with no long-term debt, capital leases, operating leases, purchase obligations, or other long-term liabilities (all $0). No material changes in internal control over financial reporting were noted, and the Audit Committee is led by financial expert Larry Klane.

• ·No changes in internal control over financial reporting during FY 2025.
• ·No off-balance sheet arrangements.
• ·Shareholder quorum requirement: at least 5% of issued common shares.
• ·Exempt from certain Nasdaq rules as foreign private issuer (e.g., proxy solicitation follows Canadian rules).
• ·Code of Business Conduct and Ethics applies to all directors, officers, and employees.

04-03-2026

Nuveen Quality Municipal Income Fund extended the final mandatory redemption date for its Series 1 Variable Rate Demand Preferred Shares ($236.8M aggregate liquidation preference) and Series 2 Variable Rate Demand Preferred Shares ($267.5M aggregate liquidation preference) from September 11, 2026, to September 11, 2056, effective March 3, 2026. This extension applies to these senior securities, which rank ahead of common shares (NAD) in liquidation and dividends, with weekly dividend rates set by a remarketing agent and liquidity support from a provider. No performance declines or flat metrics were reported in this disclosure.

• ·Dividends on VRDPs set weekly by remarketing agent, subject to maximum rate that increases during extended unsuccessful remarketing.
• ·Liquidity feature allows holders to sell to liquidity provider if remarketing fails.
• ·VRDPs not registered under Securities Act of 1933; disclosure not an offer to sell.

04-03-2026

On March 3, 2026, the NYSE suspended trading in Vicarious Surgical Inc.'s Class A common stock (RBOT) after determining the company's average global market capitalization fell below the $15M threshold over a consecutive 30 trading day period under Section 802.01B, and commenced delisting proceedings via Form 25 following any appeal. The company is evaluating an appeal within 10 business days and has approval to quote on the OTCID market tier starting March 4, 2026, but this shift to a less liquid OTC market is expected to depress the stock price, reduce liquidity, limit equity financing access, and impair employee equity incentives. No positive financial metrics or performance improvements were reported.

• ·Appeal of delisting determination must be filed within 10 business days of March 3, 2026 notification.
• ·Company headquartered at 78 Fourth Avenue, Waltham, MA 02451.

04-03-2026

European Wax Center, Inc. reported FY 2025 total revenue of $206.6M, down 4.7% YoY from $216.9M, with system-wide sales at $947.3M (-0.4%) and same-store sales up a flat 0.2%; however, net centers decreased 1.9% to 1,047, GAAP net income fell 19.2% to $11.9M, and Adjusted EBITDA declined 3.0% to $73.3M. In Q4 FY2025, revenue dropped 9.3% to $45.1M, system-wide sales decreased 1.6% to $225.6M with same-store sales down 0.1%, leading to a net loss of $1.5M and Adjusted EBITDA down 33.1% to $12.7M. The company also noted its agreement to be taken private by General Atlantic and repurchased 1.4M shares for $5.7M.

• ·Franchisees opened 11 and closed 31 centers in FY 2025.
• ·Net cash provided by operating activities: $53.0M in FY 2025.
• ·SG&A as % of revenue increased 110 bps to 28.2% in FY 2025.
• ·Cumulative repurchases under $50M authorization: $45.9M.
• ·No outstanding borrowings under revolving credit facility at FY end.

04-03-2026

Bath & Body Works reported Q4 2025 net sales of $2.7B, down 2% YoY from $2.8B, with adjusted EPS of $2.05 slightly below prior year's $2.09, though results exceeded guidance; FY 2025 net sales were $7.3B, down 0.2% YoY, with adjusted EPS of $3.21 versus $3.29 last year and operating income declining to $1.1B from $1.3B. The company repurchased $400M in shares and ended with $953M in cash, up from $674M, but FY 2026 guidance projects net sales down 2.5-4.5% and adjusted EPS of $2.40-$2.65.

• ·U.S./Canada stores sales down 2.6% in Q4 but up 0.9% FY; Direct channel down 5.4% FY; International up 8.6% Q4 and 4.9% FY.
• ·Net cash from operating activities $1.1B in FY2025, up from $886M.
• ·Long-term debt reduced to $3.6B from $3.9B.
• ·Q1 2026 adjusted EPS guidance $0.24-$0.30 vs. $0.49 reported in Q1 2025.

04-03-2026

TScan Therapeutics reported Q4 and FY 2025 financial results with revenue surging 286% YoY to $2.6M in Q4 and 267% to $10.3M FY due to Amgen collaboration timing, alongside QoQ declines in R&D (-32% to $20.0M) and G&A (-20% to $6.4M) expenses from heme program prioritization. However, FY net loss widened slightly 2% YoY to $129.8M, cash decreased 15% to $152.4M (sufficient into H2 2027), and the solid tumor PLEXI-T trial was discontinued. Positive clinical progress included favorable ASH data for TSC-101 (100% relapse-free at 2 years in treated vs 25% control), FDA IND clearances for TSC-102-A01/A03, and Cohort C enrollment completion in ALLOHA trial.

• ·FDA cleared INDs for TSC-102-A01 and TSC-102-A03 in Feb 2026 targeting CD45 in HLA-A*01:01 and A*03:01 patients.
• ·Upcoming: Q2 2026 Cohort C data and TSC-101 pivotal trial launch; H2 2026 updated Cohort C data and TSC-102 Phase 1 start.
• ·ASH data: TSC-101 overall survival HR=0.61 (p=0.52).
• ·Total assets $228.8M as of Dec 31, 2025 (down from $371.1M prior year).

04-03-2026

Holley reported strong Q4 2025 results with net sales up 10.9% YoY to $155.4M, net income of $6.3M versus a $37.8M loss last year, and Adjusted EBITDA up to $33.2M from $29.1M. For full year 2025, net sales grew modestly 1.9% to $613.5M with Adjusted EBITDA rising to $124.0M from $110.5M; however, free cash flow declined to $34.2M from $41.8M, adjusted net income fell to $21.2M from $24.8M, and overall sales growth was supported mainly by core business excluding divestitures.

• ·Core business net sales excluded $3.2M non-core in Q4 2024 and $26.8M for FY 2024.
• ·Net debt to EBITDA leverage ratio of 3.75x at FY 2025 end, below 4.0x target.
• ·Total debt prepayments of $100M since September 2023.
• ·Generated ~$20M cost savings for FY 2025.
• ·FY 2026 guidance: Net Sales $625-655M; Adjusted EBITDA $127-137M.
• ·Conference call on March 4, 2026 at 8:30 a.m. ET.

04-03-2026

Post Holdings, Inc. announced on March 4, 2026, its intention to commence a private offering of $500M aggregate principal amount of 6.250% senior notes due 2034 to eligible purchasers, subject to market conditions. The net proceeds will repay the outstanding balance of its revolving credit facility as of December 31, 2025, with any remainder for general corporate purposes such as debt repayment, share repurchases, acquisitions, capital expenditures, or working capital. No financial performance metrics or period comparisons were disclosed.

• ·Offering subject to market and other conditions
• ·Press release attached as Exhibit 99.1

04-03-2026

Cellectar Biosciences reported 2025 financial results with cash and equivalents declining 43% to $13.2M from $23.3M, sufficient to fund operations into Q3 2026, alongside sharp reductions in R&D expenses (down 56% to $11.5M) and G&A (down 55% to $11.5M), resulting in a narrower net loss of $21.8M ($8.35/share) versus $44.6M ($36.52/share) in 2024. Pipeline advancements include plans for Q3 2026 Conditional Marketing Authorization submission to EMA for iopofosine I 131 in Waldenström Macroglobulinemia, FDA Breakthrough Therapy Designation, and initiation of a Phase 1b study for CLR 125 in triple negative breast cancer with data expected mid-2026. However, ongoing cash burn and lack of revenue underscore funding risks ahead of key milestones.

• ·Common shares outstanding increased to 4,240,129 from 1,535,996 YoY.
• ·Phase 1b CLR 125 study evaluates doses of 32.75 mCi/m²/dose (up to 4 cycles), 62.5 mCi/m²/dose (up to 3 cycles), and 95 mCi/m²/dose (up to 2 cycles).
• ·Secured supply agreement with Ionetix for cGMP-grade Actinium-225 (Ac-225) and Astatine-211 (At-211).

04-03-2026

Daktronics reported fiscal Q3 2026 sales of $181.9 million, up 21.6% YoY from $149.5 million, with new orders at $201.1 million (+7.6% YoY) and product backlog rising 25.3% YoY to $342.3 million; operating income turned positive at $1.9 million from a $3.6 million loss, and net income was $3.0 million versus a $17.2 million loss. However, gross profit margin dipped slightly to 24.0% from 24.6% YoY due to revenue mix shifts, operating expenses rose modestly to $41.7 million from $40.4 million, and order growth was partially offset by declines in Live Events and International units.

• ·Acquired Display Business from XDC on Dec 22, 2025, consisting of IP, equipment, and other assets; did not materially impact financials.
• ·Entered $71.5M senior credit facility on Nov 26, 2025, enhancing financial flexibility.
• ·Working capital ratio of 2.2 to 1 at Q3 FY2026 end.
• ·Effective tax rate 14.3% in Q3 FY2026 vs 3.7% in Q3 FY2025.

04-03-2026

Advanced Flower Capital Inc. (AFCG) reported Q4 2025 GAAP net income of $0.9 million ($0.04 per share) and full-year 2025 GAAP net loss of $20.7 million ($0.95 per share loss), while Distributable Earnings were negative at $(2.8) million ($(0.12) per share) for Q4 but positive at $8.7 million ($0.39 per share) for the full year. Net interest income reached $5.2 million in Q4 and $24.6 million for the year, supported by $6.6 million and $31.3 million in interest income, respectively, though high expenses of $7.8 million in Q4 and a $22.6 million provision for credit losses annually contributed to the GAAP loss. The board declared a $0.05 per share dividend for Q1 2026, payable April 15, 2026.

• ·Q4 2025 unrealized gains on loans at fair value: $3.5M
• ·FY 2025 unrealized losses on loans at fair value: $7.9M
• ·Q4 2025 management and incentive fees, net: $0.7M (after $0.2M rebate)
• ·FY 2025 stock-based compensation: $6.8M
• ·FY 2025 BDC conversion expenses: $1.2M
• ·Basic weighted average shares Q4 2025: 22.7M; FY 2025: 22.2M

04-03-2026

Abercrombie & Fitch Co. reported record Q4 FY2025 net sales of $1.7B, up 5% YoY with comparable sales +1%, and FY2025 net sales of $5.3B, up 6% YoY with comparable sales +3%, driven by Hollister's 15% FY growth while Abercrombie declined 1% FY. However, FY operating margin fell to 13.3% from 15.0% prior year, Q4 margin dropped to 14.1% from 16.2%, and FY EPS was $10.46 vs $10.69 prior. The company repurchased 5.4M shares for $450M (11% of shares outstanding) and outlooked FY2026 net sales growth of 3-5% with operating margin of 12.0-12.5%.

• ·Cash and equivalents flat at ~$760M YoY; inventories up to $601M from $575M.
• ·Liquidity stable at $1.2B.
• ·FY2026 outlook includes Q1 sales growth 1-3%, op margin ~7%; assumes 15% US tariff impact (290bps Q1, 70bps FY).
• ·Depreciation and amortization $155M FY2025 vs $154M FY2024.

04-03-2026

On March 4, 2026, SharonAI Holdings Inc. (SHAZ) issued a press release announcing a strategic relationship with World Wide Technology for the deployment of large-scale high-performance compute infrastructure in Australia and Asia-Pacific. This partnership is intended to support the company's expansion in the region. No financial terms or quantitative details were disclosed in the filing.

• ·Company address: 745 Fifth Avenue, Suite 500, New York, NY 10151
• ·Securities: Class A Ordinary Common Stock, $0.0001 par value, trading as SHAZ on Nasdaq Stock Market LLC
• ·Emerging growth company status: Yes

04-03-2026

Astrana Health, Inc. updated its corporate presentation on March 4, 2026, for use at conferences and meetings, furnished as Exhibit 99.1 under Item 7.01. The filing discloses forward-looking statements regarding the expected filing of its Form 10-K for the year ended December 31, 2025, on or before the extension deadline following a Form 12b-25, with an anticipated material weakness in internal control over financial reporting and consistency of financial statements with prior earnings release. No financial metrics or period comparisons are provided in the filing.

• ·Form 10-K for year ended December 31, 2025, expected to be filed on or before Form 12b-25 extension deadline
• ·Expected material weakness in internal control over financial reporting

04-03-2026

Republic Airways Holdings Inc. reported Q4 2025 revenues of $464.1M, up 20.6% YoY from $384.8M, with net income of $5.0M ($0.12/share) and full-year revenues of $1.68B, up 13.7% YoY from $1.47B, achieving net income of $76.2M ($1.87/share). The company completed a debt-free merger with Mesa Air Group on November 25, 2025, adding 60 E175 aircraft and growing the fleet to 311 aircraft, while generating $322.0M in operating cash flow and holding $296.5M in cash despite total debt and lease liabilities of $1.2B. However, results were impacted by $26.3M in merger-related costs, $15.3M Q4 executive separation expenses, and $8.1M additional tax expense from non-deductible items, though adjusted metrics showed stronger performance with FY adjusted net income of $114.0M.

• ·29 additional E175 aircraft on order with deliveries through 2029.
• ·Secured $299.4M financing and made $231.6M debt repayments in FY 2025.
• ·2026 guidance: at least 865,000 block hours, capex ~$90M, debt extinguishment ~$165M.
• ·Q4 aircraft rent expense down to $0.7M from $0.9M YoY.

04-03-2026

On February 27, 2026, Timothy Go resigned from the Board of Directors of Celanese Corporation, effective as of that date. The resignation is not the result of any disagreement with the Company's operations, policies, or practices. The Board and Company expressed gratitude for Mr. Go’s service as a Director.

• ·Filing date: March 4, 2026
• ·Event reported date: February 27, 2026
• ·Registrant state of incorporation: Delaware
• ·Commission File Number: 001-32410
• ·IRS Employer Identification No.: 98-0420726

04-03-2026

Innventure, Inc. filed an 8-K on March 4, 2026, under Item 7.01 to disclose a press release announcing operating and financial milestones that demonstrate accelerating momentum across its operating companies and an improved capital outlook. The company, an emerging growth company listed on Nasdaq (INV), provided no specific quantitative details in the filing. No declines or flat performance were mentioned.

• ·Registrant is an emerging growth company.
• ·Common Stock (par value $0.0001) trades as INV on Nasdaq Stock Market, LLC.
• ·Principal executive offices: 6900 Tavistock Lakes Blvd, Suite 400, Orlando, Florida 32827.

04-03-2026

SmartRent reported Q4 2025 total revenue of $36.5 million, up 3% YoY from $35.4 million, driven by 13% ARR growth to $61.6 million, 20% higher hardware revenue, and positive Adjusted EBITDA of $0.2 million versus a $7.4 million loss prior year. However, full-year 2025 revenue fell 13% to $152.3 million from $174.9 million due to 30% lower hardware sales and flat hosted services, with net loss widening to $60.6 million including a $24.9 million goodwill impairment, and Adjusted EBITDA loss of $16.4 million worse than $9.9 million prior year. Units Deployed grew 10% to 890,870, supported by strong Q4 bookings up 24%, while maintaining $105 million cash and no debt.

• ·Hardware Units Shipped Q4 2025: 20,003 (-17% YoY)
• ·SaaS ARPU Q4 2025: $5.83 (+3% YoY)
• ·Q4 gross margin: 38.6% (+990 bps YoY)
• ·FY operating expenses reduced by $13.2M
• ·Remaining share repurchase authorization: $16.8M
• ·Hub amortization revenue expected < $5.0M in 2026

04-03-2026

SM Energy Company announced plans, subject to market conditions, to privately offer $750M aggregate principal amount of senior notes due 2034 and commence a cash tender offer for up to $750M of its outstanding $1.35B 8.375% senior notes due 2028, originally issued by Civitas Resources. The filing includes audited historical financial statements for Civitas for fiscal years ended December 31, 2025 and 2024, unaudited pro forma condensed combined financial information for SM Energy and Civitas, and Civitas' reserve report as of December 31, 2025. These transactions carry forward-looking risks including market conditions and closing contingencies.

• ·Notes offering exempt under Rule 144A and Regulation S; unregistered under Securities Act.
• ·Tender offer terms detailed in offer to purchase dated March 4, 2026.
• ·Civitas financial statements cover fiscal years ended December 31, 2025 and 2024.

04-03-2026

Orion Group Holdings reported full-year 2025 revenue of $852.3 million, up 7% YoY from $796.4 million, with Adjusted EBITDA rising 8% to $45.2 million and GAAP net income of $2.5 million versus a prior-year loss; gross profit increased 16% to $105.6 million driven by strong execution. However, total backlog declined 12% to $640 million from $729 million, with Marine backlog dropping 18% to $480 million despite Concrete backlog growth of 10% to $160 million, amid delayed customer decisions. The company completed a $60 million acquisition of J.E. McAmis, refinanced with a $120 million credit facility, and initiated 2026 guidance for revenue of $900-950 million (9% growth at midpoint) and Adjusted EBITDA of $54-58 million.

• ·Completed $120M UMB Credit Facility on Dec 23, 2025, with $60M revolver, $20M equipment term, $40M acquisition term, plus $25M accordion; interest SOFR +2.5-3.0%.
• ·As of Dec 31, 2025: unrestricted cash $1.6M, total debt $8M; borrowed $47M under new facility for J.E. McAmis acquisition.
• ·2026 guidance: Capex $25-35M; Adjusted EPS $0.36-0.42.
• ·J.E. McAmis has $1.4B pipeline and $34M in marine/real estate assets.
• ·Recent awards: $86M USACE shoreline project.

04-03-2026

LM Funding America reported its highest monthly Bitcoin production in February 2026 at 8.7 BTC mined (up 11.5% MoM from 7.8 BTC in January), with energized hashrate increasing slightly to 0.78 EH/s and total machines rising to 7,513 after deploying 300 Bitmain S21 XP miners. However, the company sold 18.1 BTC, resulting in Bitcoin HODL declining 2.6% MoM to 354.7 BTC valued at $23.8M ($1.11 per diluted share), while its stock closed at $0.40 on March 2; it also extended its $11M Galaxy Digital loan maturity to April 24, 2026.

• ·BTC sold in Feb 2026: 18.1 BTC
• ·Oklahoma hashrate: 0.55 EH/s (up from 0.54 EH/s MoM)
• ·Mississippi hashrate flat at 0.23 EH/s MoM
• ·Loan maturity extended from original to April 24, 2026

04-03-2026

Aeries Technology, Inc. held its 2026 Annual General Meeting on March 3, 2026, with a quorum of 68.4% of ordinary shares (34,321,846 Class A ordinary shares and 1 Class V ordinary share present out of 50,209,716 Class A outstanding). All five resolutions were approved, including the election of directors Alok Kochhar, Biswajit Dasgupta, Nina B. Shapiro, and Bhisham (Ajay) Khare; ratification of Manohar Chowdhry & Associates as auditors for FY ended March 31, 2026; and authorization for a share consolidation up to 1-for-10 ratio with related amendments to the memorandum and articles. Voting showed strong support with minimal opposition across all proposals.

• ·Authorized share capital: $50,500.0001 divided into 500,000,000 Class A ordinary shares of $0.0001 par value each, 1 Class V ordinary share, and 5,000,000 preference shares.
• ·Proxy statement filed with SEC on February 6, 2026; record date January 28, 2026 at 5:00 p.m. ET.
• ·Highest against votes: Resolution No. 3 (607,167 Class A against), No. 5 (626,006 Class A against), but all passed.

04-03-2026

Brown-Forman reported Q3 FY26 net sales up 2% to $1.1B (+1% organic) and operating income up 21% to $340M (flat organic), but year-to-date FY26 net sales declined 2% to $3.0B (flat organic) with operating income flat at $905M (-3% organic) and diluted EPS down 8% to $1.41. While Whiskey net sales grew 2% and Emerging markets/Travel Retail rose 16%/9%, declines hit Tequila (-6%), US (-8%), Developed International (-2%), Rest of Portfolio (-34%), and non-branded/bulk (-64%). The company completed a $400M share repurchase, boosted cash from operations to $709M (+$263M YoY), and reaffirmed FY26 outlook for low-single-digit organic declines in net sales and operating income.

• ·Gross margin expanded 50 bps to 59.9%; operating margin up 70 bps to 30.0%.
• ·FY26 outlook: organic net sales and operating income decline low-single digits; capex $110-120M; effective tax rate 19-21%.
• ·Regular quarterly dividend of $0.2310/share payable April 1, 2026 (record date March 9, 2026).
• ·Conference call held March 4, 2026 at 10:00 a.m. ET.

04-03-2026

Edible Garden AG Incorporated entered into a Note Purchase Agreement dated March 3, 2026, with Streeterville Capital, LLC, issuing a secured promissory note with $1.625M principal for a $1.5M purchase price, incorporating a $120K original issue discount and $5K transaction expenses. The note is secured by all company assets (excluding Tetra Pak-related property) and guaranteed by subsidiaries 2900 Madison Ave Holdings, LLC and Edible Garden Corp., providing immediate cash influx but imposing restrictive covenants limiting future debt, equity issuances, and liens. While offering liquidity, the high OID signals elevated financing costs amid ongoing obligations.

• ·Closing Date: March 3, 2026, via electronic signatures at offices in Lehi, Utah
• ·Collateral excludes all assets, equipment, or property purchased from Tetra Pak, Inc. (including replacements and proceeds)
• ·Covenants restrict Restricted Issuances, new liens (except Tetra Pak assets), subsidiary equity/debt changes, and require timely SEC filings and listing maintenance on NYSE/Nasdaq American

04-03-2026

A. O. Smith Corporation's DEF 14A Proxy Statement, filed March 4, 2026, solicits votes for the 2026 Annual Meeting on April 13, 2026, at The Ritz-Carlton in Charlotte, NC, including electing the Board of Directors (six by Class A Common stockholders, four by Common stockholders), an advisory vote on named executive officer compensation, and ratification of Ernst & Young LLP as independent auditors for FY 2026. Record date is February 17, 2026, with 25.9M Class A Common shares and 112.4M Common shares outstanding entitled to vote. The statement highlights the transition to new CEO Steve Shafer under Executive Chairman Kevin J. Wheeler, with no financial performance metrics or period-over-period comparisons provided.

• ·Class A Common Stock: 1 vote per share for all matters; Common Stock: 1 vote for directors, 1/10th vote for other matters.
• ·Quorum requires majority of outstanding shares; directors elected by plurality vote per class.
• ·Pre-registration for meeting required by April 10, 2026; stockholder list available April 3, 2026.

04-03-2026

Gulfport Energy Corporation entered into a purchase agreement on March 3, 2026, to repurchase 84,416 shares of its common stock from accounts managed by Silver Point Capital, L.P. at $204.22 per share, for a total of approximately $17.2 million, reflecting a 2.3% discount to the NYSE closing price on March 2, 2026. This repurchase is part of the company's existing $1.5B common share repurchase program and is expected to close on March 9, 2026, reducing remaining availability under the program.

• ·Filing dated March 4, 2026
• ·Date of earliest event: March 3, 2026

04-03-2026

Elutia Inc. announced on March 4, 2026, that it has regained compliance with Nasdaq's Minimum Bid Price Requirement, with its Class A common stock closing at $1.00 per share or higher for 10 consecutive business days from February 13 to February 27, 2026. The company also regained compliance with the Minimum Market Value of Listed Securities (MVLS) Requirement, achieving $35M or greater for 11 consecutive business days from January 21 to February 4, 2026. Both compliance matters, previously flagged in November and December 2025, are now closed.

• ·Initial non-compliance notifications: Minimum Bid Price on November 7, 2025; MVLS on December 23, 2025.
• ·Nasdaq determination letters: MVLS compliance on February 5, 2026; Minimum Bid Price on March 2, 2026.
• ·Press release attached as Exhibit 99.1.

04-03-2026

BIO-key International, Inc. (BKYI) secured a $1.04M one-year license renewal and expansion (up 30% YoY) for its biometric identity solution from a foreign retail bank customer since 2015, now serving 30M clients (up from 7M initially) and managing over 300M fingerprints. Year-end cash position stands at $2.7M, with anticipated renewals and collections providing sufficient liquidity to fund growth internally. No declines or flat metrics reported.

• ·Solution supports in-branch teller stations, assisted kiosks, ATMs, and KYC processes tied to national identity verification.
• ·Approximately 10,000 bank employees authenticate daily using fingerprint technology.

04-03-2026

On March 3, 2026, Hexcel Corporation entered into a Cooperation Agreement with Vision One Fund, LP and affiliates, appointing Neal J. Keating to the Board of Directors and Audit Committee, nominating him for the 2026 Annual Meeting, and limiting Board size to 10 directors until the 2026 Annual Meeting and 9 thereafter until the Expiration Date. Vision One Parties agreed to withdraw their 2026 Annual Meeting nominees, adhere to standstill restrictions, and vote for Board nominees. No financial terms or impacts were disclosed.

• ·Board size limited to no more than 10 directors until 2026 Annual Meeting and 9 directors from 2026 Annual Meeting until Expiration Date (earlier of 30 days prior to 2027 stockholder nomination deadline or 150 days prior to 2026 Annual Meeting one-year anniversary).
• ·Neal J. Keating, age 70, previously Chairman, President, and CEO of Kaman Corporation (2008-2020), Executive Chairman until 2021; COO of Hughes Supply; CEO of GKN Aerospace.
• ·Mr. Keating serves on Hubbell Incorporated board since 2010 (chairs nominating/governance committee); former lead director of Triumph Group (2022-July 2025) and Barnes Group Inc. (2023-2025).
• ·No arrangements or understandings other than Cooperation Agreement for appointment; no reportable related party transactions under Item 404(a).

04-03-2026

Grayscale Bittensor Trust (TAO) announced a change in the index used for valuing its Bittensor (TAO) holdings, switching from the Coin Metrics Real-Time Rate to the CoinDesk Bittensor Benchmark Rate effective March 6, 2026, for NAV and NAV per Share calculations. The new index employs a volume-weighted algorithm from Constituent Trading Platforms selected based on IOSCO-aligned criteria including market quality, security, regulatory compliance, and others. Detailed methodology covers platform selection, price determination every 5 seconds, outlier detection, inactivity adjustments, and contingency plans if the index is unavailable.

• ·Index Price calculated every 5 seconds over 24-hour period at 4:00 p.m. New York time on business days
• ·Registration Statement on Form 10 filed December 9, 2025
• ·Index License Agreement dated February 1, 2022
• ·Constituent Trading Platforms must serve customers in jurisdictions including US (FinCEN), UK (FCA), EU (MiCA), Hong Kong (SFC), Singapore (MAS), UAE (VARA, ADGM), Gibraltar (GFSC)

04-03-2026

04-03-2026

Select Medical Holdings Corporation (SEM) issued definitive additional proxy materials (DEFA14A) for its 2026 Annual Meeting of Stockholders on April 23, 2026, at 11:00am ET virtually. Key proposals include election of Class II directors, advisory vote on executive compensation, ratification of PricewaterhouseCoopers LLP as auditors for FY 2026, amendment to phase out the classified board structure, and competing advisory votes on special meeting rights at 25% (company) vs. 10% (stockholder) ownership thresholds. The Board recommends FOR proposals 1-5 and AGAINST the stockholder proposal 6; materials available online with paper requests due by April 13, 2026.

• ·Virtual meeting access: https://meetnow.global/MKMHXJW
• ·Online materials: www.envisionreports.com/SEM
• ·Phone for requests: 1-866-641-4276
• ·Email for requests: investorvote@computershare.com

04-03-2026

Camber Energy, Inc., through its indirect majority-owned subsidiary Viking Protection Systems, LLC, successfully completed live transmission-line validation testing of its patented Broken Conductor Protection Technology (BCPT) on a 138 kV transmission line approximately 63 miles in length, operated by a U.S. electric utility, on February 27, 2026. The BCPT, implemented in SEL-411L relays, detected simulated single-phase open-conductor conditions at both ends of the line in less than one second under live system loading, with no false operations during additional security tests. A Validation Report summarizing the results was issued on or about March 2, 2026, by co-inventor Robert Stuart, P.Eng.

• ·Validation test involved simulation of open-conductor conditions at both ends of the line.
• ·Trip logic and protection elements operated as designed, confirmed by relay sequence-of-events records and oscillography.
• ·Redacted Validation Report attached as Exhibit 99.2.

04-03-2026

Bunker Hill Mining Corp. filed an 8-K on March 4, 2026, announcing via press release (Exhibit 99.1) an update to its previously announced LIFE offering of C$30 million units on a best efforts basis and a reverse stock split. No specific outcomes, proceeds, or ratios for the offering or split were detailed in the filing.

04-03-2026

Microbot Medical Inc. issued a press release on March 4, 2026, commending the American Medical Association’s efforts to protect health care professionals from ionizing radiation. The press release is furnished as Exhibit 99.1 under Item 7.01 and is not deemed filed for liability purposes.

04-03-2026

Tivic Health Systems, Inc. (Nasdaq: TIVC) appointed Michael K. Handley as CEO effective March 4, 2026, succeeding Jennifer Ernst, who has led since the company's founding in 2016 and will continue supporting the transition. The leadership change supports a strategic pivot to late-stage immunotherapies and biopharma expansion via the Velocity Bioworks CDMO subsidiary. Handley brings over two decades of experience, including US approvals and commercialization of 17 products generating billions in revenue at Amgen and Genentech.

• ·Tivic founded in 2016; Annual Report on Form 10-K for year ended December 31, 2024, filed March 21, 2025.
• ·Velocity Bioworks is a wholly owned full-service CDMO subsidiary based in San Antonio, Texas.
• ·Entolimod™ is a TLR5 agonist in late-stage development for Acute Radiation Syndrome (ARS) under FDA’s Animal Rule.

04-03-2026

XFLH Capital Corporation announced on March 4, 2026, that holders of its IPO units (XFLHU) may elect to separately trade the ordinary shares and rights, with separate trading commencing on the NYSE on March 9, 2026, under symbols XFLH and XFLHR, respectively. Unseparated units will continue trading as XFLHU, and brokers must contact transfer agent Continental Stock Transfer & Trust Company to effect separations. The company issued a press release attached as Exhibit 99.1.

• ·Ordinary shares have $0.0001 par value
• ·Rights entitle holders to one-seventh (1/7th) of one ordinary share
• ·Registrant is an emerging growth company

04-03-2026

Haymaker Acquisition Corp. 4 secured Investor Support Agreements from holders of 49.8% of its outstanding public warrants and a Sponsor Warrant Support Agreement from Haymaker Sponsor IV, LLC, ensuring majority support for a Warrant Amendment to exchange SPAC Warrants for $2.25 cash and 0.075 Ordinary Shares per warrant, totaling approximately $25.9M cash and 862,500 Ordinary Shares prior to closing the Business Combination with Suncrete, Inc. The amendment is expected to be approved at the Warrantholder Meeting. However, Haymaker retains sole discretion on implementation, and the Business Combination faces risks such as failure to meet closing conditions, high shareholder redemptions, and potential legal proceedings.

• ·Business Combination Agreement originally entered October 9, 2025
• ·Exchange of warrants relies on Section 3(a)(9) exemption from Securities Act registration
• ·Press release issued March 4, 2026

04-03-2026

Nexxen International Ltd. (NEXN) filed its 20-F Annual Report on March 04, 2026, defining key non-GAAP metrics including Contribution ex-TAC (gross profit plus depreciation/amortization attributable to cost of revenues minus TAC), Adjusted EBITDA (adjusted for foreign currency, financing, tax, depreciation, stock-based compensation, restructuring, acquisition-related costs, delisting costs, and other expenses), active customers/publishers (users of platform in trailing 365 days), unique users (unduplicated visitors in one-month period), and Contribution ex-TAC retention rate (from prior-year customers). The filing highlights forward-looking risks such as dependence on adding new advertisers/publishers and platform usage growth, as well as reliance on a limited number of DSPs, agencies, and advertisers for ad spend, which could be reduced or terminated.

04-03-2026

Aptiv PLC announced on March 4, 2026, the commencement of a $1.5 billion private offering of senior notes due 2031 and senior notes due 2034 by its subsidiaries Cyprium Corporation and Cyprium Holdings Luxembourg S.à r.l. These notes are offered by subsidiaries of Versigent Limited, the holding company for Aptiv's Electrical Distribution Systems segment, ahead of a planned spin-off to shareholders. The offering targets qualified institutional buyers under Rule 144A and offshore investors under Regulation S.

• ·Offering exempt from registration pursuant to Rule 144A and Regulation S under the Securities Act
• ·Press release issued pursuant to Rule 135c

04-03-2026

Tevogen Bio Holdings Inc. adopted a Certificate of Amendment to its Certificate of Incorporation, authorizing a 1-for-50 reverse stock split of its common stock, effective March 6, 2026, at 12:01 a.m. ET, with no fractional shares issued and cash payments in lieu thereof. Authorized capital stock remains 820M total shares, comprising 800M common shares and 20M preferred shares, each with $0.0001 par value. The amendment was approved by the Board and stockholders without changes to other sections.

• ·Reverse split applies automatically without further action by holders.
• ·Filed with Delaware Secretary of State; executed March 3, 2026.

04-03-2026

Alerus Financial Corp reported net interest income surging 61.1% YoY to $172.5M in 2025, fueled by a wider net interest margin of 3.53%, while retirement and benefit services AUA grew 10.3% to $44.9B and mortgage originations doubled to $484.8M. However, noninterest income plunged 54.9% YoY to $51.9M, noninterest expenses rose 11.4% to $201.2M, resulting in net income dipping 1.9% to $17.4M, diluted EPS falling to $0.68 from $0.83, and ROA declining to 0.33%. Loans increased modestly 1.4% to $4.05B, but deposits contracted 4.2% to $4.19B and nonperforming loans rose to 1.71%.

• ·Provision for loan losses decreased sharply to $556K from $18.1M YoY.
• ·Investment securities declined to $768.5M from $863.6M.
• ·Efficiency ratio worsened to 84.10% from 77.92%.
• ·Dividend payout ratio increased to 122.06% from 95.18%.
• ·Allowance for credit losses coverage of nonperforming loans fell to 89.65% from 95.30%.

04-03-2026

Entera Bio Ltd. (ENTX) announced on March 4, 2026, the submission of a Phase 3 protocol to the FDA to initiate a registrational trial of EB613 for postmenopausal women with osteoporosis. This milestone advances the company's clinical development program for the oral anabolic osteoporosis treatment. The press release was furnished as Exhibit 99.1 under Item 7.01.

• ·Securities registered: Ordinary Shares (ENTX) on Nasdaq Capital Market.
• ·Registrant address: Kiryat Hadassah, Minrav Building – Fifth Floor, Jerusalem, Israel 9112002.
• ·Telephone: +972-2-532-7151.

04-03-2026

KALA BIO, Inc. announced a strategic initiative to deploy an on-premises AI infrastructure platform 'Researgency' for the biotech industry, entering into a Platform Development and Exclusive License Agreement with Younet AI (2624465 Ontario Inc.) for an exclusive worldwide license in biotechnology for an initial 12-month term with renewal options. The company will first apply it internally to its MSC-S biological datasets and KPI-012 clinical program before scaling to external clients via a platform-as-a-service model to generate recurring revenue. This targets an underserved market where the top 20 pharmaceutical companies invested $167B in R&D in 2024, with AI drug discovery spending projected to grow from $4B in 2025 to $25B by 2030.

• ·Exclusive worldwide license for Researgency in biotechnology field
• ·Initial 12-month term with successive 12-month renewal options at KALA's discretion
• ·Phased rollout: Phase 1 internal validation on KALA data; Phase 2 external licensing; Phase 3 platform expansion
• ·Over 3,200 US biotech companies as potential addressable market for on-premises AI
• ·Younet AI experience deploying 100+ custom AI agents across sectors

04-03-2026

Azenta, Inc. (AZTA) completed the strategic acquisition of UK Biocentre Limited through its subsidiary Azenta UK Ltd for total consideration of GBP 20.5 million net of cash, inclusive of up to GBP 1.8 million in contingent consideration. UK Biocentre, which generated GBP 15.3 million in revenue over the twelve months ending September 30, 2025, will operate as a European hub to expand Azenta's biorepository capabilities. On a pro forma basis, the acquisition is expected to dilute 2026 Adjusted EBITDA margin by 35 basis points, while being accretive to 2027 and 2028 organic revenue growth and Adjusted EBITDA margin expansion.

• ·Conference call and webcast scheduled for March 10, 2026 at 10:00 am Eastern Time; replay available March 11, 2026.
• ·UK Biocentre founded in 2014.
• ·Azenta headquartered in Burlington, MA, with operations in North America, Europe, and Asia.

04-03-2026

Boxabl Inc. issued a promotional newsletter via StockTwits highlighting its SPAC merger with FG Merger II Corp. (FGMC), including a deadline extension to March 31, 2026, pending regulatory and shareholder approvals, following the merger agreement signed on August 4, 2025. Boxabl touted its $230M crowdfunding from over 60,000 investors since 2020 and products like the 361 sq ft Casita and 120 sq ft Baby Box. However, the communication emphasizes significant risks, including potential shareholder redemptions, regulatory delays, historical net losses, and failure to achieve commercialization.

• ·Boxabl founded in 2017
• ·FGMC final prospectus filed with SEC on January 29, 2025
• ·Boxabl Annual Report on Form 10-K filed April 14, 2025
• ·FGMC CIK: 1816937
• ·Surviving entity to be renamed BOXABL Inc. with ticker $BXBL
• ·FGMC address: 104 S. Walnut Street, Unit 1A, Itasca, Illinois 60143
• ·Boxabl address: 5345 E North Belt Rd, Las Vegas NV 89115

04-03-2026

Citius Oncology announced positive topline results from an investigator-initiated Phase 1 trial (n=14) of LYMPHIR™ (denileukin diftitox-cxdl) administered prior to commercial CD19-directed CAR-T therapy in high-risk relapsed/refractory DLBCL, showing 86% ORR (57% CR, 29% PR), 77% 1-year PFS, and 84% 1-year OS. LYMPHIR was well-tolerated with no dose-limiting toxicities, effective Treg depletion, and manageable low-grade adverse events including 43% CRS and 21% ICANS. The data, presented at the 2026 ASTCT® & CIBMTR® Tandem Meetings, support exploring LYMPHIR's Treg modulation in combinations, though the study was not powered for efficacy.

• ·LYMPHIR doses tested: 5, 7, or 9 µg/kg
• ·Median Treg reduction: 24 Tregs/µL (range 8–65), nadir at 24 hours post-dose
• ·Adverse events: manageable Grade 1–2 capillary leak syndrome, fever, transient liver enzyme elevations; Grade 3 cytopenias consistent with lymphodepletion
• ·LYMPHIR FDA-approved and launched in US December 2025 for r/r CTCL after ≥1 prior systemic therapy

04-03-2026

Citius Oncology, majority-owned subsidiary of Citius Pharmaceuticals (CTXR), announced positive topline Phase 1 data from an investigator-initiated trial of LYMPHIR™ (denileukin diftitox-cxdl) administered prior to commercial CD19 CAR-T therapy in 14 high-risk relapsed/refractory DLBCL patients, showing 86% ORR (57% CR, 29% PR), 77% 1-year PFS, and 84% 1-year OS. LYMPHIR was well-tolerated with no dose-limiting toxicities, effective Treg depletion, and manageable low-grade adverse events including 43% CRS and 21% ICANS. The data supports further exploration in larger studies to enhance CAR-T efficacy.

• ·LYMPHIR doses tested: 5, 7, or 9 µg/kg
• ·Median Treg reduction: 24 Tregs/µL (range 8–65), nadir at 24 hours post-dose
• ·LYMPHIR FDA-approved and launched in U.S. December 2025 for relapsed/refractory CTCL
• ·License acquired in 2021 for markets excluding India, Japan, and certain Asia

04-03-2026

Ventyx Biosciences, Inc. (VTYX) filed an 8-K on March 04, 2026, including its Fourth Amended and Restated Certificate of Incorporation (Exhibit 3.1), coinciding with Items 2.01 (acquisition completion), 3.01, 3.03, 5.01 (change in control), 5.02 (director departures), 5.03 (new directors), and 9.01. The certificate updates the business address to Eli Lilly and Company Global Headquarters in Indianapolis, Indiana, and reduces authorized common stock to 100 shares at $0.0001 par value per share. No financial metrics or performance data are provided in the exhibit.

• ·Registered office: 1209 Orange Street, Wilmington, New Castle County, Delaware 19801.
• ·Directors may be removed with or without cause by majority vote of common stockholders.
• ·Standard indemnification and liability protections for directors and officers affirmed.

04-03-2026

Integrated Media Technology Ltd (IMTE) filed a 20-F/A amendment on March 04, 2026, which includes a Section 302 Sarbanes-Oxley Act certification. The certifying officer affirms that the financial statements and other financial information fairly present the company's financial condition, results of operations, and cash flows as of and for the periods presented in the report. No specific financial metrics or period-over-period changes are disclosed in the provided content.

04-03-2026

Air T, Inc. filed this 8-K/A amendment to its Original 8-K (dated December 18, 2025) to provide required financial statements and pro forma financial information under Item 9.01 following the completion of its acquisition of all outstanding capital stock of Regional Express Holdings Limited (Rex Express) on December 17, 2025, via its subsidiary Air T Rex Acquisition, Inc. Exhibit 99.1 includes audited financial statements of Rex Express prepared by Deloitte Touche Tohmatsu, while Exhibit 99.2 provides unaudited pro forma condensed combined balance sheet as of September 30, 2025, and statements of operations for the fiscal year ended March 31, 2025, and the six months ended September 30, 2025.

• ·Date of earliest event reported: December 15, 2025
• ·Original 8-K filing date: December 18, 2025
• ·Auditor for Rex Express financials: Deloitte Touche Tohmatsu

04-03-2026

Winmark Corporation's DEF 14A proxy statement solicits votes for its Annual Meeting on April 22, 2026, proposing to set the Board at seven members and elect seven directors, including incumbents Brett D. Heffes and Lawrence A. Barbetta; an advisory vote on executive compensation; and ratification of Grant Thornton LLP as auditors for fiscal 2026. The record date is March 2, 2026, with 3,577,421 shares of common stock outstanding entitled to vote. No financial performance metrics or period-over-period changes are detailed in the filing.

• ·Annual Meeting location: 605 Highway 169 N, Suite 100, Minneapolis, Minnesota 55441 at 3:00 p.m. Central Daylight Time
• ·Record date voting eligibility: close of business on March 2, 2026
• ·Proxy materials first mailed on or about March 18, 2026
• ·Proxy solicitation by Brett D. Heffes and Anthony D. Ishaug if no board recommendation

04-03-2026

Invech Holdings, Inc. (IVHI) entered into an Asset Purchase Agreement and completed the acquisition of the domain www.paragonrentals.ai, along with logo, code base, front end, backend, and admin panel, from Andrew Chase Cochran for a total purchase price of $450,000, financed via a Convertible Promissory Note. The note carries no interest, is payable in full by March 3, 2027, or automatically convertible into 10,000,000 shares of IVHI common stock at $0.045 per share, with conversion mechanics limiting the holder to no more than 9.9% ownership. The transaction closed on March 3, 2026, with assets sold 'as is' and no warranties beyond those stated.

• ·Convertible Promissory Note payment due date: March 3, 2027 (or earlier prepayment or automatic conversion)
• ·Note is non-interest bearing and sold 'as is' with no express or implied warranties except as stated
• ·Governing law: Alabama
• ·Holder ownership cap upon conversion: 9.9% of common stock
• ·Company address: 1603 Capitol Ave Suite 413 PMB 1777, Cheyenne, WY 82001

04-03-2026

SunOpta Inc. reported FY2025 revenues of $818M, up 13.0% YoY from $724M, driven by 13.5% volume/mix growth in beverages, broths, and fruit snacks, though partially offset by a -0.2% price impact and -0.3% from smoothie bowls exit. Gross profit rose 20.4% to $116M with margin expansion to 14.2% (up 0.9pt), and operating income surged 154.6% to $40M (margin 4.9%, up 2.7pt), leading to net earnings of $16M from a prior loss of $17M; however, COGS increased 11.8%, other non-operating expense rose 213%, and non-cash asset impairments totaled $3.2M.

• ·FY2025 revenue drivers: volume/mix +$97M (13.5%), price -$1M (-0.2%), smoothie bowls exit -$2M (-0.3%)
• ·FY2024 vs FY2023: revenues up 15.5% to $724M, but gross margin declined 0.4pt to 13.3%; SG&A flat at +1.0%
• ·Gross profit FY2025 improvements included $16M lower start-up costs and $14M higher volumes, offset by $10M labor/infrastructure investments and $2M depreciation
• ·Operating income FY2025 aided by $6M lower op ex (incl. consultancy savings) and $4M lower stock comp, but hurt by $3M impairments and $2M prior gain reversal
• ·Midlothian, Texas facility: $1M savings from lower wastewater charges

04-03-2026

Crown Holdings, Inc. (NYSE: CCK) elected packaging industry executive Michael P. Doss to its Board of Directors, effective March 3, 2026, expanding the board to ten members. Doss, former President, CEO, and Director of Graphic Packaging Corporation (2016-2025), also serves as a director at Regal Rexnord Corporation since 2023. Chairman and CEO Timothy J. Donahue praised Doss's expertise in packaging, manufacturing, and governance.

• ·Announcement dated February 26, 2026.
• ·SEC 8-K filing date: March 04, 2026.
• ·Doss's prior roles at Graphic Packaging span 25+ years.

04-03-2026

Coca-Cola Europacific Partners plc (CCEP) announced that Independent Non-executive Director Guillaume Bacuvier will retire from the Board at the conclusion of the Annual General Meeting (AGM) on 28 May 2026, after serving since January 2024. Uvashni Raman, current CFO of Booking.com, has been appointed as a new Independent Non-executive Director effective the same date, bringing extensive financial and operational experience from roles at Adevinta, Naspers, South 32, and BHP. The changes are part of the Board's succession planning.

• ·Guillaume Bacuvier served on the Remuneration Committee.
• ·Uvashni Raman's prior roles: Group CFO of Adevinta (2019-2023), CFO for Naspers Video Entertainment Division (2016-2019), South 32 Australian Region (2015-2016), multiple roles at BHP.
• ·CCEP listed on Euronext Amsterdam, NASDAQ, London Stock Exchange, Spanish Stock Exchanges; constituent of NASDAQ 100 and FTSE 100.

04-03-2026

Ocugen reported Q4 and FY 2025 financial results with R&D expenses increasing to $10.7M (Q4, +29% YoY) and $39.8M (FY, +24% YoY), G&A expenses slightly down to $6.1M in Q4 (-3% YoY) but up to $27.6M FY (+3% YoY), wider net losses ($0.06/share Q4 vs $0.05, $0.23/share FY vs $0.20), and cash declining sharply to $18.9M from $58.8M, though bolstered by $22.5M raised in Jan 2026 extending runway to Q4 2026. Significant clinical progress includes completed enrollment in OCU400 Phase 3 liMeliGhT trial (140 patients, topline Q1 2027) and positive OCU410 Phase 2 preliminary data (46% lesion growth reduction vs control, p=0.015). OCU410ST Phase 2/3 nearing enrollment completion with interim data Q3 2026.

• ·OCU410ST Phase 2/3 GARDian trial enrollment nearing completion in Q1 2026; interim data Q3 2026, topline Q2 2027
• ·OCU400 first regional licensing agreement with Kwangdong for Korea (upfront, milestones, royalties)
• ·OCU200 Phase 1/2 no SAEs or AEs related to product to date; enrollment completion Q1 2026
• ·OCU500 Phase 1 to initiate Q2 2026 by NIAID
• ·Total liabilities $55.7M as of Dec 31, 2025 vs $52.8M prior year

04-03-2026

Joint definitive proxy statement for the annual stockholder meeting of nine Cohen & Steers closed-end funds, including Cohen & Steers Real Estate Opportunities & Income Fund (RLTY), to elect three Directors for each Fund for terms ending at the 2029 annual meeting. The meeting is scheduled for April 22, 2026, at 10:00 a.m. ET in New York, NY, with a record date of February 13, 2026. No financial performance data or period-over-period comparisons are provided in the filing.

• ·Proxy materials first mailed on or about March 11, 2026
• ·Quorum requires holders of a majority of shares outstanding for each Fund
• ·Meeting may be adjourned up to 120 days after record date if quorum not present
• ·RLTY fiscal year end: March 15; PTA fiscal year end: October 31; others December 31

04-03-2026

Regional Health Properties, Inc. and Erin Property Holdings, LLC entered into Forbearance Agreements with Cadence Bank, N.A. on February 27, 2026 (effective February 1, 2026) due to defaults on the USDA Note ($5M principal) and SBA Note ($800K principal), both due July 27, 2036. The agreements require immediate payments of $21,047.76 (one-time forbearance) and $6,764.21 (USDA renewal fee), with monthly principal and interest payments during the Forbearance Period ending February 1, 2027, after which full balances including late fees are due. This provides temporary relief from remedies but highlights ongoing payment defaults and obligations.

• ·Forbearance Agreements attached as Exhibits 10.1 (USDA Note) and 10.2 (SBA Note).
• ·Notes issued pursuant to Security Agreement dated July 27, 2011.
• ·During Forbearance Period, interest continues to accrue per original Note terms.

04-03-2026

AmBase Corporation entered into a Litigation Funding Agreement (RAB 2026 LFA) with CEO Richard A. Bianco for up to $6M to fund operations and the 111 West 57th Property litigation, including conversion of $4M existing promissory notes and $2M in new cash infusions. BARC Investments LLC simultaneously converted its $2M note (plus ~$200k accrued interest) into a pari-passu LFA (BARC 2026 LFA). However, these deals dilute future litigation proceeds significantly, with funders prioritized for up to 1.8x multiples on funding amid persistent going concern qualifications and uncertain litigation outcomes requiring additional capital.

• ·Accrued interest on RAB and BARC notes matures in 3 years from end of execution month.
• ·Funding approved by Special Committee of one independent director, advised by outside counsel.
• ·Litigation funding terms evaluated as fair despite prior unsuccessful third-party funding search.
• ·Company continues to seek additional capital; no assurance of success or litigation recovery.

04-03-2026

Moody’s Corporation's 2026 Proxy Statement outlines the virtual Annual Meeting of Stockholders on April 14, 2026, at 9:30 a.m. EDT, with stockholders voting on electing ten director nominees for one-year terms, ratifying KPMG LLP as independent auditors for 2026, and an advisory resolution on executive compensation. The record date is February 18, 2026, and proxy materials were made available starting March 4, 2026. No financial performance metrics or period-over-period comparisons are detailed in the provided filing content.

• ·Annual Meeting held virtually at www.virtualshareholdermeeting.com/MCO2026
• ·Company address: 7 World Trade Center, 250 Greenwich Street, New York, New York 10007
• ·Investor Relations contact: ir@moodys.com or (212) 553-0300
• ·2025 Annual Report covers year ended December 31, 2025

04-03-2026

Old Second Bancorp, Inc. (OSBC) announced on March 4, 2026, its intention to redeem $30M aggregate principal amount of its 3.50% Fixed-to-Floating Rate Subordinated Notes due 2031 on April 15, 2026, at 100% of principal plus accrued and unpaid interest. The company has received non-objection from the Federal Reserve Bank of Chicago for the redemption. Following the redemption, $30M aggregate principal amount of the Notes will remain outstanding.

• ·Notes originally issued on April 6, 2021.
• ·Redemption to be made only upon presentation and surrender of Notes to the Paying Agent.
• ·Interest on redeemed Notes will cease to accrue on and after April 15, 2026.

04-03-2026

Texas Instruments Incorporated (TXN) filed Definitive Additional Proxy Materials (DEFA14A) on March 04, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required. No substantive financial or operational details are provided in the available content.

04-03-2026

Sensus Healthcare reported revenues of $27.5M for FY 2025, a 34% YoY decline from $41.8M, resulting in a net loss of $7.7M compared to net income of $6.6M in FY 2024, driven by higher R&D ($7.8M, +85%) and selling expenses ($6.5M, +31%). While cash and equivalents remained stable at $22.1M and operating cash flow improved to positive $0.5M from negative $0.8M, total assets fell 15% to $53.0M amid a sharp 69% drop in accounts receivable to $6.0M.

• ·Stock repurchases of 50,360 shares for $0.3M in FY 2025.
• ·Deferred tax assets increased to $4.1M from $2.2M.
• ·Total stockholders’ equity declined to $48.1M from $55.8M.
• ·Company notes potential need for additional funding in future.

04-03-2026

Sturm, Ruger & Company, Inc. (RGR) hosted a post-earnings release conference call and webcast on March 2, 2026, to discuss its 2025 financial results, with the transcript furnished as Exhibit 99.1 under Regulation FD Disclosure. The information is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act. A replay is available on the company's website at Ruger.com/corporate.

• ·Securities registered: Common Stock, $1 par value (RGR) on NYSE; Common Stock Purchase Rights (N/A) on NYSE.
• ·Filing signed by Thomas A. Dineen on March 4, 2026.

04-03-2026

On March 4, 2026, Sirius XM Holdings Inc. issued a press release announcing the pricing terms of a previously announced cash tender offer by its subsidiary Sirius XM Radio LLC for any and all of its outstanding 3.125% Senior Notes due 2026. The press release is attached as Exhibit 99.1 and incorporated by reference.

• ·Filing includes Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits) with Exhibit 99.1 as the press release and Exhibit 104 as Inline XBRL cover page.

04-03-2026

Westlake Chemical Partners LP's 2025 annual results showed total net sales of $1.17B, up 2.7% YoY from $1.14B, with net sales to Westlake rising 8.7% to $1.03B while third-party co-products sales declined 28% to $133M; the increase was driven by 10.4% higher average sales prices offsetting an 8.2% volume drop. However, gross profit fell 17% to $348M amid 50.7% higher natural gas fuel costs and 32.8% higher ethane feedstock costs, resulting in income from operations down 18% to $320M, net income to LP down 22% to $48.7M (or $1.38 per unit from $1.77), and MLP distributable cash flow down 20% to $53.4M. EBITDA decreased 11% to $450M, and net cash from operations dropped sharply 42% to $280M.

• ·Property, plant and equipment, net declined to $886M from $904M.
• ·Long-term debt payable to Westlake stable at $400M.
• ·Distributions to unitholders remained flat at approximately $66M.
• ·Cash and cash equivalents ended at $44M, down from $58M.

04-03-2026

On March 4, 2026, Ameren Corporation sold $400 million principal amount of its 5.00% Senior Notes due 2036, receiving net proceeds of approximately $396.6 million before expenses. The offering was conducted pursuant to a prospectus supplement dated February 26, 2026, under an effective S-3 registration statement from October 13, 2023.

• ·Underwriting Agreement dated February 26, 2026, with BNY Mellon Capital Markets, LLC, J.P. Morgan Securities LLC, RBC Capital Markets, LLC, U.S. Bancorp Investments, Inc., and Wells Fargo Securities, LLC.
• ·Registration Statement on Form S-3 (File No. 333-274977) effective October 13, 2023.

04-03-2026

At the Jack in the Box Inc. annual shareholder meeting on February 27, 2026, all ten director nominees were elected and four proposals passed, including ratification of KPMG LLP as auditors for FY ending September 27, 2026 (87% support), advisory approval of executive compensation, amendment to the 2023 Omnibus Incentive Plan to increase shares available (62% support), and ratification of the Stockholder Protection Rights Agreement extending it to July 1, 2028. However, significant shareholder opposition was evident, with say-on-pay receiving only 65% support, the incentive plan amendment 62%, the Rights Agreement 70%, and director David Goebel facing a near-split vote (46% for vs 46% against).

• ·All director elections used plurality voting, allowing election despite opposition (e.g., David Goebel: 7,171,171 For, 7,010,617 Against, 1,213,528 Abstain)
• ·Broker non-votes: 561,088 across proposals 3-5

04-03-2026

For the three months ended January 31, 2026, Highwater Ethanol reported revenues of $34.4M, up 3.6% YoY from $33.2M, driven by strong 27% growth in corn oil sales to $3.3M, while modified distillers grains sales declined 8% to $1.5M and dried distillers grains remained flat at $3.8M. Gross profit surged to $3.5M from $1.0M YoY due to lower COGS, yielding operating income of $2.1M versus a prior loss, but net income fell to $5.6M from $8.3k primarily due to timing of $3.3M tax credits. Cash and total assets declined QoQ to $19.8M and $87.4M, respectively, amid $6.7M member distributions.

• ·Operating expenses increased to $1.4M from $1.3M YoY.
• ·Net cash provided by operating activities was $4.3M versus $(9.7M) YoY.
• ·Capital expenditures of $1.4M in the quarter.
• ·Distributions declared per unit: $1,400 (2026) vs $1,700 (2025).
• ·Net income per unit: $1,180.54 (2026) vs $1.75 (2025).

04-03-2026

First Financial Corp (THFF) reported 2025 net income of $79.2M, up 67.5% YoY from $47.3M, fueled by 25.6% growth in net interest income to $219.9M and a reduced provision for credit losses to $8.2M from $16.2M. However, deposits declined 3.6% YoY to $4.55B amid rising borrowings to $480.7M, non-interest expenses increased 7.3% to $154.9M, and securities holdings fell to $1.15B. Total assets grew 3.6% to $5.76B, loans expanded 5.7% to $4.06B, ROE rose to 13.3% from 8.8%, and cash dividends increased to $2.04 per share.

• ·Securities declined to $1.15B from $1.20B YoY.
• ·Non-interest income slightly down to $42.0M from $42.8M.
• ·Cash dividends declared per share increased quarterly, reaching $0.56 in Q4 2025 from $0.51 in Q4 2024.
• ·Stock price high reached $61.25 in Q4 2025, up from $50.61 in Q4 2024.

04-03-2026

On March 4, 2026, First Keystone Corporation, parent of First Keystone Community Bank, issued a press release announcing the declaration of its first quarter dividend. The press release is filed as Exhibit 99.1. No specific dividend amount or other financial metrics were disclosed in the filing.

04-03-2026

Transglobal Management Group, Inc. (TMGI), formerly Marquie Group, Inc., filed a Form S-1 registration statement on March 4, 2026, to register securities for a potential public offering under the Securities Act of 1933. The Florida-based radio broadcasting company discloses balance sheet periods ending May 31, 2023, 2024, and 2025, along with extensive related-party transactions including payables to CEO's wife and mother, and numerous notes payable and convertible notes. No specific financial metrics such as revenue or net income are detailed in the filing excerpt, highlighting operational complexity with multiple lenders and service providers.

• ·Fiscal year end: May 31
• ·State of incorporation: Florida
• ·EIN: 262091212
• ·SIC: Radio Broadcasting Stations [4832]
• ·Business address: 7901 4th St. N., Suite 4887, St. Petersburg, FL 33702
• ·SEC file number: 333-293995
• ·Name change from Marquie Group, Inc. to Transglobal Management Group, Inc.: April 15, 2019
• ·Numerous related-party notes payable (e.g., to CEO's wife, mother) and 28+ individual notes payable as of May 31, 2025
• ·13 convertible notes and multiple lenders (A, B, C, D, others) referenced

04-03-2026

Regen BioPharma, Inc. issued 77,849,847 common shares between February 4 and February 27, 2026, to satisfy $53,474 in principal convertible indebtedness, $4,249 in accrued interest, and $11,000 in fees, totaling approximately $68,723 in obligations. This unregistered issuance under Section 4(a)(2) was conducted directly through management without underwriters or commissions. As of March 3, 2026, the company has 212,318,424 common shares issued and outstanding, representing significant dilution for existing shareholders.

• ·Shares issued pursuant to Section 4(a)(2) of the Securities Act with no underwriters, commissions, advertisement, or general solicitation.
• ·Issuance period: February 4 to February 27, 2026.

04-03-2026

Oil States International, Inc. (OIS) reported FY2025 revenues of $669M, down 3.4% YoY from $693M, driven by an 8.4% increase in Products to $436M but a 19.8% decline in Services to $233M; Offshore Manufactured Products grew 8.3% to $431M with operating income up 6% to $69M, while Completion and Production Services fell 30% but swung to $4M profit from a $23M loss. The company posted a net loss of $109M versus $11M in 2024, primarily due to $100M in impairments (up from $25M) leading to an operating loss of $98M, though operating cash flow rose 129% to $105M and long-term debt dropped to $1.7M from $125M.

• ·Total assets declined to $883M from $1,005M YoY.
• ·Stockholders’ equity fell to $573M from $681M, impacted by $109M net loss and $17M stock repurchases.
• ·Inventory impairment of $21M in FY2025.
• ·Treasury stock purchases totaled $17M in FY2025.

04-03-2026

Voya Credit Income Fund (CIF) has issued a proxy statement for a special virtual shareholder meeting on May 19, 2026, at 1:00 p.m. (MST), seeking approval to amend its fundamental investment restriction to permit purchasing, selling, or holding real estate and commodities to the extent allowed by law, providing greater investment flexibility. The Board unanimously approved the proposal on January 22, 2026, and recommends voting FOR; shareholders of record as of February 23, 2026, are eligible to vote, with proxies due by May 18, 2026. No financial performance data or period comparisons are provided in the filing.

• ·Meeting held virtually only at https://www.viewproxy.com/voyafunds/broadridgevsm/; physical attendance not possible
• ·Voting methods: Internet (www.proxyvote.com/voya), telephone, mail, or virtually at meeting
• ·Solicitor contact for questions: 1-888-290-2487
• ·Fund address: 7337 East Doubletree Ranch Road, Suite 100, Scottsdale, Arizona 85258-2034; Phone: 1-800-992-0180

04-03-2026

UNL's net asset value per share declined 9.6% YoY to $7.34 at December 31, 2025, from $8.12, amid a 20.9% drop in average daily total net assets to $14.3M and ongoing net loss of $971k (narrowed 20% from $1.2M in 2024). While Partners’ Capital remained stable at $18.7M with slight 0.2% growth, total assets fell 1.2% to $18.8M and dividend/interest income decreased 35% to $586k with yield down to 4.09%. Commodity futures trading showed mixed results with $1.86M realized gains but $3.19M unrealized losses.

• ·Unrealized loss on open commodity futures contracts: $(2.07M) at Dec 31 2025 vs gain $1.12M at Dec 31 2024.
• ·Realized gain on closed commodity futures: $1.86M in 2025 vs loss $(7.41M) in 2024.
• ·Net cash from operating activities: $1.95M in 2025 vs $(6.33M) in 2024.
• ·Tax risk: Potential reallocation of income/gain items by IRS could make UNL liable for federal income tax.

04-03-2026

Aimfinity Investment Corp. I issued an interest-free promissory note for $500 to I-Fa Chang, its CEO and Chairman, dated February 28, 2026. The note is due upon consummation of the pending Business Combination with Docter, Inc. (per merger agreement dated October 13, 2023) or the company's expiry, with option to convert into PubCo ordinary shares at $10 per share. This represents a minor insider financing with no performance metrics or period comparisons available.

• ·Note is non-interest bearing unless overdue (then at prevailing short-term US Treasury Bill rate)
• ·Conversion: outstanding principal divided by $10.00 per PubCo share; no fractional shares (cash in lieu)
• ·Governed by New York law; payable from non-Trust Account funds if no Business Combination

04-03-2026

RemSleep Holdings Inc. (RMSL) reported the passing of founder Thomas Wood, its Chairman and CEO, on February 26, 2026, creating vacancies in those roles. Effective March 2, 2026, Anita Michaels was elected Chairman of the Board, Jeffrey Marshall was appointed CEO and Director with an employment agreement including up to 7% equity incentives, and Alexander Johnson was appointed Director. The transition emphasizes continuity with Michaels retaining interim financial oversight amid no immediate financial disruptions noted.

• ·Anita Michaels, 72, is Thomas Wood's sister and inherited his ownership including super voting preferred shares.
• ·Jeffrey Marshall, 48, founder of HPM Marketing LLC, will continue limited outside consulting.
• ·Alexander Johnson, 52, previously consulted for the Company on capital formation and governance.

04-03-2026

Bankwell Financial Group, Inc. reported strong recovery in 2025 with net income surging 260% YoY to $35.2M from $9.8M in 2024, fueled by net interest income growth of 19% to $98.9M, total revenue up 25% to $108.3M, and provision for credit losses dropping sharply to $1.0M from $22.6M. Asset quality improved markedly with nonperforming assets to total assets at 0.49% versus 1.88% in 2024, and return on average assets rose to 1.09% from 0.31%. However, noninterest expenses increased 15% YoY to $58.8M due to higher salaries and professional services, while efficiency ratio improved modestly to 54.1% from 57.9%.

• ·Provision for credit losses declined to $1.0M in 2025 from $22.6M in 2024.
• ·Net (recoveries) charge-offs to average loans at -0.01% in 2025 vs 0.81% in 2024.
• ·Tier 1 capital to risk-weighted assets for Bankwell Bank at 11.87% in 2025 (up from 11.64%).
• ·Gains and fees from sales of loans jumped to $5.1M in 2025 from $0.5M in 2024.

04-03-2026

CreditRiskMonitor.com, Inc. (CRMZ) announced the termination of Chief Accounting Officer David Reiner's position on February 27, 2026, with his last day being the same date. The company thanked Mr. Reiner for his service. The filing was signed by CEO and President Michael I. Flum on March 4, 2026.

04-03-2026

Columbus McKinnon Corporation (CMCO) filed an 8-K/A on March 4, 2026, amending its prior 8-K to include audited consolidated financial statements of acquired Kito Crosby Limited for years ended December 31, 2024 and 2023 (audited by Deloitte & Touche LLP), unaudited interim condensed consolidated financial statements as of September 30, 2025 and December 31, 2024 (for three and nine months ended September 30, 2025 and 2024), and unaudited pro forma condensed combined financial information reflecting the acquisition. The acquisition was completed on February 3, 2026, pursuant to a Stock Purchase Agreement dated February 10, 2025. No specific financial metrics or period-over-period changes are detailed in the filing text itself.

• ·Original 8-K filed February 4, 2026
• ·Date of earliest event reported: January 29, 2026
• ·Kito Crosby audited FS report dated June 13, 2025
• ·Interim FS incorporated by reference from 8-K dated January 14, 2026

04-03-2026

Keros Therapeutics, Inc. updated its corporate presentation on March 4, 2026, for use in meetings with investors, analysts, and others. The presentation is available on the Company's website and attached as Exhibit 99.1 to this Form 8-K filing. No financial results or material updates were disclosed in the filing itself.

• ·Securities registered: Common Stock ($0.0001 par value, KROS) and Preferred Share Purchase Rights on Nasdaq.
• ·Company address: 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.

04-03-2026

On March 2, 2026, Alignment Healthcare, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC and a selling stockholder for the underwritten offering of 13,167,733 shares of the Company's common stock. The offering closed on March 4, 2026, pursuant to a Registration Statement on Form S-3ASR (File No. 333-293928) filed that day, with the Company receiving no proceeds from the sale. The agreement includes customary representations, warranties, covenants, and indemnification obligations.

• ·Registration Statement File No. 333-293928 filed March 2, 2026
• ·Common stock par value $0.001 per share, traded as ALHC on NASDAQ

04-03-2026

MYR Group Inc. filed its DEF 14A Proxy Statement on March 4, 2026, for the virtual 2026 Annual Meeting of Shareholders on April 23, 2026, at 8:00 a.m. Mountain Time, with a record date of February 27, 2026. Shareholders will vote on electing eight director nominees for one-year terms, advisory approval of named executive officer compensation, and ratification of the independent registered public accounting firm. The statement includes sections on corporate governance, director nominees, executive compensation discussion and analysis, pay versus performance, and audit matters.

• ·Virtual meeting accessible at virtualshareholdermeeting.com/MYRG2026; opens at 7:45 a.m. Mountain Time.
• ·Shareholders of record as of February 27, 2026, entitled to vote.
• ·Proxy materials available at investor.myrgroup.com/financial-information/annual-reports and proxyvote.com.
• ·Includes Pay Versus Performance disclosure and compensation data for years 2021-2025 for PEO (Swartz) and average Non-PEO NEOs (Johnson, Cooper, Fry, Waneka).
• ·2025 Annual Report on Form 10-K referenced.

04-03-2026

Sight Sciences reported fourth quarter 2025 total revenue of $20.4 million, up 7% YoY, with Interventional Glaucoma revenue increasing 5% to $19.7 million and Interventional Dry Eye surging from $0.3 million. However, full year 2025 revenue declined 3% to $77.4 million, as Interventional Glaucoma remained flat at $75.7 million and Interventional Dry Eye dropped to $1.6 million from $4.0 million. Operating expenses fell 13% to $103.8 million for the year, improving net loss to $38.4 million from $51.5 million, with 2026 guidance projecting revenue growth of 6-14% to $82-88 million.

• ·Q4 2025 cash usage: $0.4 million.
• ·FY 2026 Interventional Glaucoma guidance: $77-81 million (+2-7%).
• ·FY 2026 Interventional Dry Eye guidance: $5-7 million.
• ·FY 2026 adjusted operating expenses guidance: $93-96 million (+6-9%).
• ·Cash and cash equivalents: $91.965 million as of Dec 31, 2025 (down from $120.357 million at Dec 31, 2024).

04-03-2026

Janus International Group reported full-year 2025 revenue of $884.2M, down 8.3% YoY from $963.8M, driven by Self-Storage declines of 9.7% and Commercial/Other down 5.1%, with Adjusted EBITDA falling 19.3% to $168.2M (19.0% margin vs. 21.6%). Q4 2025 revenue decreased 1.9% to $226.3M, with Self-Storage flat at -0.4% but Commercial/Other down 5.0%; however, Adjusted EBITDA rose 7.5% to $37.2M with a 140bps margin expansion to 16.4%. The company provided 2026 guidance of $940-980M revenue (+8.6% at midpoint) and $165-185M Adjusted EBITDA (+4.0%), repurchased 1.9M shares for $16M, and announced the acquisition of Kiwi II Construction.

• ·Conference call scheduled for March 5, 2026 at 10:00 a.m. Eastern time.
• ·Inorganic revenue guidance for 2026: $90-100M included in total revenue guidance.
• ·Adjusted EPS for FY2025: $0.60 vs. $0.72 in FY2024.

04-03-2026

Everspin Technologies reported Q4 2025 total revenue of $14.8M, up 12% YoY from $13.2M, driven by MRAM product sales growth of 23% to $13.5M, though licensing and royalty revenue declined 41% to $1.3M and gross margin slipped 0.5 ppts to 50.8%. Full year 2025 revenue increased 10% YoY to $55.2M with product sales up 14% to $48.3M, but licensing revenue fell 16% to $6.9M, gross margin declined 0.6 ppts to 51.2%, operating expenses rose 5% to $34.8M, and GAAP net loss was $0.6M versus $0.8M income in 2024. Cash and equivalents grew to $44.5M from $42.1M, supported by 238 design wins versus 178 in 2024.

• ·Q1 2026 outlook: total revenue $14.0M to $15.0M; GAAP net loss per diluted share ($0.03) to net income $0.02; Non-GAAP net income per diluted share $0.07 to $0.12.
• ·GAAP net income flat at $1.2M for Q4 2025 vs Q4 2024.
• ·Q4 2025 revenue up 5% QoQ from Q3 2025 $14.1M.
• ·Total assets increased to $84.6M from $77.8M YoY.
• ·Operating cash flow for full year 2025: $10.0M vs $7.1M in 2024.

04-03-2026

Smith Micro reported Q4 FY2025 revenue of $4.0M, down 20% YoY from $5.0M, and FY2025 revenue of $17.4M, down 16% YoY from $20.6M, with gross margins improving slightly to 76.4% and 74.1% respectively. GAAP net losses narrowed to $4.7M ($0.20/share) in Q4 from $4.4M ($0.25/share) and to $30.1M ($1.46/share) for FY from $48.7M ($3.94/share), with non-GAAP losses also improving. William W. Smith Jr. is transitioning to Executive Chairman at month-end, with Tim Huffmyer becoming President and CEO, supported by $4M funding from Smith and his wife.

• ·Total assets declined to $25.0M as of Dec 31, 2025 from $48.0M as of Dec 31, 2024.
• ·Goodwill fully impaired to $0 as of Dec 31, 2025 from $11.1M as of Dec 31, 2024.
• ·Accounts receivable net declined to $1.8M as of Dec 31, 2025 from $5.7M as of Dec 31, 2024.
• ·Reverse stock split (1-for-8) effective April 10, 2024.
• ·Investor conference call on March 4, 2026 at 4:30 p.m. ET.

04-03-2026

BillionToOne reported Q4 2025 total revenue of $96.1M, up 113% YoY from $45.1M, and full year 2025 revenue of $305.1M, up 100% YoY from $152.6M, driven by prenatal revenue growth of 99% in Q4 and 90% FY, and oncology surging 735% in Q4 and 748% FY. However, Clinical Trial Support and Other Services revenue declined 18% FY YoY to $3.1M, while operating expenses rose 56% in Q4 and 50% FY. The company achieved Q4 operating income of $10.3M (vs. $11.7M loss prior) and FY operating income of $16.0M (vs. $47.1M loss), raised 2026 revenue guidance to $430M-$445M (41-46% growth), and holds $496M in cash.

• ·Gross profit Q4 2025: $68.6M (71% margin) vs. $25.7M (57% margin) Q4 2024.
• ·FY 2025 gross margin: 68% vs. 53% in 2024.
• ·Q4 2025 net income available to common shareholders: $4.4M ($0.11 per diluted share) vs. net loss $11.5M ($1.13 per diluted share).
• ·FY 2025 net cash flow excluding IPO proceeds: $12.5M.
• ·Overall ASP Q4 2025: $561 vs. $382 Q4 2024 (+47%).
• ·New products launched: Red Blood Cell and Platelet Fetal Antigen NIPT in Feb 2026; Northstar PGx and Northstar Select CH in Q1 2026.
• ·Conference call: March 4, 2026 at 1:30pm PT / 4:30pm ET.

04-03-2026

Aware, Inc. reported Q4 2025 revenue of $4.7M, down 2.8% YoY from $4.8M due to a decline in perpetual license revenue, though partially offset by increases in maintenance and services; full-year 2025 revenue was $17.3M, down 0.6% YoY from $17.4M. Net loss widened to $1.5M ($0.07/share) in Q4 and $5.9M ($0.28/share) for the year, driven by higher R&D and operating expenses, while adjusted EBITDA loss remained flat at $0.8M in Q4 but worsened to $4.6M annually. Operational highlights included new federal deployments, partnerships, certifications, and leadership hires, with recurring revenue growing 4.7% YoY in Q4 to $3.5M and 5.6% for the year to $12.6M.

• ·Software licenses revenue: Q4 $2.1M (down from $2.5M YoY), FY $7.3M (down from $7.7M YoY)
• ·R&D expenses: Q4 $2.3M (up from $1.8M YoY), FY $8.3M (up from $7.8M YoY)
• ·Webcast scheduled for March 4, 2026 at 5:00 p.m. ET

04-03-2026

ImmuCell Corporation reported 2025 product sales of $27.6 million, up 4.3% YoY from $26.5 million, with gross margin expanding to 41.4% from 30% due to higher volumes (380,000 units/month vs. 345,000) and efficiencies, resulting in net operating income of $1.6 million versus a $1.6 million loss in 2024. However, the company posted a net loss of $1.0 million, improved from $2.2 million but driven by one-time charges including a $2.7 million Re-Tain asset write-down, $651,000 colostrum inventory write-down, and $297,000 CEO transition expenses; Q4 saw a net loss of $2.8 million versus a $0.5 million profit. Balance sheet showed stable cash at $3.8 million but a slight decline in stockholders' equity to $27.1 million from $27.5 million.

• ·EBITDA for 2025 was $2.2 million vs. $1.1 million in 2024.
• ·Cash from operating activities improved to $2.5 million in 2025 from $0.4 million in 2024.
• ·Total assets decreased to $42.5 million as of Dec 31, 2025 from $45.1 million as of Dec 31, 2024.
• ·Conference call scheduled for March 5, 2026 at 9:00 AM ET.

04-03-2026

ChargePoint reported Q4 FY2026 revenue of $109.3M, up 7% YoY, driven by 10% growth in networked charging systems and 11% in subscription revenue, with GAAP gross margin improving to 31% from 28%. However, full FY2026 revenue declined 1% YoY to $411.2M due to an 8% drop in networked charging systems despite 13% subscription growth, and while GAAP net loss narrowed to $220.2M from $277.1M, adjusted EBITDA loss widened slightly in Q4.

• ·Cash and cash equivalents: $141.6M as of January 31, 2026.
• ·Q1 FY2027 revenue guidance: $90M to $100M.
• ·ChargePoint network connects to over 1.37M charging ports worldwide and has facilitated 21B electric miles.
• ·Appointed Jaser Faruq as Chief Product and Software Officer.

04-03-2026

Horizon Bancorp, Inc. announced the elimination of the Chief Administration Officer position at the company and its subsidiary Horizon Bank, effective March 31, 2026, leading to the departure of Mark E. Secor, Executive Vice President and Chief Administration Officer, to pursue other opportunities. The departure is not related to any disagreement on financial, accounting, or other matters. In connection, the company expects to provide Mr. Secor with severance of one week of pay per full year of service (maximum 13 weeks) based on his then-current weekly rate, plus a pro-rated 2026 Executive Officer Bonus at target, subject to a seven-day revocation period.

• ·Announcement made on March 3, 2026
• ·SEC filing dated March 4, 2026
• ·Includes customary general release of claims, non-disclosure, non-disparagement, and confidentiality covenants

04-03-2026

CervoMed Inc. filed a Form 8-K on March 04, 2026, under Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific details on the nature of the disclosures, events, or exhibits are provided in the filing metadata. No quantitative metrics, financial impacts, or scheduled events are mentioned.

04-03-2026

Insulet Corporation entered into a severance agreement and release with its former Chief Financial Officer, Ana M. Chadwick, on February 27, 2026. The agreement implements previously disclosed severance and post-termination benefits without any material changes or additional compensation terms. The filing was made on March 4, 2026, signed by Patricia K. Dolan, Vice President and Secretary.

• ·Severance Agreement references Company's Form 8-K filed September 16, 2025, Amended and Restated Executive Severance Plan filed April 28, 2025, and Confidentiality, Non-Solicit, Non-Compete, and IP Assignment Agreement dated April 7, 2024.
• ·Includes standard provisions for release of claims, mutual non-disparagement, and compliance with prior agreements.

04-03-2026

Grocery Outlet Holding Corp. reported FY ended January 3, 2026 net sales of $4.69B, up 7.3% YoY from $4.37B, with gross profit rising 7.4% to $1.42B and adjusted EBITDA improving to $254M from $237M. However, the company recorded an operating loss of $222M versus prior-year income of $78M, net loss of $225M versus $39M profit, driven by $149M goodwill impairment, $114M long-lived assets impairment, restructuring charges up 189% to $46M, and SG&A expenses up 8.5%; comparable store sales increased only 0.5% (flat, down from 2.7%). Store count reached 570, up from 533, but new stores opened fell to 42 from 67.

• ·GAAP diluted EPS: $(2.30) vs $0.40 prior year; Adjusted diluted EPS flat at $0.76 vs $0.77.
• ·EBITDA: $(91M) vs $187M prior year.
• ·Adjusted net income: $75M vs $76M prior year (flat).

04-03-2026

On February 26, 2026, the Board of Directors of WhiteHorse Finance, Inc., at the recommendation of the Audit Committee, dismissed Crowe LLP as its independent registered public accounting firm effective upon issuance of the FY ended December 31, 2025 financial statements and appointed Deloitte & Touche LLP for the fiscal year ending December 31, 2026. Crowe had served since 2006 with no disagreements, reportable events, or qualified audit opinions for fiscal years 2023 and 2024. No prior consultations occurred with Deloitte regarding accounting matters.

• ·Crowe served as auditor since 2006 due to affiliated fund relationships.
• ·Company provided Crowe with draft Form 8-K; Crowe's agreeing letter dated March 4, 2026 attached as Exhibit 16.1.

04-03-2026

On February 26, 2026, Wheeler Real Estate Investment Trust, Inc. issued 60,000 shares of common stock in exchange for 4,000 shares of Series B Convertible Preferred Stock and 2,000 shares of Series D Cumulative Convertible Preferred Stock from an unaffiliated holder, with the preferred shares retired and no cash proceeds received. Separately, the Company issued 80,000 shares of Series D Preferred Stock to an unaffiliated investor in exchange for 120,000 shares of subsidiary Cedar Realty Trust, Inc.'s Series C Cumulative Redeemable Preferred Stock, which were subsequently retired. Both transactions relied on Securities Act exemptions and do not constitute public offerings.

• ·Transactions relied on Section 3(a)(9) exemption for common stock exchange and Section 4(a)(2) for Series D issuance as non-public offerings.
• ·Each exchange transaction involved 30 shares of Common Stock for 2 shares of Series B Preferred and 1 share of Series D Preferred.

04-03-2026

Verastem, Inc. reported total revenue of $30.9M for the year ended December 31, 2025, driven by $30.9M in new product revenue, up significantly from $10M in 2024 from the COPIKTRA license sale to Secura. However, operating expenses increased 61% YoY to $201M, with R&D up 41% to $114.6M and SG&A surging 86% to $81.1M, leading to a widened net loss of $209.5M from $130.5M in 2024. The company highlighted risks including regulatory approval delays, commercialization challenges, and potential impacts on milestone payments and royalties from Secura.

• ·Optional third tranche purchase of up to $50M Notes available prior to December 31, 2026, contingent on trailing six-month net sales of avutometinib and defactinib reaching at least $55M.
• ·Cost of sales - product: $4.6M in 2025; Cost of sales - intangible amortization: $0.7M in 2025.
• ·Loss from operations worsened to $(170.1M) in 2025 from $(115.0M) in 2024.

04-03-2026

Aimei Health Technology Co., Ltd issued a promissory note dated March 4, 2026, with a principal amount of $34,330.96, payable equally to Aimei Investment Ltd and United Hydrogen Group Inc ($17,165.48 each) upon consummation of a Business Combination. The note carries no interest and may be converted into private units at $10.00 per unit if notice is provided at least two business days prior to the Business Combination closing. No period-over-period data is available.

• ·Note payable only from funds other than Trust Account Funds if no Business Combination is consummated.
• ·Governed by New York law.
• ·Payees waive claims against trust account funds from IPO proceeds.

04-03-2026

On February 26, 2026, Lipocine Inc. filed a prospectus supplement under its existing Sales Agreement with A.G.P./Alliance Global Partners, originally entered on April 26, 2024, to offer and sell up to $50M of common stock from time to time. The filing includes a legal opinion from Dorsey & Whitney LLP validating the shares. No sales have been reported yet, representing a potential equity financing event.

• ·Commission File No. 001-36357
• ·IRS Employer Identification Number: 99-0370688
• ·Principal executive offices: 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108

04-03-2026

Rigetti Computing reported Q4 2025 total revenues of $1.9 million and full-year 2025 revenues of $7.1 million, alongside substantial losses including a Q4 operating loss of $22.6 million, Q4 GAAP net loss of $18.2 million, and FY GAAP net loss of $216.2 million. While financial performance remains weak with low revenues relative to losses, the company holds a strong cash position of $589.8 million and secured significant orders such as $8.4 million from C-DAC for a 108-qubit system and $5.7 million in Novera on-premises systems. Technological progress includes achieving 99.9% two-qubit gate fidelity at 28 nanosecond gate speed and advancements in chiplet-based 108-qubit systems.

• ·Japanese research organization Novera QPU order with delivery expected in April 2026
• ·C-DAC 108-qubit system deployment expected in second half of 2026
• ·Q4 2025 GAAP net loss per share $(0.06); non-GAAP $(0.03)
• ·FY 2025 GAAP net loss per share $(0.70); non-GAAP $(0.16)
• ·Anticipated significant Q1 2026 YoY revenue growth from Novera shipments
• ·Conference call held March 4, 2026 at 5:00 pm ET

04-03-2026

Emmaus Life Sciences, Inc. entered into an Exclusive Supply Agreement with NeoImmuneTech, Inc. on March 2, 2026, as contemplated by the prior License and Exclusive Distribution Agreement dated December 24, 2025, granting NIT exclusive rights to market, sell, and distribute Endari® and generic equivalents for sickle cell disease in the U.S., its territories, and Canada. Under the Supply Agreement, Emmaus will exclusively supply the products to NIT at cost plus a specified double-digit percentage margin, subject to the License Agreement's Effective Date. However, the Effective Date depends on NIT obtaining necessary regulatory approvals and other conditions, with no assurance of occurrence and potential termination by either party if not achieved by October 1, 2026.

• ·License Agreement previously reported in 8-K filed December 31, 2025
• ·Field: sickle cell disease
• ·Territory: U.S. and its territories/possessions, Canada
• ·Full agreements to be filed as exhibits to 10-K for year ended December 31, 2025 and 10-Q for three months ended March 31, 2026

04-03-2026

BrightSpring Health Services, Inc. entered into an underwriting agreement on March 2, 2026, with Goldman Sachs & Co. LLC for the secondary offering of 20,000,000 shares of common stock by selling stockholders KKR Phoenix Aggregator L.P. and Management Selling Stockholders at $41.15 per share (totaling $823M), with closing on March 4, 2026. The company repurchased 1,464,807 shares from the underwriter as part of the offering and received no proceeds except from cash exercises of stock options by management sellers. No underwriting fees were paid on the repurchased shares.

• ·Underwriting agreement filed as Exhibit 1.1
• ·Registration statement on Form S-3ASR (File No. 333-287916) filed June 10, 2025
• ·Preliminary prospectus supplement filed March 2, 2026; final March 3, 2026

04-03-2026

On February 26, 2026, Dror Ortho-Design, Inc. entered into a Securities Purchase Agreement for a private placement, selling debentures with an aggregate principal amount of $200,000, bearing 0% interest and due April 27, 2026. The debentures are convertible into common stock upon consummation of a public offering at the offering price, subject to a 9.99% beneficial ownership limit, with potential issuance of warrants equal to 100-150% of related shares depending on timing. The transaction was consummated for $200,000 and exempt from registration under Section 4(a)(2) and Regulation D.

• ·Debentures maturity date: April 27, 2026, extendable by holder in 60-day increments.
• ·Warrants, if issued, exercisable immediately at Public Offering price, expire 5 years from issuance.
• ·Filing date: March 04, 2026; event date: February 26, 2026.

04-03-2026

On March 3, 2026, a subsidiary of SITE Centers Corp. completed the sale of its interests in the property located at 3030 North Broadway (Chicago, Illinois) to L3 3030 Broadway LLC for $50.1 million in cash. The transaction is subject to customary adjustments for closing pro-rations, allocations, and credits. No additional financial metrics, comparisons, or impacts were disclosed.

04-03-2026

Diamond Hill Investment Group, Inc. disclosed assets under management (AUM) totaling $28.072 billion as of February 28, 2026, for its wholly owned subsidiary Diamond Hill Capital Management, Inc. By investment vehicle, proprietary funds represented the largest portion at $17.754 billion, followed by separately managed accounts at $4.880 billion. By investment strategy, large cap strategies held $12.450 billion, while short duration securitized bond accounted for $5.321 billion.

• ·Collective investment trusts AUM: $1.523B
• ·Other pooled vehicles AUM: $3.915B
• ·Small Cap strategy AUM: $288M
• ·Core Fixed Income strategy AUM: $3.897B

04-03-2026

Cardlytics reported Q4 2025 total revenue of $56.1 million, down 24.2% YoY from $74.0 million, and full-year 2025 revenue of $233.3 million, down 16.2% YoY from $278.3 million, driven by a 35.0% decline in Q4 ACPU to $0.12 despite 18.4% MQUs growth to 227.0 million. While net losses narrowed to $(8.3) million in Q4 (from $(15.6) million) and $(103.5) million for the year (from $(189.3) million), with Adjusted EBITDA rising 33.4% to $8.5 million in Q4 and dramatically to $10.1 million annually, billings and Adjusted Contribution also declined significantly YoY. Q1 2026 guidance forecasts billings of $57.5-$63.5 million (-41% to -35% YoY) and revenue of $35.0-$40.0 million (-43% to -35% YoY), signaling continued pressure.

• ·Q4 2025 Net cash provided by operating activities: $13.0M, up $10.0M YoY
• ·Q4 2025 Free Cash Flow: $10.5M, up $11.9M YoY from negative
• ·FY 2025 Free Cash Flow: $(6.5)M, improved $21.6M YoY
• ·Q1 2026 Adjusted EBITDA guidance: ($7.5M) to ($3.5M), mixed YoY from ($3.1M) to $0.9M
• ·Dependence on key FI partners: Chase, Wells Fargo, American Express

04-03-2026

Oaktree Specialty Lending Corp held its 2026 annual meeting of stockholders on March 3, 2026, electing John B. Frank and Bruce Zimmerman to the Board until the 2029 annual meeting, and ratifying Ernst & Young LLP as independent auditors for the fiscal year ending September 30, 2026, with overwhelming support (58,021,388 votes for vs. 842,271 against). However, a concurrent special meeting to authorize issuing up to 25% of common stock below net asset value was adjourned due to lack of quorum. As of the January 5, 2026 record date, 88,085,523 shares of common stock were outstanding.

• ·Proxy statement filed with SEC on January 16, 2026
• ·Special Meeting proposal: authorize Company, with Board approval, to issue common stock below NAV per share, not exceeding 25% of then-outstanding common stock

04-03-2026

Helmerich & Payne, Inc. declared a quarterly cash dividend of $0.25 per share on its common stock at a Board of Directors meeting on March 4, 2026. The dividend is payable on June 1, 2026, to stockholders of record at the close of business on May 18, 2026.

• ·Securities registered: Common Stock ($0.10 par value) under ticker HP on NYSE

04-03-2026

Okta reported Q4 FY26 total revenue of $761M, up 11% YoY, and full-year revenue of $2.919B, up 12% YoY, with RPO growing 15% to $4.827B and non-GAAP operating income reaching $202M (26% margin). GAAP operating income improved to $46M from $8M YoY, and full-year GAAP net income rose to $235M. However, Q4 operating cash flow declined to $258M from $286M YoY, free cash flow fell to $252M from $284M, and FY27 revenue guidance of $3.17B-$3.19B implies only 9% growth amid a professional services headwind.

• ·Q4 FY26 GAAP diluted net income per share: $0.35 (vs. $0.13 prior year)
• ·FY26 GAAP diluted net income per share: $1.31 (vs. $0.06 prior year)
• ·Non-GAAP diluted net income per share Q4 FY26: $0.90 (vs. $0.78 prior)
• ·FY27 Q1 revenue guidance: $749M to $753M
• ·FY27 Q1 non-GAAP operating income guidance: $176M to $180M
• ·Effective Feb 1, 2026, non-GAAP tax rate reduced to 21% from 26% due to One Big Beautiful Bill Act

04-03-2026

Hain Celestial Group (Nasdaq: HAIN) completed the sale of its North American Snacks business, including Garden Veggie Snacks™, Terra® chips, and Garden of Eatin'® snacks, to Snackruptors Inc. Proceeds from the transaction will be used to reduce debt, strengthening the company's financial position and leverage profile. The divestiture sharpens focus on higher-margin core categories such as yogurt, tea, and baby & kids foods, with retained global brands including Celestial Seasonings® teas, The Greek Gods® yogurt, Earth's Best® Organic, and Ella's Kitchen®.

• ·Headquartered in Hoboken, N.J.
• ·Products marketed and sold in over 70 countries.
• ·Filing Date: March 04, 2026; Announcement Date: March 2, 2026

04-03-2026

Resources Connection, Inc. (RGP) entered into a Separation and General Release Agreement with Chief Operating Officer Bhadreskumar Patel on March 3, 2026, with his last day of employment set for May 15, 2026. Patel will continue receiving his current salary through the separation date and is eligible for severance including a $1.65M lump sum (1.5x base salary plus target bonus), COBRA cost approximation for 18 months, and accelerated vesting of all unvested equity awards. The company does not plan to appoint a replacement COO, with business unit Presidents reporting directly to CEO Roger Carlile thereafter.

• ·Separation Agreement provides full term to exercise outstanding stock options
• ·Original Employment Agreement dated April 3, 2024
• ·Performance-based RSUs to vest at target level

04-03-2026

National Presto Industries reported 2025 net sales of $503.5M, up 29.7% YoY from $388.2M, primarily driven by a 42.9% increase ($121.9M) in Defense segment sales from higher backlog shipments, which also boosted Defense operating earnings 36.2% ($15.5M). However, net earnings fell 20.2% to $33.1M ($4.63 per share) from $41.5M ($5.82 per share), due to Housewares/Small Appliance segment sales declining 7.0% ($7.2M) and operating losses from Trump tariffs, distribution center relocation, and supplier bankruptcy. The Board declared a regular 2026 dividend of $1.00 per share with no extra dividend, while Safety segment showed modestly increased sales but still nominal with a reduced loss.

• ·Dividend record date: March 9, 2026; payment date: March 20, 2026
• ·82-year unbroken dividend history
• ·2026 annual shareholder meeting: May 19, 2026 (record date March 24, 2026)
• ·Safety segment: increased sales (nominal) and reduced comparative loss
• ·Tariffs treated as period costs under LIFO inventory method

04-03-2026

Innoviz Technologies Ltd. reported FY2025 revenues of $55.1M, surging 127% YoY from $24.3M, with gross profit turning positive at $12.9M (23% margin) versus a $1.2M gross loss (-5% margin) in 2024; operating expenses fell 20% to $80.6M from $100.8M, narrowing the operating loss to $67.7M and net loss to $67.8M ($0.34/share) from $101.9M and $94.8M ($0.57/share), respectively. However, R&D expenses remained high at $56.5M (down 23% YoY but still substantial), and the company warns that ongoing heavy R&D investments and costly strategic initiatives to expand inside/outside automotive may further pressure profitability without sufficient revenue growth.

• ·Filing date: March 04, 2026
• ·Sales and marketing expenses declined to $5.8M from $7.5M YoY
• ·General and administrative expenses declined to $18.4M from $19.5M YoY
• ·Financial income net dropped sharply to $0.1M from $7.3M

04-03-2026

Veeva Systems Inc. reported strong Fiscal Year 2026 results with total revenues of $3,195.3M, up 16% YoY from $2,746.6M, and subscription revenues of $2,684.2M, up 17% YoY from $2,284.7M. Q4 FY2026 total revenues reached $836.0M, up 16% YoY from $720.9M, with operating income up 30% YoY to $245.9M and net income up 25% YoY to $244.2M. The company ended the year with 1,552 customers and provided upbeat guidance for FY2027 total revenues of $3,585-3,600M.

• ·Q1 FY2027 guidance: Total revenues $855-858M; Non-GAAP operating income $378-381M; Non-GAAP EPS $2.13-2.14.
• ·FY2027 guidance: Total revenues $3,585-3,600M; Non-GAAP operating income ~$1,590M; Non-GAAP EPS ~$8.85.
• ·Subscription revenues breakdown FY2026: Veeva Commercial Solutions $1,257.6M (up from $1,104.9M); Veeva R&D and Quality Solutions $1,426.6M (up from $1,179.8M).

04-03-2026

Edgemode, Inc. entered into a securities purchase agreement on February 24, 2026, issuing a convertible promissory note with a $150,000 principal amount and $15,000 original issuance discount to CFI Capital LLC, receiving net proceeds of $130,000 after $5,000 in legal costs for working capital. The note accrues 6% annual interest payable in shares, matures on February 24, 2027, and becomes convertible after six months at 60% of the lowest trading price over the prior 15 trading days, with a 9.99% ownership cap. Standard events of default apply, potentially adjusting the conversion price to 45%.

• ·Promissory note prepayment subject to penalties and premiums.
• ·Issued in reliance on Section 4(a)(2) exemption from Securities Act registration.
• ·Events of default include failure to honor conversion notices, SEC reporting delays, or delisting from OTC Markets.

04-03-2026

SCYNEXIS INC reported total revenue of $20.6M for the year ended December 31, 2025, surging 449.9% YoY from $3.7M, driven by $1.4M in new product revenue and license agreement revenue up 411.4% to $19.2M. Operating expenses declined 10.2% to $36.7M, narrowing the net loss 59.6% to $8.6M from $21.3M; however, total assets contracted to $59.0M from $90.6M, short-term investments fell to $18.8M from $43.2M, and stockholders' equity decreased to $49.4M from $55.1M.

• ·Net cash used in operating activities improved to $(5.3M) in 2025 from $(24.0M) in 2024.
• ·Net cash provided by investing activities was $24.3M in 2025 vs $6.2M in 2024.
• ·Weighted average common shares outstanding basic and diluted: 49,933,381 in 2025 vs 48,513,073 in 2024.
• ·Stock-based compensation expense: $2.9M in 2025 vs $3.3M in 2024.

04-03-2026

Alexion Pharmaceuticals informed Xencor on March 2, 2026, that it disputes owing additional royalties on U.S. sales of Ultomiris and will cease future payments under their Option and License Agreement, potentially impacting Xencor's expected $100-120M in royalties through 2028. Xencor disagrees and is evaluating options, while Alexion will continue royalties on ex-U.S. sales. Despite the dispute, Xencor expects $380-400M in cash at end-2026, sufficient to fund operations into mid-2028.

• ·U.S. Patent 12,492,253 issued, announced December 9, 2025
• ·Royalties characterized as low single-digit on U.S. net sales

04-03-2026

Niagen Bioscience reported strong FY 2025 results with net sales up 30% YoY to $129.4M, net income surging 103% to $17.4M, and Adjusted EBITDA rising 139% to $20.4M, driven by Tru Niagen® (+27%) and Niagen ingredient sales (+45%). However, Q4 net income declined to $4.1M from $7.2M due to higher operating expenses and the absence of prior-year one-time benefits like royalty reversals, despite 16% sales growth to $33.8M. The company ended 2025 with $64.8M in cash (up from $44.7M) and guides for 10-15% sales growth in 2026 excluding the recently sold reference standards segment.

• ·Q4 2025 operating expenses increased 59% YoY to $17.6M, driven by higher G&A excluding prior-year benefits.
• ·FY 2025 selling and marketing expense improved to 27.4% of net sales (down 220 bps YoY).
• ·2026 G&A expected to increase $4.0M to $5.0M due to infrastructure, legal, and share-based compensation.
• ·Dec 2025 acquisition of core NR patent portfolio from Queen’s University Belfast.
• ·Nov 2025 launch of Tru Niagen® Beauty for skin, hair, and nail health.

04-03-2026

Oculis Holding AG reported a widened net loss of $99M for the year ended December 31, 2025, up 15.4% YoY from $86M in 2024, driven by higher R&D expenses (up 9.6% to $57M) and G&A expenses (up 18.2% to $26M), along with a deteriorated finance result. However, grant income grew 74.8% YoY to $1.2M, cash and cash equivalents rose to $81M from $28M, total assets doubled to $236M from $120M, and net cash increased by $60M supported by $187M in financing inflows (up 246.3% YoY). Operating cash outflow worsened to $66M (up 35.5% in magnitude), while investing outflows surged 278.9% to $61M.

• ·Amended and Restated Loan Agreement with Kreos Capital dated July 31, 2025.
• ·Sales Agreement with Leerink Partners dated May 8, 2024.
• ·Share-based compensation within R&D: $9M in 2025 (up 78.9% YoY); within G&A: $7M (up 48.2% YoY).
• ·Warrant liabilities decreased to $14M from $20M as of Dec 31, 2025.

04-03-2026

On March 4, 2026, the Board of Directors of Vir Biotechnology, Inc. appointed Marianne De Backer, M.Sc., Ph.D., MBA, the company's Chief Executive Officer and principal executive officer, to the additional position of President. There are no arrangements or understandings with other persons regarding the appointment, no family relationships with directors or executive officers, and no direct or indirect interests in transactions requiring disclosure under Item 404(a) of Regulation S-K. Biographical information for Dr. De Backer is incorporated by reference from the company's definitive proxy statement filed on April 17, 2025.

04-03-2026

Crane Harbor Acquisition Corp. II, a blank check company, made available its PFIC Annual Statement for Class A ordinary shares on March 4, 2026, covering the tax period from June 19, 2025, to December 31, 2025, to enable shareholders to make a QEF Election. The statement reports minimal ordinary earnings of $0.0010103085 per unit per day, no net capital gains, and no cash or property distributions. No other financial activity or changes were disclosed.

• ·PFIC status for U.S. federal income tax purposes; QEF Election optional for shareholders
• ·Net Capital Gains: NONE
• ·Distributions: Cash NONE; Fair Market Value of Property: NONE
• ·Date of Incorporation: 6/19/2025
• ·EIN: 98-1868608
• ·Class A ordinary shares par value: $0.0001 per share

04-03-2026

MicroVision reported Q4 2025 revenue of $0.2M, down 86% YoY from $1.7M, and full-year 2025 revenue of $1.2M, down 74% YoY from $4.7M, driven by sharp declines in cost of revenue and large impairment charges leading to a Q4 net loss of $37.8M (up 21% worse YoY) while full-year net loss improved slightly to $95.0M from $96.9M. Positively, the company shipped initial MOVIA L sensors on repeatable orders, completed strategic asset acquisitions from Luminar Technologies and Scantinel Photonics, and bolstered cash with $43M in senior secured convertible notes in February 2026. It also plans to reduce global workforce by 20% in 1H2026 to streamline operations post-acquisitions.

• ·Q4 2025 Adjusted EBITDA loss of $12.0M vs $10.6M in Q4 2024.
• ·Cash and cash equivalents ended Q4 2025 at $32.4M (down from $54.5M at end 2024), with investment securities at $42.5M.
• ·$43.0M remaining under ATM facility.
• ·Conference call held March 4, 2026 at 1:30 PM PT.

04-03-2026

Federal Agricultural Mortgage Corporation (Farmer Mac) issued a press release on March 4, 2026, announcing the date and time of its upcoming Investor Day webcast to discuss growth opportunities and strategic priorities. The filing lists various registered securities including Class A and Class C common stock and multiple series of preferred stock. No financial results or performance metrics were disclosed.

04-03-2026

VICI Properties Inc. filed an amended S-4/A registration statement detailing the proposed PropCo Subsidiary Merger under the Master Transaction Agreement, where each Golden Common Stock share converts to 0.902 VICI Common Stock shares (fixed ratio), with recent market value ranging from $24.86 to $27.63 per Golden share. Risks include no adjustment for VICI stock price fluctuations, potential delays or non-completion by the November 5, 2026 outside date (extendable to February 5, 2027), $37M termination fee payable by Golden in certain cases, and post-merger dilution where former Golden shareholders own only 2.29% of VICI versus continuing VICI stockholders' 97.71%. The deal involves up to $135M debt financing for the related OpCo Sale and requires Golden shareholder approval.

• ·Market value of 0.902 VICI shares per Golden share ranged from $24.86 low to $27.63 high (Nov 5, 2025 to Mar 3, 2026 closing prices).
• ·Transactions expected to close in mid-2026, subject to Gaming and Liquor Approvals.
• ·Golden subject to 'no-shop' restrictions post-No-Shop Period Start Date, with limited ability to pursue superior proposals except upon termination fee payment.

04-03-2026

At Nordson Corporation's 2026 Annual Meeting on March 2, 2026, 91.66% of outstanding shares (51,055,498 of 55,703,436) were represented, constituting a quorum. Shareholders elected Christopher L. Mapes (45.2M For, 1.3M Withheld), Sundaram Nagarajan (45.5M For, 1.1M Withheld), and Michael Merriman, Jr. (42.5M For, 4.0M Withheld) to the Board, ratified Ernst & Young LLP as auditors for FY ending October 31, 2026 (49.6M For), and approved advisory say-on-pay (44.1M For). All proposals passed with strong support, though Merriman, Jr. received notably higher withheld votes.

• ·Proposal 1 detailed votes: Christopher L. Mapes - 45,226,332 For, 1,317,484 Withheld; Michael Merriman, Jr. - 42,501,024 For, 4,042,793 Withheld; Sundaram Nagarajan - 45,461,301 For, 1,082,515 Withheld.
• ·Proposal 2 (Auditor Ratification): 49,580,119 For, 1,345,801 Against, 129,576 Abstain.
• ·Proposal 3 (Say-on-Pay): 44,107,303 For, 2,269,515 Against, 166,998 Abstain.

04-03-2026

PennantPark Floating Rate Capital Ltd. entered into a Second Supplemental Indenture with Equiniti Trust Company, LLC, for the issuance of $200M aggregate principal amount of 6.75% notes due 2029, generating net proceeds of approximately $195.9M after underwriting discounts and expenses. The Company intends to use the proceeds to repay outstanding indebtedness under its multi-currency senior secured revolving credit facility with Truist Bank and other lenders, invest in portfolio companies, and for general corporate purposes. The notes are general unsecured obligations, ranking pari passu with existing unsecured debt but effectively subordinated to secured indebtedness.

• ·Notes mature on March 4, 2029, with interest payable semi-annually on March 4 and September 4, commencing September 4, 2026.
• ·Base Indenture dated March 23, 2021; credit facility initially entered August 12, 2021.
• ·Indenture includes covenants for compliance with Investment Company Act asset coverage requirements and change of control repurchase at 100% principal plus accrued interest.
• ·Notes offered under Registration Statement on Form N-2 (File No. 333-279726); prospectus supplements dated February 25, 2026.

04-03-2026

Cracker Barrel Old Country Store, Inc. reported Q2 FY2026 total revenue of $874.8 million, down 7.9% YoY from $949.4 million, driven by comparable store restaurant sales declining 7.1% and retail sales falling 9.2%. GAAP net income dropped to $1.3 million ($0.06 per diluted share) from $22.2 million ($0.99 per diluted share), with adjusted EBITDA decreasing to $38.2 million from $74.6 million. However, the company ended the quarter with total debt of $531.5 million and a low consolidated senior leverage ratio of 0.3x, expects a $46 million net cash benefit from litigation settlements in Q3, and updated its FY2026 outlook to $3.24-3.27 billion in revenue and $85-100 million adjusted EBITDA while declaring a $0.25 quarterly dividend.

• ·Six months FY2026 net loss of $23.3 million vs net income of $27.1 million prior year.
• ·Q2 FY2026 operating income of $0.5 million vs $29.1 million prior year (-98%).
• ·Capital expenditures outlook for FY2026: $105-115 million.
• ·2 new Cracker Barrel stores planned for FY2026.
• ·Quarterly dividend of $0.25 per share payable May 13, 2026 to shareholders of record April 10, 2026.

04-03-2026

Sabre GLBL Inc., a wholly owned subsidiary of Sabre Corporation, completed the redemption of all $91.6M aggregate principal amount of its 8.625% Senior Secured Notes due 2027 on March 1, 2026, at a redemption price of 102.156% of the principal plus accrued and unpaid interest. This redemption, as previously announced on December 23, 2025, terminates the related Indenture dated September 7, 2023, with Computershare Trust Company, N.A. as trustee.

• ·Indenture dated September 7, 2023
• ·Redemption notice provided December 23, 2025

04-03-2026

NCS Multistage Holdings, Inc. filed a Form 8-K on 2026-03-04 disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific quantitative financial metrics such as revenue, earnings, margins, or period-over-period comparisons are mentioned in the provided filing details. This appears to be a standard voluntary earnings-related disclosure with no detailed performance data available.

04-03-2026

H2O America (NASDAQ: HTO) announced a proposed underwritten public offering of $550M in common stock, consisting of $150M direct issuance by the company and $400M via forward sale agreements with JPMorgan and Wells Fargo affiliates, with a 30-day underwriter option for up to $82.5M additional shares. Net proceeds, along with debt financing, are intended primarily to fund the Quadvest Acquisition and related expenses, or for general corporate purposes if the acquisition does not close, as the offering is not conditioned on it. The announcement highlights no immediate financial metrics but notes risks including regulatory approvals and integration challenges for the acquisition.

• ·Announcement date: March 2, 2026
• ·Filing date: March 4, 2026
• ·Forward sale agreements settlement by March 2, 2028 at company's discretion
• ·Underwriter option period: 30 days
• ·Operates across approximately 409,000 water and wastewater service connections serving 1.6 million people

04-03-2026

NN, Inc. reported Q4 2025 net sales of $104.7M, down 1.7% YoY from $106.5M, and full-year 2025 net sales of $422.2M, down 9.1% YoY from $464.3M, primarily due to rationalization of underperforming businesses, plant closures, and lower volumes in Mobile Solutions (down 14.1% YoY). However, adjusted EBITDA improved to $12.9M (12.3% margin) in Q4 from $12.1M and $49.0M for the full year (11.6% margin), with operating losses narrowing 38.3% in Q4 and 31.3% full year; Power Solutions sales rose 16.1% in Q4 while full-year was flat at -1.1%. The company secured $70M in new business wins, exceeding guidance, and forecasts 2026 net sales of $445-465M and adjusted EBITDA of $50-60M, signaling a return to growth.

• ·Q4 2025 GAAP net loss of $11.3M or $0.35 per share; full-year $24.4M or $1.07 per share.
• ·Full-year 2025 adjusted operating income of $14.2M, up 180% YoY.
• ·Conference call scheduled for March 5, 2026 at 9 a.m. ET.

04-03-2026

Costamare Inc. discloses its containership fleet in its 20-F annual report filed on March 04, 2026, consisting of 69 operating vessels with capacities ranging from 1,078 to 14,424 TEU and charter expirations from October 2026 to March 2036, primarily with charterers like Evergreen, MSC, COSCO, and Maersk. Average daily charter rates are provided for select vessels, such as $40,613 for the 14,424 TEU TRITON and $34,881 for the 9,469 TEU SHANGHAI, with TEU-weighted durations up to 6.9 years. Additionally, 10 newbuildings of 3,100 TEU each are under construction, with deliveries scheduled from Q2 2027 to Q4 2028 and employment secured upon delivery.

• ·Largest vessels: Five 14,424 TEU ships (TRITON, TITAN, TALOS, TAURUS, THESEUS) chartered to Evergreen, expiring 2036.
• ·Earliest charter expirations: October 2026 (MAERSK PUELO, ARKADIA), with some extendable.
• ·Many charter details confidential (marked with *) including rates and exact expirations.
• ·Newbuilding deliveries: Q2-Q4 2027 (4 vessels), Q1-Q4 2028 (6 vessels), with long-term or medium-term employment.

04-03-2026

Ardent Health reported Q4 2025 total revenue of $1.61B, down 0.1% YoY (or up ~3% adjusted for prior New Mexico payments) driven by 2.0% adjusted admissions growth offset by a 2.4% decline in net patient service revenue per adjusted admission, while Adjusted EBITDA fell 26.6% to $134M. Full-year 2025 showed revenue growth of 6.0% to $6.32B and Adjusted EBITDA expansion of 9.3% to $545M (margin +20bps), bolstered by operating cash flow surging 49% to $471M and net leverage improving to 2.5x with $710M cash. 2026 guidance projects revenue of $6.4-6.7B but Adjusted EBITDA of $485-535M, reflecting headwinds from payor denials and expense pressures despite IMPACT program savings of $55M.

• ·Q4 2025 net income $45M ($0.32 per diluted share) vs. $114M ($0.81 per diluted share) in Q4 2024.
• ·Available liquidity $1B as of Dec 31, 2025.
• ·$47M remaining under share repurchase authorization.
• ·2026 guidance: Net income $129-183M, diluted EPS $0.90-1.27, adjusted admissions growth 1.5-2.5%, capex $225-265M, REIT rent expense $168M.

04-03-2026

CompX International Inc. reported Q4 2025 net sales of $37.7 million, down 1.8% YoY from $38.4 million due to lower Security Products sales to the healthcare market, though partially offset by higher Marine Components sales to the industrial market. Operating income increased 14.3% YoY to $5.6 million, supported by higher Marine Components sales and improved gross margins in both segments. For FY 2025, net sales rose 8.6% YoY to $158.3 million, operating income surged 32.9% to $22.6 million, and net income grew 17.5% to $19.5 million, driven by higher sales across Security Products (government security) and Marine Components (towboat, government, industrial).

• ·Weighted average diluted common shares outstanding: 12.3 million for both Q4 and FY periods.
• ·Q4 2025 basic and diluted EPS: $0.38 vs. $0.37 in Q4 2024.
• ·FY 2025 basic and diluted EPS: $1.58 vs. $1.35 in FY 2024.
• ·Operates from three U.S. locations.

04-03-2026

Ooma reported strong Q4 FY2026 results with total revenue of $74.6 million, up 15% YoY from $65.1 million, driven by subscription and services revenue growth to $68.7 million (92% of total) and $6.1 million contribution from December 2025 acquisitions of FluentStream and Phone.com. Full year FY2026 revenue increased 7% YoY to $273.6 million, with GAAP net income of $6.5 million versus a prior year loss, non-GAAP net income up 62% to $29.2 million, and Adjusted EBITDA up to $33.9 million from $23.3 million; however, full year growth was more modest compared to Q4 acceleration. The company issued positive FY2027 guidance for revenue of $321-325 million.

• ·Acquisitions of FluentStream and Phone.com closed December 2025.
• ·Q1 FY2027 guidance: total revenue $79.6-80.4M; non-GAAP net income $8.8-9.2M.
• ·FY2027 guidance: GAAP net income $9.3-10.8M; non-GAAP net income $35.5-37.0M.
• ·Balance sheet as of Jan 31, 2026: cash $20.1M (up from $17.9M), total debt ~$57.9M (new), intangible assets $62.5M (up from $22.2M), goodwill $49.8M (up from $23.1M).
• ·Conference call: March 4, 2026 at 5:00 p.m. ET.

04-03-2026

Broadcom Inc. reported record Q1 FY2026 revenue of $19.3B, up 29% YoY, driven by 52% growth in Semiconductor solutions to $12.5B and 106% YoY increase in AI revenue to $8.4B; however, Infrastructure software grew only 1% YoY to $6.8B. GAAP net income rose 34% YoY to $7.3B but declined 14% QoQ from $8.5B, while Adjusted EBITDA hit $13.1B (+30% YoY, 68% margin). Q2 guidance projects $22.0B revenue (+47% YoY) at 68% Adjusted EBITDA margin, alongside a $0.65/share dividend and new $10B share repurchase program through Dec 31, 2026.

• ·Cash and equivalents decreased to $14.2B from $16.2B prior quarter.
• ·Q1 stock-based compensation expense totaled $2,176M.
• ·Dividend payable March 31, 2026 to shareholders of record March 23, 2026.

04-03-2026

Farmer Bros. Co. has filed a DEFA14A proxy statement providing additional information in connection with its proposed merger with BP I Brew Merger Sub Inc., a wholly-owned subsidiary of Royal Cup, Inc., pursuant to a Merger Agreement dated March 3, 2026. The filing urges stockholders to read the forthcoming definitive proxy statement and other SEC documents for details on the transaction, with information on participants in the solicitation available in prior SEC filings including the Annual Report for the year ended June 30, 2025. Forward-looking statements highlight risks such as potential failure to complete the merger, legal proceedings, and business disruptions.

• ·Merger Agreement executed on March 3, 2026.
• ·Annual Report on Form 10-K for year ended June 30, 2025, filed September 11, 2025; Amendment No. 1 filed October 24, 2025.
• ·Company address for document requests: 14501 N Fwy, Fort Worth, Texas 76177.

04-03-2026

MDJM LTD (UOKA), a Cayman Islands holding company with UK subsidiaries in hospitality, filed a Form F-3 shelf registration statement on March 4, 2026, to register up to $70M of Class A ordinary shares (par value $0.025), preferred shares, debt securities, warrants, rights, and units on a delayed basis, replacing a prior shelf (File No. 333-261347) with $67.5M of unsold securities carried forward. The company's Class A shares closed at $0.0772 on March 3, 2026, with a public float of approximately $99.1M based on 43.1M shares at $2.30 on February 9, 2026. Recent offering proceeds totaling over $10M since 2024 were deposited directly into UK subsidiary accounts rather than the parent.

• ·Prior registration statement (File No. 333-261347) initially filed November 24, 2021, effective March 6, 2023, scheduled to expire March 6, 2026.
• ·Company operates as foreign private issuer with reduced reporting requirements; shares listed on Nasdaq Capital Market (UOKA).
• ·Principal offices at Fernie Castle, Letham Cupar, Fife, KY15 7RU, United Kingdom.
• ·No dividends or distributions from UK subsidiaries to parent or US investors as of filing date.

04-03-2026

PepGen Inc. reported a slightly narrower net loss of $89.7M for the year ended December 31, 2025, compared to $90.0M in 2024, with operating expenses declining 4.2% YoY to $93.6M driven by a 7.1% drop in R&D expenses, though G&A rose 6.2%. Cash and equivalents grew 22.5% to $60.5M, bolstered by $108M net proceeds from a public offering, resulting in a net cash increase of $11.1M versus a $31.4M decrease prior year; however, interest income fell 43.7% to $4.0M and shares outstanding more than doubled to 68.9M, diluting EPS to $(2.12) from $(2.85). Total assets expanded 15.3% to $173.9M, but accumulated deficit widened to $361.1M.

• ·Stock-based compensation expense declined to $10.6M from $11.5M YoY.
• ·Net cash used in investing activities improved to $(15.2M) from $(37.7M), with lower purchases of marketable securities.
• ·Accumulated deficit increased to $361.1M from $271.5M.
• ·Employment agreements executed with executives on May 20, 2025 (Kasra Kasrarian, PhD), August 19, 2024 (Paul D. Streck), and December 8, 2025 (Joseph Vittiglio).

04-03-2026

Liminatus Pharma, Inc. disclosed via 8-K an amendment to its Amended and Restated Bylaws, originally adopted on April 30, 2025, with the latest amendment adopted on February 27, 2026. The bylaws outline corporate offices, stockholder meeting procedures—including board control over annual and special meetings—and detailed advance notice requirements for director nominations and shareholder proposals, limiting special meetings to be called only by the Board, Chair, CEO, or President. These governance changes impose strict timelines (e.g., 120-150 days prior to annual meeting anniversary) and extensive disclosure obligations on proposing stockholders, with no financial impacts

04-03-2026

Stevanato Group S.p.A. reported FY2025 revenue of €1,186.3 million, up 7.4% YoY from €1,104.0 million, driven by 11.2% growth in Biopharmaceutical and Diagnostic Solutions to €1,038.2 million (with high-value solutions surging 29.4%), while gross profit rose 13.7% to €343.9 million and operating profit increased 23.4% to €198.8 million. However, the Engineering segment revenue declined 21.4% to €281.0 million from €357.6 million, with its gross margin dropping to 11.0% from 15.7% and operating margin falling to 3.3% from 9.3%; additionally, revenue from other containment and delivery solutions decreased 3.8% to €491.8 million. Net profit attributable to equity holders grew 18.7% to €139.8 million, with total headcount at 6,010 as of December 31, 2025.

• ·Dividend approved per share €0.054 (up 1.9% YoY), equivalent to $0.061 (up 7.0% YoY).
• ·Basic and diluted EPS €0.51 (up 17.9% YoY from €0.43).
• ·R&D expenses declined 19.7% to €25.4 million.
• ·Finance expense increased 58.0% to €22.7 million.
• ·Total liabilities up €133.1 million to €1,057.5 million.

04-03-2026

Hess Midstream LP announced a $60M accretive repurchase, consisting of $18M (455,811 Class B units at $39.49 each) from a Chevron affiliate via its subsidiary Hess Midstream Operations LP, and $42M of Class A shares through an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank. The transactions, unanimously approved by the conflicts committee, are expected to boost distributable cash flow per Class A share, supporting at least 5% annual distribution growth through 2028, while preserving approximately $1B in financial flexibility. Funding will come from the existing revolving credit facility, with unit repurchase closing on March 4, 2026, and ASR settling in March 2026.

• ·Unit repurchase represents approximately 0.2% of the consolidated company.
• ·Post-unit repurchase (pre-ASR): ownership 62.2% public and 37.8% Chevron.
• ·ASR final shares based on volume-weighted average prices during term.
• ·Transactions unanimously approved by Board based on conflicts committee recommendation.

04-03-2026

Hudson Technologies reported strong Q4 2025 revenue growth of 28% to $44.4M from $34.6M prior year, driven by higher sales volume, and full-year 2025 revenue increased 4% to $246.6M from $237.1M with 6% growth in refrigerant sales volume and 18% rise in reclamation volume. However, Q4 gross margin fell to 8.0% from 16.7% due to $4.2M inventory costs, leading to an operating loss of $11.2M versus $3.2M prior year, while full-year operating income declined to $18.6M from $29.3M and gross margin slipped to 25.2% from 27.7%. The company completed the acquisition of Refrigerants Inc. in December 2025, repurchased $14M in shares, approved a $20M share repurchase authorization for 2026, and held $39.5M in cash at year-end.

• ·New ERP system went live February 1, 2026, expected to cause Q1 2026 startup inefficiencies negatively impacting revenues but anticipates low-to-mid single digit revenue growth vs Q1 2025; inefficiencies not expected into Q2 2026.
• ·Q4 SG&A $13.9M vs $8.0M prior year (includes $4.0M severance); Non-GAAP Adjusted SG&A $9.9M vs $8.0M.
• ·Q4 net loss $8.6M or $0.20/share vs $2.6M or $0.06/share prior year.
• ·FY SG&A $40.2M vs $33.0M prior year; Non-GAAP Adjusted $36.2M vs $32.6M.
• ·Total assets $318.6M at Dec 31, 2025 vs $302.7M at Dec 31, 2024.

04-03-2026

On March 4, 2026, Charging Robotics Inc. entered into a securities purchase agreement with accredited investors for a private placement of 500,000 shares of common stock or pre-funded warrants at $4.00 per share or $3.9999 per pre-funded warrant, expecting approximately $2.0 million in gross proceeds before expenses. The transaction is expected to close upon the effectiveness of the company's uplisting to a national securities exchange, subject to customary conditions. A registration rights agreement requires filing a resale registration statement with the SEC within 30 days post-closing.

• ·Pre-Funded Warrants exercisable at $0.0001 per share and do not expire until fully exercised.
• ·Resale Registration Statement must be declared effective within 60 days (if not reviewed by SEC) or 90 days (if reviewed) after filing.
• ·Securities offered pursuant to Section 4(a)(2) of the Securities Act exemption.
• ·Company is an emerging growth company.

04-03-2026

MarineMax, Inc. (HZO) issued a press release on March 4, 2026, announcing a new stock repurchase program, as disclosed in an 8-K filing under Item 8.01 Other Events. The press release is attached as Exhibit 99.1. The filing was signed by Michael H. McLamb, Executive Vice President, Chief Financial Officer, and Secretary.

04-03-2026

SES AI reported FY2025 revenue of $21M, up nearly 10x YoY from $2M in 2024, with Q4 revenue at $4.6M reflecting 124% YoY growth, though $1.5M was delayed to Q1 2026 due to logistics; operating expenses declined 15% YoY to $93.9M (GAAP), net loss improved to $73.0M from $100.2M, and liquidity stood at $200M. However, Q4 gross margin fell to 11.3% GAAP due to lower-margin ESS mix, Adjusted EBITDA loss narrowed but remained at $62.6M for the year, and cash burn was $58.4M. 2026 outlook projects $30-35M revenue (43-67% growth) with blended gross margin around 15%, alongside 15% op ex reduction.

• ·UZ Energy signed multiyear $20M contract with major distributor at InterSolar.
• ·Hisun JV has 150,000-ton annual capacity for materials.
• ·Drone batteries target 400-500 Wh/kg energy density.
• ·NDAA-compliant since 2021; converting Korea facility to 10Ah drone cells.
• ·Q4 non-GAAP gross margin 11.7%; FY non-GAAP gross margin 55.7%.
• ·2026 ESS gross margin ~15%; drone >20%; materials 10-20%.

04-03-2026

On February 18, 2026, CRH plc subsidiary APAC-Kansas, Inc. received a Section 107(a) imminent danger order from MSHA at its Harrisonville Quarry in Missouri for three employees conducting maintenance on an elevated scalping screen without fall protection. The mine manager immediately withdrew the employees and instructed them on safety protocols, resulting in MSHA terminating the order promptly. No ongoing shutdown or patterns of violations were reported.

• ·Incident location: Harrisonville Quarry, Harrisonville, Missouri
• ·Order issued under Federal Mine Safety and Health Act of 1977, Section 107(a)

04-03-2026

Tri Pointe Homes, Inc. announced a merger agreement dated February 13, 2026, with Sumitomo Forestry Co., Ltd., under which a wholly-owned subsidiary, Teton NewCo, Inc., will merge with Tri Pointe, resulting in Tri Pointe becoming an indirect wholly-owned subsidiary of Sumitomo. A special stockholder meeting is scheduled for [●], 2026, to vote on adopting the merger agreement (requiring majority approval of outstanding shares), an advisory vote on executive compensation related to the merger, and an adjournment proposal if needed. The Board unanimously recommends voting 'FOR' all proposals, with a fairness opinion from Moelis & Company LLC.

• ·Merger Agreement dated February 13, 2026
• ·Special Meeting record date: close of business on [●], 2026
• ·Proxy materials to be mailed on or about [●], 2026
• ·References risks in 10-K for year ended December 31, 2025

04-03-2026

On February 26, 2026, the Board of Directors of CoastalSouth Bancshares, Inc. appointed J. Simon Fraser as a director, effective immediately, with his term set to expire at the 2026 Annual Meeting of Stockholders, after which he is expected to join the Audit Committee and Nominating and Governance Committee. Mr. Fraser is determined to be an independent director under applicable SEC and NYSE standards. The appointment involves no arrangements with other persons, no family relationships, and only ordinary course loans from subsidiary Coastal States Bank.

• ·Loans to Mr. Fraser from Coastal States Bank were made in the ordinary course of business on substantially the same terms as comparable transactions with non-related persons, with no more than normal risk of collectability.
• ·No transactions between Mr. Fraser and the Company required to be reported under Item 404(a) of Regulation S-K, except the described loans.

04-03-2026

FreightCar America, Inc. issued a press release on March 4, 2026, announcing its annual general meeting (AGM) scheduled for April 10, 2026 at 10:00 Central Time, with the record date set for the close of business on February 10, 2026. The press release is attached as Exhibit 99.1.

• ·Company headquartered at 125 South Wacker Drive, Suite 1500, Chicago, Illinois 60606.
• ·Telephone: (800) 458-2235.
• ·Securities: Common Stock (RAIL) and Preferred Stock Purchase Rights on The Nasdaq Global Market.

04-03-2026

Crane Harbor Acquisition Corp., a blank check company, filed an 8-K on March 4, 2026, making available its PFIC Annual Statement for fiscal year 2025 (January 2 to December 31, 2025) to Class A ordinary shareholders to facilitate optional QEF elections. The statement discloses minimal ordinary earnings of $0.0011219650 per-unit per-day, with no net capital gains or distributions reported.

• ·Taxpayer Identification Number: 98-1830736
• ·Country of Incorporation: Cayman Islands
• ·Date of Incorporation: January 2, 2025
• ·Principal Address: 1845 Walnut Street, Suite 1111, Philadelphia, PA 19103

04-03-2026

OmniAb reported Q4 2025 revenue of $8.4 million, down 22% YoY from $10.8 million, and full-year 2025 revenue of $18.7 million, down 29% YoY from $26.4 million, primarily due to declines in license, milestone, and service revenue. Net loss widened slightly to $14.2 million ($0.11/share) in Q4 and $64.8 million ($0.57/share) for the year, though cash position stood at $54.0 million; the company highlighted growth to 107 active partners and 407 programs, launch of OmniUltra™, and issued 2026 guidance for $25-30 million revenue. While partner pipeline and new technologies show promise, revenue declines and ongoing losses reflect challenges in legacy programs.

• ·Q4 2025 R&D expense $13.9M (up from $13.3M YoY due to $3.9M impairment charge)
• ·2026 guidance: costs and operating expenses $80-85M; cash costs and operating expenses $50-55M; ending cash $30-35M
• ·New license agreements in Q4 with Dana Farber Cancer Institute, Mabtrx Biosciences, and two global pharma companies

04-03-2026

Office Properties Income Trust announced settlements from two mediations in its Chapter 11 bankruptcy cases: the UCC Settlement provides Unsecured Noteholders with 6.3% Reorganized Common Equity plus warrants and a $35M equity rights offering, while Priority Guaranteed Unsecured Notes recover 100% in equity; however, the 2027 Settlement involves a $385M promissory note and staggered cash payments totaling $60M to 2027 Senior Secured Note holders amid ongoing restructuring. Existing common shares will be cancelled on the Plan Effective Date with no recovery for shareholders. Monthly Operating Reports for January 2026 were also filed, though unaudited and limited in scope.

• ·UCC Mediation concluded February 24, 2026; 2027 Mediation concluded March 2, 2026.
• ·Trade and Vendor Claims to be paid in full in cash post-Plan Effective Date.
• ·Debtors filed Monthly Operating Reports for January 1-31, 2026 (Exhibit 99.3).
• ·Bankruptcy cases commenced October 30, 2025, Case No. 25-90530.

04-03-2026

Greenlane Holdings, Inc. (GNLN) issued press releases on March 3, 2026, announcing an investor overview on its Berachain Digital Asset Treasury Strategy and providing an update on BERA holdings. As of February 27, 2026, the Company held approximately 70.4 million units of BERA, after acquiring about 9 million units between December 4, 2025, and February 27, 2026, at prices ranging from $0.40 to $0.93 per unit, and had deployed approximately 50 million units into validator infrastructure on the Berachain network. The publicly reported annualized Proof of Liquidity staking rate on Berachain was approximately 25%.

• ·Press releases furnished as Exhibit 99.1 (Investor Overview) and 99.2 (BERA Update)
• ·Information under Item 7.01 not deemed 'filed' under Section 18 of the Exchange Act

04-03-2026

CenterPoint Energy's 2026 Proxy Statement outlines 2025 governance updates, including September bylaws amendments aligning with Texas legislative changes (e.g., 3% ownership threshold for derivative suits, jury trial waiver, exclusive forum provisions) and an increase in director retirement age from 73 to 75 years for greater Board flexibility. In October 2025, the Board approved a combined Chair/CEO role for Jason Wells with Theodore O. Franklin as Lead Independent Director to enhance strategic execution amid a $65.5B ten-year capital plan, while maintaining 100% independent committees and 10 independent directors. No waivers of ethics codes or related-party transactions occurred in 2025, with majority voting for uncontested director elections.

• ·No waivers granted for Code of Ethics or Ethics and Compliance Code to executive officers or directors in 2025.
• ·No related-party transactions required to be reported under SEC rules since January 1, 2025.
• ·Majority voting standard applies to uncontested director elections; plurality for contested.
• ·Corporate Governance Guidelines, Bylaws, and related policies available at https://investors.centerpointenergy.com/governance.

04-03-2026

On March 4, 2026, Independent Bank Corp. (INDB) filed an 8-K under Item 8.01 announcing that Jeffrey Tengel, President and Chief Executive Officer of Rockland Trust Company and INDB, issued a letter to employees regarding a recently diagnosed medical condition, with the letter attached as Exhibit 99.1. The filing was signed by Patricia M. Natale, General Counsel. This disclosure raises potential concerns about leadership continuity.

04-03-2026

Alto Ingredients, Inc. reported Q4 2025 gross profit of $15.2M, up $16.6M from a $1.4M loss in Q4 2024, net income of $21.5M or $0.28/share versus a $42.0M loss, and Adjusted EBITDA of $27.9M versus negative $7.7M. For FY 2025, gross profit rose to $34.9M from $9.7M, with net income of $12.1M versus a $60.3M loss and Adjusted EBITDA of $44.7M from negative $8.5M; however, net sales declined slightly to $232.0M in Q4 (-1.9% YoY) and $917.9M for the year (-4.9% YoY), while cash equivalents fell to $23.4M from $35.5M.

• ·Total assets at Dec 31, 2025: $388.8M, down from $401.4M at Dec 31, 2024.
• ·SG&A expenses Q4 2025: $6.9M, down from $7.4M YoY; FY 2025: $27.2M, down from $29.7M.
• ·Interest expense FY 2025: $10.8M, up from $7.6M YoY.
• ·Pekin Campus net sales Q4 2025: $150.6M, up from $142.5M YoY.

04-03-2026

Atlas Lithium Corp reported total assets of $87.7M as of Dec 31, 2025, up 51.6% YoY from $57.9M, driven by cash and equivalents surging 131% to $35.9M and property/equipment rising 23.4% to $48.0M. However, accumulated deficit widened 18.8% to $171.6M from $144.4M, reflecting higher G&A expenses up $6.7M, while total liabilities remained nearly flat at $35.2M and stockholders' equity grew 138% to $52.5M amid share count increasing 68% to 27.0M shares outstanding.

• ·Current liabilities increased to $14.8M from $5.7M YoY.
• ·Trade receivables declined to $28,539 from $47,682.
• ·Capitalized exploration costs decreased $1.6M to $2.9M from $4.5M.
• ·G&A expenses increased $6.7M due to personnel and infrastructure growth.
• ·Exploration costs decreased $3.0M due to capitalization.
• ·Intangible assets acquisition decreased $0.4M.

04-03-2026

Pulmonx reported full year 2025 worldwide revenue of $90.5 million, up 8% YoY (7% constant currency), driven by strong 23% international growth (19% CC), while U.S. revenue grew only 1%; however, Q4 revenue declined 5% YoY to $22.6 million (-7% CC), with U.S. down 11% and international up 8%. Gross margins improved to 78% in Q4 (from 74%) and held at 74% for the year, operating expenses fell 11% in Q4 but rose 1% for the year, and net losses narrowed to $54.0 million for FY2025 (from $56.4 million). FY2026 guidance projects flat revenue of $90-92 million, 75% gross margin, and $113-115 million operating expenses.

• ·Cash, cash equivalents, and marketable securities decreased ~$32M YoY to $69.8M as of Dec 31, 2025.
• ·Refinanced debt with up to $60M committed capital under 5-year interest-only facility maturing 2031.
• ·FY2026 expected cash decrease of ~$23M assuming no additional credit facility drawdowns.
• ·Adjusted EBITDA loss improved to $30.6M for FY2025 from $31.3M in FY2024.

04-03-2026

ASPAC III Acquisition Corp. reported net income of $1.34M for the year ended December 31, 2025, a turnaround from a $0.23M loss in 2024, driven by $2.17M in interest income (+502% YoY), though operating losses widened to $0.83M (+41% YoY) due to higher G&A (+40%) and legal expenses (+41%). However, the balance sheet deteriorated sharply with total assets falling 94% YoY to $3.94M from $62.08M, primarily due to massive redemptions reducing trust account investments by 95% to $2.98M and cash declining 45% to $0.87M, while shareholders' equity dropped 89% to $0.42M.

• ·Promissory note - related party: $0 as of Dec 31, 2025 (down from $276,221 as of Dec 31, 2024)
• ·Basic and diluted net income per redeemable Class A share: $0.47 (2025) vs $0.50 (2024)
• ·Basic and diluted net loss per non-redeemable Class A and B share: ($0.49) (2025) vs ($0.38) (2024)
• ·Up to 206,250 Class B shares subject to forfeiture related to underwriter over-allotment option

04-03-2026

Xperi Inc. has issued its DEF 14A Proxy Statement for the 2026 Annual Meeting of Stockholders on April 17, 2026, at 7:15 a.m. PT in Calabasas, CA, seeking to elect seven director nominees (Darcy Antonellis, Laura J. Durr, Jeremi T. Gorman, David C. Habiger, Jon E. Kirchner, Roderick K. Randall, and Christopher Seams) to serve until the 2027 meeting and to ratify Deloitte & Touche LLP as the independent auditor for the year ending December 31, 2026. The Board highlights strong governance practices, including a 7-member board with all directors except the CEO being independent, 100% independent key committees, and policies like stock ownership requirements (5x base salary for CEO), clawback provisions, and prohibitions on hedging/pledging. No financial performance metrics or declines are discussed.

• ·Record date: February 23, 2026
• ·Proxy materials available on or about March 4, 2026 via http://www.proxyvote.com and investor.xperi.com
• ·2025 Annual Report on Form 10-K filed with SEC on February 26, 2026
• ·All directors attended at least 75% of Board and committee meetings in 2025
• ·Minimum stock ownership: 5x base salary (CEO), 1.5x base salary (other executives), 3x annual cash retainer (independent directors)

04-03-2026

iPower Inc. (IPW) filed a DEF 14A proxy statement on March 4, 2026, for its annual meeting on April 13, 2026, seeking shareholder approval for the election of five directors: Chenlong Tan (Chairman, CEO, President, Interim CFO), Yi Yang, Bennet Tchaikovsky (Independent, Audit Chair), Hanxi Li (Independent, Compensation Chair), and Yue Guo (Independent). The board held 3 meetings and 5 written consents during the year ended June 30, 2025, with all directors attending at least 75% of meetings; three directors are independent per Nasdaq standards, while Mr. Tan holds multiple key roles with no lead independent director designated. No family relationships or legal proceedings involving directors or officers were reported.

• ·Director appointments: Yi Yang (June 6, 2025), Yue Guo (May 8, 2025), Hanxi Li (December 23, 2021), Bennet Tchaikovsky (May 2021).
• ·Chenlong Tan previously served as Interim CFO until January 2021.
• ·No involvement in bankruptcies, criminal proceedings, or securities violations by any director or officer in past 10 years.
• ·Board determines majority independent: Tchaikovsky, Li, Guo qualify under Nasdaq standards.

04-03-2026

Aquestive Therapeutics reported Q4 2025 total revenues of $13.0M, up 10% YoY from $11.9M, driven by manufacture and supply revenue growth to $12.0M, while FY 2025 revenues declined 3% to $44.5M excluding prior-year deferred revenue recognition, with manufacture and supply revenue flat at $40.2M. Net losses widened significantly to $31.9M in Q4 (incl. $13.6M one-time legal) and $83.8M for FY 2025 (incl. $14.3M one-time legal), versus $17.1M and $44.1M prior year, due to higher SG&A and commercial spending for Anaphylm launch prep; however, the company met 2025 guidance excluding one-time items and guides to $70M cash at end-FY2026. Pipeline updates include Anaphylm NDA resubmission targeted for Q3 2026 post-CRL, with RTW revenue sharing extended to June 30, 2027, a $5M share purchase commitment, and warrant for 375,000 shares.

• ·CRL received Jan 30, 2026 for Anaphylm NDA (human factors/PK issues, no CMC/clinical concerns)
• ·RTW agreements dated March 3, 2026: revenue sharing extension to June 30, 2027; warrant exercise price $4.00 expiring March 3, 2029; $5M share purchase in 90 days
• ·Libervant tentatively approved until Jan 2027 (orphan exclusivity expiration)
• ·AQST-108 IND opened Dec 2025; Phase 1 dosing complete Q1 2026
• ·Confidential settlement with Neurelis Dec 2025; 2026 cash impact same/lower than prior forecast
• ·Conference call March 5, 2026

04-03-2026

BRT Apartments Corp. reported that George Zweier retired as Chief Financial Officer on February 27, 2026, with Isaac Kalish, previously Senior Vice President, assuming the CFO position. This followed anticipation disclosed in a prior 8-K filing on September 11, 2025. Upon retirement, Zweier's 42,800 restricted stock shares vested, while all his restricted stock units were forfeited.

• ·Event originally anticipated in 8-K filed September 11, 2025
• ·8-K/A filed March 4, 2026

04-03-2026

Xanadu Quantum Technologies Inc. hosted its 2026 Analyst Day on March 4, 2026, outlining its strategic roadmap and business combination with Crane Harbor Acquisition Corp., implying a $3.1B pro forma enterprise value, $500M gross proceeds including a $275M PIPE, and $455M expected net cash at closing assuming no redemptions. The event highlighted Xanadu's photonic quantum computing leadership with products like Aurora and PennyLane, targeting commercialization by 2029+, while noting well-capitalized position post-merger. However, risks include historical net losses, substantial doubt about going concern, potential redemptions reducing cash, and technical challenges in quantum computing commercialization.

• ·Shareholder meetings scheduled for March 19, 2026
• ·Transaction expected to close in Q1 2026
• ·Registration Statement on Form F-4 declared effective by SEC on February 27, 2026
• ·Crane Harbor trust account value as of September 30, 2025
• ·NewCo expected to trade on Nasdaq and Toronto Stock Exchange under ticker XNDU

04-03-2026

StubHub reported FY2025 GMS of $9.2B, up 6% YoY (18% underlying excluding Taylor Swift Eras Tour), Adjusted EBITDA of $232M (13% margin), and $900M debt reduction, strengthening its balance sheet. However, revenue was flat at $1.7B (down 1.4% YoY), Q4 revenue declined 16% to $449M, and net loss widened to $1.9B due to one-time charges including $1.4B stock-based compensation. The company issued FY2026 guidance of $9.9B-$10.1B GMS (up ~8-10% YoY) and $400M-$420M Adjusted EBITDA (80% growth).

• ·Q4 2025 Adjusted EBITDA $63M (14% margin).
• ·FY2025 stock-based compensation charge $1.4B (non-cash).
• ·FY2025 non-recurring valuation allowance expense $479M (non-cash).
• ·Q4 2025 paid down $150M USD term loan principal.
• ·Conference call March 4, 2026 at 5:00 PM ET.

04-03-2026

Cross Country Healthcare reported Q4 2025 revenue of $236.8M, down 24% YoY and 5% QoQ, and full-year 2025 revenue of $1.05B, down 22% YoY, reflecting a challenging travel staffing market. Gross profit margin was stable at 20.3% but Adjusted EBITDA declined 56% YoY to $4.1M in Q4 and 45% to $26.8M for the year, with net loss widening to $82.9M in Q4 due to a $77.9M goodwill impairment and $29.6M valuation allowance; however, operating cash flow remained positive at $18.2M in Q4 and $48.3M for the year, bolstered by a $20M Aya merger termination fee, $109M cash with no debt, and 0.8M shares repurchased for $6.5M.

• ·95% of MSP and vendor neutral clients live on Intellify®.
• ·Q1 2026 guidance: Revenue $235M-$240M (-20% to -18% YoY), Adjusted EBITDA $4.0M-$5.0M (-54% to -42% YoY).
• ·Nurse and Allied Staffing: Average FTE 6,318 (-17% YoY), revenue per FTE/day $333 (-8% YoY).
• ·Physician Staffing: Total days filled 18,599 (-27% YoY), revenue per day $2,286 (+10% YoY).
• ·ABL borrowing base availability $114.6M, net availability $96.3M as of Dec 31, 2025.
• ·$34.0M remaining for share repurchases as of Dec 31, 2025.

04-03-2026

Diversified Energy Company (NYSE: DEC, LSE: DEC) announced the execution of a purchase and sale agreement to acquire high-working interest natural gas properties and facilities in east Texas from Sheridan Production for $245M in cash, expected to close in Q2 2026 and funded via existing liquidity. The acquisition adds ~62 MMcfepd (~10 MBoepd) of 2026 production with low ~6% annual declines, ~$52M NTM EBITDA, and ~397 Bcfe PDP reserves at $310M PV-10, at an accretive ~PV-15 net valuation. The assets are contiguous to existing operations, offering synergies, with no declines in consolidated production profile pro forma.

• ·Assets based on NYMEX strip as of February 2, 2026, with terminal prices of $3.75/MMBtu gas and $65/Bbl oil
• ·Expected to maintain unchanged consolidated decline rate pro forma
• ·Includes opportunities for future operating efficiencies and upside from undeveloped acreage

04-03-2026

Miller Industries Inc. (MLR) reported net sales of $790.3M for the year ended December 31, 2025, down 37.2% YoY from $1.26B in 2024, with gross profit declining 29.5% to $120.4M and net income falling 63.8% to $23.0M from $63.5M. While selling, general, and administrative expenses rose modestly 3.1% to $89.0M, operating cash flow improved dramatically 485.2% to $98.7M, driving a net increase in cash to $44.7M, and long-term obligations decreased to $31.1M from $65.0M. Total assets stood at $589.7M with shareholders' equity up to $420.6M despite the revenue drop.

• ·Diluted EPS $1.98 in 2025 vs $5.47 in 2024 (down 63.8%)
• ·Cash dividends declared per share $0.80 in 2025 (up from $0.76 in 2024)
• ·Inventories net flat at $184.2M vs $186.2M YoY
• ·Allowance for credit losses $1.876M (0.9% of receivables) vs $1.850M (0.6%) YoY
• ·Weighted-average diluted shares 11,615 thousand in 2025 (up slightly from 11,602 thousand)

04-03-2026

MOZAYYX Acquisition Corp., a blank check company, consummated its upsized initial public offering on February 26, 2026, of 30,000,000 units at $10.00 per unit, generating $300M in gross proceeds, including 3,900,000 units from partial over-allotment exercise. Simultaneously, it completed a private placement of 3,610,000 warrants for $7.22M to its sponsor and Cantor Fitzgerald & Co. The balance sheet as of February 26 reflects $301.64M total assets with $300M in trust, but shows a $11.38M shareholders' deficit and $13.02M liabilities primarily from deferred underwriting fees of $12.78M.

• ·Of private placement warrants: 2,305,000 to sponsor and 1,305,000 to Cantor Fitzgerald & Co.
• ·Prepaid expenses: $10,500; Related party payable: $142,934; Accrued expenses: $98,115.
• ·Class B ordinary shares include up to 375,000 subject to forfeiture related to over-allotment.

04-03-2026

M/I Homes, Inc. announced that independent Director Norman L. Traeger has decided to retire from the Board upon the expiration of his term, having served since 1997. Chairman and CEO Robert H. Schottenstein commended Traeger's guidance, wisdom, and contributions to the company's success and growth. The announcement is neutral with no financial impacts disclosed.

• ·Company homebuilding operations in: Columbus and Cincinnati, Ohio; Indianapolis, Indiana; Chicago, Illinois; Minneapolis/St. Paul, Minnesota; Detroit, Michigan; Tampa, Sarasota, Fort Myers/Naples and Orlando, Florida; Austin, Dallas/Fort Worth, Houston and San Antonio, Texas; Charlotte and Raleigh, North Carolina; Nashville, Tennessee.

04-03-2026

Fennec Pharmaceuticals Inc. announced on March 4, 2026, that the Tampa General Hospital Cancer Institute is initiating a real-world study evaluating the clinical utility of PEDMARK® (sodium thiosulfate injection) in reducing ototoxicity risk for adolescent, young adult, and adult cancer patients receiving cisplatin-based chemotherapy. This development supports expanded evidence for the product's use beyond pediatric indications. A copy of the press release is furnished as Exhibit 99.1.

04-03-2026

Star Gold Corp. (SRGZ) closed a private placement of common stock and warrants on February 27, 2026, raising $3,677,850 through the sale of 91,946,250 units at $0.04 per unit under Section 4(a)(2) and Rule 506(b) of Regulation D. Each unit includes one share of common stock and a warrant to purchase one-half additional share at $0.08 within 12 months. The offering involved 40 investors, including 38 accredited investors and 6 company affiliates (CFO, CEO, President, and all 3 board members).

• ·Private placement conducted pursuant to Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.
• ·Warrants exercisable within 12 months from February 27, 2026.

04-03-2026

Albemarle Corporation (NYSE: ALB) appointed Michelle T. Collins and Mark R. Widmar to its Board of Directors, effective February 26, 2026, as part of regular succession planning to enhance governance and long-term value creation. Collins, a former Vice Chair and Senior Audit Partner at Deloitte & Touche LLP with over 40 years of experience, will join the Audit & Finance Committee and Governance & Public Policy Committee. Widmar, CEO of First Solar since 2016, will join the Executive Compensation & Talent Development Committee and Safety, Sustainability, Operations & Capital Committee.

• ·Press release dated March 2, 2026; SEC filing dated March 4, 2026
• ·Collins served on Deloitte U.S. Board for six years as Vice Chair, Chair of Finance and Audit Committee, and Chair of Governance Committee
• ·Widmar previously CFO at First Solar, GrafTech (2006-2011), and held financial roles at NCR Inc. and Dell Inc.; career started at Ernst & Young in 1987

04-03-2026

Viper Energy, Inc. announced the pricing of a secondary public offering of 17,391,304 shares of Class A common stock by Diamondback Energy, Inc. and affiliates of EnCap Investments, L.P. and Oaktree Capital Management, L.P., generating approximately $798M in gross proceeds solely for the selling stockholders, with Viper receiving no proceeds. Concurrently, Viper agreed to purchase 1,000,000 units in VNOM Holding Company LLC from Oaktree affiliates at the offering price per share equivalent. The offering is expected to close on March 4, 2026, subject to customary conditions, with underwriters granted a 30-day option for up to 2,608,696 additional shares.

• ·Selling Stockholders granted underwriters a 30-day option to purchase up to 2,608,696 additional shares solely for over-allotments.
• ·Concurrent OpCo Unit Purchase is conditioned on Secondary Offering completion, but not vice versa.
• ·J.P. Morgan and Goldman Sachs & Co. LLC acting as joint book-running managers.

04-03-2026

ACRES Commercial Realty Corp. reported a GAAP net loss allocable to common shares of $3.0 million, or $(0.43) per diluted share, for the fourth quarter ended December 31, 2025. Positively, the company originated $571 million in high-quality commercial real estate loans during the quarter, with momentum continuing into Q1 2026 via the closing of a $1 billion CRE CLO in February. Management noted strong asset management progress, reducing watchlist assets to a handful with resolution plans in place.

• ·Earnings conference call scheduled for March 5, 2026 at 10:00 a.m. ET; replay available through March 19, 2026.
• ·Full detailed presentation available at www.acresreit.com.

04-03-2026

CPS Technologies reported record FY2025 revenue of $32.6M, up 54% YoY from $21.1M, driven by strong demand and expanded production, with Q4 revenue at $8.2M (+39% YoY from $5.9M) and gross margin improving to 14.6% from a -5.1% loss. However, Q4 operating loss narrowed to $(0.1M) from $(1.3M) amid higher SG&A expenses of $1.3M (up from $1.0M due to variable compensation and commissions), while full-year net income turned positive at $0.4M from a $3.1M loss. The company secured a $15.5M follow-on order and raised $9.5M net from a public offering on Oct 8, 2025, bolstering its balance sheet to $29.5M in total assets.

• ·Q4 FY2025 net income $12,594 ($0.00 per diluted share) vs Q4 FY2024 net loss $(995,153) ($0.07 per diluted share).
• ·FY2025 income from operations $443,974 vs FY2024 loss $(4,380,928).
• ·Total current assets $24.8M as of Dec 27, 2025 vs $14.2M as of Dec 28, 2024.
• ·Conference call scheduled for March 3, 2026 at 9:00 a.m. Eastern (dial-in: 1-844-943-2942, passcode 641664).

04-03-2026

Westwood Holdings Group, Inc. reported 2025 total revenues of $97.8M, up 3% YoY from $94.7M, with net income attributable to the company surging 219% to $7.1M from $2.2M amid lower expenses and higher net operating income. However, total AUM dipped 0.4% to $16.5B from $16.6B, reflecting worsened net client outflows of $1.0B versus $0.8B in 2024, with declines in Wealth Management (-1.7%) and Mutual Funds & ETFs (-0.6%) AUM partially offset by flat Institutional AUM. Economic Earnings doubled 105% to $14.3M, while Advisory net income rose 13% to $19.9M.

• ·Asset-based advisory fees grew 7% YoY to $74.7M in 2025, while performance-based fees declined 37% to $0.9M.
• ·Total expenses decreased 1% YoY to $92.8M in 2025.
• ·AUA end 2025 at $942M, down from $960M end 2024.
• ·2024 quarterly revenues: Q1 $17.2M, Q2 $15.6M, Q3 $15.4M, Q4 $20.5M.

04-03-2026

AEO Inc. reported strong Q4 FY2025 results with total net revenue up 10% YoY to a record $1.8B, driven by +8% comparable sales including Aerie +23% and American Eagle +2%. However, full FY2025 revenue grew only 3% to $5.5B with American Eagle comps flat (0%), gross margin down 230 basis points to 36.9%, adjusted operating income down to $328M from $445M, and adjusted diluted EPS declining to $1.50 from $1.74. The company returned $341M to shareholders via buybacks and dividends, exited the Quiet Platform logistics business incurring $102M in charges, and provided FY2026 guidance for operating income of $390-410M.

• ·Q4 FY2025 GAAP operating profit $96M impacted by $84M impairments/restructuring; adjusted $180M (+27% YoY).
• ·FY2025 capex $261M; FY2026 guidance $250-260M.
• ·Q1 FY2026 outlook: comps high-single digit, operating income $20-25M.
• ·Cash and equivalents $239M at Jan 31, 2026 (down from $309M prior year); current ratio 1.52 (flat YoY).

04-03-2026

Lithia Motors, Inc. entered into the Seventh Amendment to its Fourth Amended and Restated Loan Agreement on February 27, 2026, extending the credit facility's expiration date to February 27, 2031, with annual 1-year extension options subject to lender consent and conditions. The amendment introduces VIN-specific reporting for Used Vehicle and Service Loaner Floorplan facilities (upon company election) and reallocates commitments to $2.7B for New Vehicle Floorplan, $1.25B for Used Vehicle Floorplan, $150M for Service Loaner Floorplan, and $2.4B for Revolving Line of Credit. It also removes the Simple SOFR Adjustment.

• ·Original Loan Agreement dated April 29, 2021
• ·Filing submitted on March 4, 2026

04-03-2026

Amprius Technologies reported record Q4 2025 revenue of $25.2 million, up 137% YoY from $10.6 million and 18% sequentially, with full-year 2025 revenue surging 202% YoY to $73.0 million and gross margins improving to 11% from -76%. However, Q4 net loss widened to $24.4 million from $11.4 million YoY due to $22.5 million one-time impairment charges, while full-year net loss remained nearly flat at $44.0 million versus $44.7 million prior year. The company expects 2026 revenue of at least $125 million, net loss under $8 million, and positive adjusted EBITDA of at least $4 million.

• ·Q4 2025 non-GAAP adjusted EBITDA of $1.8 million, first positive quarterly figure.
• ·FY 2025 non-GAAP adjusted EBITDA improved $18.1 million YoY to $(5.3) million.
• ·Terminated 15-year Colorado facility lease in January 2026, eliminating over $110 million in future obligations.
• ·Customer base expanded to over 550.
• ·2026 outlook assumes capex under $10 million and depreciation/amortization of $4.7 million.

04-03-2026

ParkOhio Holdings Corp. reported Q4 2025 revenue of $395M, up 2% YoY from $388.4M, driven by 3% growth in Supply Technologies with 240 basis point margin expansion to 11.1%, alongside strong operating cash flow of $49M and free cash flow of $36M, enabling $40M debt reduction. However, full-year 2025 revenue declined 3% to $1.6B from $1.7B, GAAP diluted EPS from continuing operations fell to $1.77 from $3.19, and Engineered Products recorded $8.9M non-cash asset impairments amid stable segment revenue. The company issued a positive 2026 outlook with net sales of $1.675B-$1.710B (5-7% growth) and adjusted EPS of $2.90-$3.20.

• ·Engineered Products record bookings of $217M in 2025.
• ·Q4 2025 EBITDA of $35.3M (8.9% margin) vs $37.0M prior year.
• ·Full year 2025 EBITDA of $137.5M (8.6% margin) vs $151.7M prior year.
• ·Adjusted diluted EPS Q4 2025: $0.65 vs $0.67 prior year.
• ·Full year 2026 free cash flow outlook: $20M to $30M.
• ·Conference call scheduled for March 5, 2026 at 9:00 a.m. ET.

04-03-2026

Stem, Inc. reported FY2025 revenue of $156.3M, up 8% YoY from $144.6M, driven by 25% growth in software, services, and edge hardware to $141.4M, achieving first-ever positive Adjusted EBITDA of $6.7M and GAAP net income of $137.8M. However, Q4 2025 revenue declined 15% YoY to $47.2M, bookings fell 13% to $32.7M, CARR dropped 4% QoQ to $67.2M, and storage operating AUM remained nearly flat at 1.7 GWh. The company introduced 2026 guidance targeting $140-190M revenue, 40-50% non-GAAP gross margin, $10-15M Adjusted EBITDA (~85% growth), and $65-70M year-end ARR (10% growth).

• ·Contracted backlog of $21.3M at end Q4 2025, up 2% YoY but down from $22.2M at end Q3 2025
• ·Solar operating AUM of 36.1 GW at end Q4 2025, up 21% YoY from 29.9 GW
• ·PowerTrack EMS selected for 90 MWh and 10 MWh BESS projects in Germany, commercial ops summer 2026
• ·Board expanded to 8 directors; Arun Narayanan appointed Class I Director effective Dec 1, 2025
• ·2026 guidance: Software, edge hardware, & services revenue $130-150M; Battery hardware resale up to $40M; Operating cash flow $0-10M

04-03-2026

TriplePoint Venture Growth BDC Corp. (TPVG) reported portfolio fair value growth of 16% YoY to $784M at December 31, 2025, supported by $283M in new debt investments, increasing total debt investments 15% to $645M primarily in growth capital loans (95.6%). However, net investment income declined 23% YoY to $42M with weighted average yield dropping to 13.7% from 15.7%, NAV per share slipped slightly to $8.73 in Q4 2025 amid a downward trend from $9.02 in Q1 2024, and shares traded at widening discounts to NAV reaching -40% at 2025 lows. Portfolio companies expanded to 55 from 44, but included higher-risk Orange (3.9%) and Red (0.6%) credits.

• ·Principal prepayments and early repayments totaled $135M in 2025 vs $179M in 2024.
• ·Credit breakdown at Dec 31, 2025: White 75.1% ($485M, 43 cos), Yellow 13.4% ($86M, 4 cos), Orange 3.9% ($25M, 4 cos), Red 0.6% ($4M, 1 co).
• ·Interest rate sensitivity: Net investment income increases $7M if rates up 300bps, resilient with $1.7M gain even if down 300bps.
• ·Distributions: Q4 2025 $0.25/share, down from $0.30/share in Q4 2024; Q1 2026 partial $0.23/share.

04-03-2026

Global Water Resources reported full-year 2025 revenue growth of 5.8% YoY to $55.8 million, driven by the acquisition of seven water systems from Tucson Water, organic connection growth of 3.2%, and higher rates, with total active service connections up 6.3% to 68,577 and water consumption increasing 5.9% to 4.28 billion gallons. However, net income declined 48.9% YoY to $3.0 million due to higher depreciation, interest expenses from a $67.3 million capital investment plan, and a $1.3 million loss on asset disposals related to the Southwest Plant recommissioning; Adjusted EBITDA was nearly flat, decreasing 0.7% to $26.5 million. The company declared monthly dividends of $0.02533 per share ($0.30396 annualized) and secured a $15 million term loan at 5.49% on December 10, 2025, while pursuing a rate case for a $4.3 million annual revenue increase.

• ·Water service revenue increased to $28.6M (+9.8% YoY), while wastewater/recycled water revenue rose modestly to $27.1M (+2.0% YoY).
• ·Operating expenses rose 12.2% to $48.6M, driven by operations and maintenance up 14.7%, depreciation up 17.9%, and general/admin up 5.8%.
• ·Acquisition of seven Tucson Water systems in July 2025 at 1.05x rate base.
• ·Rate case hearings commence August 2026, expected conclusion late 2026.
• ·Conference call scheduled for March 5, 2026 at 1:00 p.m. ET.

04-03-2026

Michael D. Lynch, Executive Vice President and Chief Financial Officer of AmeriServ Financial, Inc., announced his retirement after a long career of over 40 years, effective May 18, 2026. The company is conducting a search for his replacement. The filing was reported on March 4, 2026, and signed by Jeffrey A. Stopko, President and Chief Executive Officer.

• ·Company headquartered at Main and Franklin Streets, Johnstown, PA 15901
• ·Telephone: 814-533-5300
• ·Common Stock traded as ASRV on NASDAQ

04-03-2026

MISTRAS Group reported Q4 2025 revenue of $181.5 million, up 5.1% YoY across all segments, with gross margin expanding 190 basis points to 28.4% and record Adjusted EBITDA of $24.8 million, up 18.2%. Full year 2025 revenue was $724.0 million, a slight decline of 0.8% YoY from $729.6 million (slight increase after excluding $7.0 million in lab consolidations), while achieving record Adjusted EBITDA of $91.1 million (+10.5%) but net income fell to $16.8 million from $19.0 million and cash from operations dropped to $33.0 million from $50.1 million.

• ·Total assets increased to $578.8 million as of Dec 31, 2025 from $523.0 million as of Dec 31, 2024.
• ·Bank leverage ratio of 2.5x at Dec 31, 2025, within maximum 3.75x.
• ·Q4 EPS of $0.12 vs prior $0.17; FY EPS $0.53 vs prior $0.60.
• ·Reclassification of $20.9 million overhead/personnel expenses from SG&A to cost of revenue for FY 2024 comparability.
• ·Conference call scheduled for March 5, 2026 at 9:00 a.m. EST.

04-03-2026

Genesis Energy, L.P. and Genesis Energy Finance Corporation closed a $750 million offering of 6.750% senior notes due May 15, 2034, on March 4, 2026, following the Underwriting Agreement dated February 18, 2026. Net proceeds will fund the redemption of all outstanding 7.75% senior notes due 2028 and general partnership purposes, including partial repayment of revolving borrowings under the senior secured credit facility. The new notes are senior unsecured obligations ranking equal with existing senior debt totaling $2.4 billion across maturities from 2029 to 2033.

• ·Interest on new notes accrues at 6.750% per year, payable semi-annually on March 15 and September 15, commencing September 15, 2026.
• ·Indenture governed by Base Indenture dated May 21, 2015, supplemented by Twenty-Fourth Supplemental Indenture dated March 4, 2026.

04-03-2026

Intrepid Potash reported FY 2025 total sales of $298.3 million, up 17% YoY from $254.7 million, with record Trio® sales volumes of 303 thousand tons (+19% YoY) driving a 37% increase in that segment to $144.5 million and Adjusted EBITDA of $63.1 million, while ending the year with $83.5 million in cash and no debt. However, potash production declined 5% YoY to 280 thousand tons despite sales up 15% to $139.6 million with flat gross margin, oilfield solutions sales fell 42% to $14.4 million, and Q4 recorded a $0.4 million net loss impacted by charges. FY 2026 production guidance calls for modestly higher total fertilizer output with potash at 270-285 thousand tons and Trio® at 285-300 thousand tons.

• ·Q1 2026 guidance: Potash sales 95-105 thousand tons at $345-355/ton; Trio® 105-115 thousand tons at $380-390/ton.
• ·FY 2026 capex guidance: $40-50 million.
• ·Credit facility matures August 2027 with no borrowings.
• ·Wendover lithium test: 92.9% extraction rate, >99.5% LiCl purity; design for 5,000 tons LCE/year.
• ·Primary Pond 8 to expand evaporative area by 35%, commission 2027, contribute from 2028.
• ·$4.0M Q4 legal settlement charge; $2.4M extraction well disposal charge.
• ·$45M cash flow from operations in FY2024 included one-time XTO payment.

04-03-2026

Johnson Outdoors Inc. announced on March 4, 2026, that David W. Johnson, its Vice President and Chief Financial Officer since November 2005, intends to retire later this year. The company has commenced a succession process to identify a successor, with Mr. Johnson expected to assist in the transition. His decision to retire is not due to any disagreement with the company's financial statements, reporting matters, or policies.

• ·Mr. Johnson has served as VP and CFO (principal financial and accounting officer) since November 2005.
• ·Company principal executive offices: 555 Main Street, Racine, Wisconsin 53403.

04-03-2026

Hyster-Yale reported Q4 2025 consolidated revenues of $923M, down 14% YoY from $1,068M, driven by 15% lower Lift Truck revenues ($871M) and 9% decline in Bolzoni ($75M) due to reduced volumes and economic uncertainty. The company posted an adjusted operating loss of $15.7M versus prior year's profit, impacted by tariffs and lower gross profit, but showed improvements in unit bookings (+42% vs Q3'25 to $540M), operating cash flow ($57M, +$20M vs Q3'25), and net debt ($371M, improved $26M vs Q3'25). For 2026, moderate operating profit is expected with strong H2 revenue growth, though tariffs remain a headwind.

• ·FY 2025 adjusted operating profit $16M; adjusted net loss $37M.
• ·Sales by region: Americas 74.7%, EMEA 15.1%, JAPIC 4.9%, Bolzoni 5.3%.
• ·2026 capex forecast $55-75M.
• ·Debt maturities: US $15M (2025-2030), EMEA $225M TLB (final 2028), ABL $300M (expires 2030).
• ·Inventory improved $185M YoY and $105M vs Q3'25 (ex. FX and tariffs).

04-03-2026

Silver North Resources Ltd. reported a sharply reduced net loss of $406k for the fiscal year ended 9/30/25 compared to $2.03M in FY24, aided by lower expenses including investor relations and a $449k flow-through share premium recovery, while total assets grew 38% to $10.8M and shareholder equity rose 42% to $9.4M on $3.8M in private placement proceeds. Cash balances strengthened to $1.8M from $0.7M, and working capital turned positive at $934k from a $361k deficit. However, revenue remained at $0, the company recorded ongoing operating cash burn of $1.1M, and share count diluted 57% to 74.9M outstanding amid continued exploration spending.

• ·Operating cash use improved slightly to $1.1M from $1.3M YoY but remains negative.
• ·Investor relations expenses declined to $451k from $603k YoY, while wages/consulting fell to $140k from $179k.
• ·USD stock average price stable at $1.40 for year ended 12/31/25 vs $1.37 prior year.
• ·No long-term debt in any period.

04-03-2026

Third Coast Bancshares, Inc. reported net income of $66.3M for the year ended December 31, 2025, up 39.1% YoY from $47.7M in 2024, fueled by net interest income growth of 21.4% to $195.2M and noninterest income increase of 28.5% to $13.7M, with net interest margin expanding to 4.06%. However, provision for credit losses rose 33.1% to $7.6M, signaling potential credit pressures, while noninterest expenses increased 13.6% to $118.5M. Compared to 2023, 2024 net income grew 42.7% to $47.7M.

• ·Average yield on gross loans declined slightly to 7.68% in 2025 from 7.80% in 2024.
• ·(Loss) gain on sale of investment securities available-for-sale worsened to ($0.6M) in 2025 from ($0.0M).
• ·Service charges and fees surged 55.1% YoY to $10.8M in 2025.
• ·Salaries and employee benefits, the largest noninterest expense, rose 18.5% to $77.2M.

04-03-2026

Actelis Networks, Inc. is convening a special stockholder meeting on April 13, 2026, at 10:00 a.m. EST in Petach Tikva, Israel, to vote on three proposals: (1) authorizing issuance of common stock under the ELOC Purchase Agreement per Nasdaq Listing Rule 5635(d), (2) approving a reverse stock split amendment at a 1-for-10 to 1-for-25 ratio to be determined by the Board, and (3) approving adjournment if needed for additional solicitation. The record date is February 13, 2026, with 8,759,402 shares outstanding requiring a quorum of 2,919,801 shares (one-third). The Board recommends voting FOR all proposals, with proxies solicited by CEO Tuvia Barlev and CFO Yoav Efron.

• ·Common stock par value: $0.0001 per share
• ·Proxy materials mailed on or about March 4, 2026
• ·Meeting location: 25 Bazel Street, Petach Tikva, Israel 4950138
• ·Transfer agent: Vstock Transfer, LLC

04-03-2026

On November 11, 2025, Blueport Acquisition Ltd entered into a consulting agreement with Hurricane Corporate Services Ltd., controlled by CFO Kulwant Sandher, for CFO services at $3,000 per month plus expenses, initially for three months with automatic renewal on February 11, 2026. Separately, in November 2025, the Company orally agreed to pay each director $7,500 per quarter for board services, terminable at any time. No departures, elections, or performance metrics were reported.

• ·Consulting Agreement includes mutual indemnification for breaches or negligent acts.
• ·Agreement filed as Exhibit 10.1.
• ·Company is an emerging growth company.

04-03-2026

Nine Energy Service, Inc. reported revenues of $561.9M for the year ended December 31, 2025, up 1% YoY from $554.1M, driven by a 2% increase in service revenues to $431.2M, while product revenues declined slightly to $130.7M. However, the company posted a larger net loss of $51.3M (25% worse YoY) versus $41.1M in 2024, with operating income dropping 74% to $2.3M and Adjusted EBITDA falling to $49.4M from $53.2M. Cash and cash equivalents decreased to $18.4M from $27.9M, total debt rose to $369.6M, and stockholders' deficit widened to $(115.0M) from $(66.1M).

• ·Gross profit slightly declined to $60.6M from $61.1M YoY.
• ·Net cash used in operating activities was $7.3M in 2025 versus $13.2M provided in 2024.
• ·Total assets decreased to $339.5M from $360.1M.
• ·ROIC worsened to -20.8% from -14.9%, while Adjusted ROIC improved to 4.4% from 3.7%.
• ·Loss per share (basic and diluted) was $(1.25) versus $(1.11) YoY.

04-03-2026

DynaResource, Inc. approved the engagement of David Keough, an experienced mining executive, through his consulting firm Vulcan’s Forge Capital Pty. Ltd. to perform the functions of Chief Operating Officer, effective June 23, 2025. Compensation includes a $20,000 monthly consulting fee, 450,000 restricted stock units vesting in three equal annual installments starting August 12, 2025, and eligibility for an annual discretionary cash bonus up to 50% of prior year fees. The consulting agreement, dated February 26, 2026 but effective August 15, 2025, includes severance provisions for termination without cause.

• ·RSUs vest in three equal annual installments on the first three anniversaries of August 12, 2025 grant date.
• ·Termination without cause entitles Consultant to nine months of fees ($180,000) plus prorated bonus.
• ·Post-change in control termination without cause or for good reason entitles to 18 months of fees plus 18 months prorated bonus.

04-03-2026

Mayville Engineering Company, Inc. (MEC) reported net sales of $546.5M for the year ended December 31, 2025, down 6% YoY from $581.6M in 2024, amid macroeconomic pressures including inflation and material costs. Net income swung to a $8.1M loss from $26.0M profit in 2024, with EBITDA dropping 54% to $37.4M (6.9% margin) and Adjusted EBITDA declining 27% to $47.1M (8.6% margin); however, free cash flow remained positive at $26.9M despite a 65% YoY drop from $77.7M.

• ·Capital expenditures: $11.6M in 2025 vs $12.1M in 2024.
• ·Interest expense: $10.2M in 2025, slightly down from $11.0M in 2024.
• ·Acquisition related costs: $3.4M in 2025.
• ·Natural disaster costs: $0.3M in 2025.

04-03-2026

Stellar V Capital Corp., a blank check company, elected Michael Braunstein as a class II director on February 28, 2026, to fill the vacancy left by his father Harry Braunstein, who passed away on November 2, 2025. Michael Braunstein, deemed independent under NASDAQ rules, will serve on the Audit Committee and Compensation Committee and chair the Nominating and Corporate Governance Committee. The appointment was recommended by the Nominating and Governance Committee.

• ·Michael Braunstein has been a partner of Braunstein Turkish LLP since September 2009 and managing member of Sunset Capital 1 LLC and affiliates since November 2025.
• ·From January 2024 to November 2025, Michael Braunstein was president of Sunset Capital 1 LLC and affiliates; from January 2019 to December 2023, vice president.
• ·Michael Braunstein holds a bachelor’s degree in music business from New York University (2004) and Juris Doctor from Brooklyn Law School (2009).

04-03-2026

Walker & Dunlop, Inc. and Walker & Dunlop, LLC entered into the Seventeenth Amendment to their Second Amended and Restated Warehousing Credit and Security Agreement with PNC Bank, effective March 2, 2026, extending the Warehousing Maturity Date to March 1, 2027. The amendment permits incremental increases to the Standard Warehousing Credit Limit in $100M minimum increments (each for 45 days) up to the Maximum Warehousing Credit Limit and a one-time Limited Bulge Increase up to $2.5B USD through May 1, 2026, subject to Lender discretion. Associated fees include an annual 10 basis points on the Standard Limit, $10,000 per $100M incremental increase, and a daily 7.5 basis points bulge commitment fee.

• ·Incremental increases to Standard Warehousing Credit Limit effective for 45 days each
• ·Limited Bulge Increase available from March 2, 2026 to May 1, 2026
• ·Original Credit Facility Agreement dated September 11, 2017, with 16 prior amendments listed

04-03-2026

Klotho Neurosciences, Inc. (Nasdaq: KLTO) announced the acquisition of Greenland Mines Corp. via a definitive merger agreement dated March 3, 2026, closing on March 4, 2026, securing an 80% interest (with option for remaining 20%) in the Skaergaard Project, one of the largest undeveloped palladium-gold-platinum deposits valued at approximately $68B in-situ resource. The deal, payable in convertible preferred stock treated as a reverse merger, positions Greenland Mines to own ~93% of fully diluted shares post-conversion, with the company planning to rebrand, add a board member, and operate dual divisions in natural resources and cell/gene therapy. No period-over-period financial metrics or declines were disclosed.

• ·Skaergaard Total Indicated and Inferred Resource: 364.37M tons at 2.17 g/t PdEq; Indicated: 158.95M tons at 2.22 g/t PdEq.
• ·Deposit open in all directions; fully permitted for exploration with environmental and metallurgical studies underway.
• ·Pricing basis: gold $5,100/oz, palladium $1,800/oz, platinum $2,175/oz (Feb 2026 market prices).
• ·Company name and ticker change planned for late March 2026; no action required by existing shareholders.

04-03-2026

Designer Brands Inc. and its subsidiaries entered into a Third Amendment to their Credit Agreement on February 27, 2026, with The Huntington National Bank as Administrative Agent, primarily to extend the Maturity Date and amend certain provisions of the existing agreement originally dated March 30, 2022. The amendment's effectiveness is conditioned on, among other things, a Borrowing Base Certificate demonstrating Availability of no less than $90,000,000 as of January 31, 2026, confirmation of no Defaults or Events of Default, and no Material Adverse Effect since November 30, 2025. All Loan Documents are ratified and reaffirmed.

• ·Previous amendments: First Amendment on February 28, 2023; Joinder and Second Amendment on June 23, 2023.
• ·Conditions include recent lien searches revealing no impermissible Liens, favorable legal opinions from Vorys, Sater, Seymour and Pease LLP and Osler, Hoskin & Harcourt LLP, and payment of fees per Third Amendment Fee Letter.
• ·Governing law: State of New York.

04-03-2026

Franklin Street Properties Corp. (FSP) closed a $320M secured credit facility with an affiliate of TPG Credit, using an initial $258.5M drawdown (net of $16.5M original issue discount) to fully repay $248.9M of outstanding indebtedness, with up to $45M available in delayed draw term loans for tenant improvements and other uses. The facility features a 9.0% initial coupon rate, 4.0% exit fee, and maturity on February 26, 2029, secured by a first priority lien on substantially all assets. Management highlighted the refinancing as addressing near-term debt maturities amid an uneven office market, while continuing review of strategic alternatives to maximize shareholder value.

• ·Facility maturity date: February 26, 2029, with potential one-year extension at company's option subject to conditions.
• ·Collateral: first priority lien on substantially all assets of the Company.
• ·Core markets: Dallas, Denver, Houston, and Minneapolis.

04-03-2026

Magnachip reported Q4 2025 consolidated revenue of $40.6 million, down 11.7% QoQ from $45.9 million and 20.7% YoY from $51.2 million, with gross profit margin declining to 9.3% from 18.6% QoQ and 21.7% YoY; however, Communications product revenue grew 24% sequentially and 68% YoY. Full-year 2025 revenue decreased 8.9% YoY to $178.9 million from $196.4 million, with gross margin down 2.1 percentage points to 17.6%, though the company launched 55 new-generation products versus 4 in 2024 and executed cost reductions for over $2 million in annualized savings. Q1 2026 guidance calls for revenue of $44.0-48.0 million (up 13.4% sequentially at midpoint) and gross margin of 14-16%.

• ·Power Analog Solutions gross margin Q4 2025: 6.5% (down 9.5 pts QoQ, 14.0 pts YoY)
• ·Power IC gross margin Q4 2025: 36.7% (down 6.5 pts QoQ, 8.2 pts YoY)
• ·GAAP operating loss Q4 2025: $(12.4) million (worsened QoQ)
• ·Adjusted EBITDA Q4 2025: $(8.9) million (down QoQ from $(4.0) million)
• ·Q1 2026 gross margin guidance: 14-16% (down YoY from 20.9% in Q1 2025)
• ·Conference call: March 4, 2026 at 2:00 p.m. PT / 5:00 p.m. ET

04-03-2026

On February 26, 2026, the Compensation Committee of Quanta Services, Inc.'s Board of Directors adopted the 2026 Incentive Plan, encompassing the annual incentive plan for corporate employees, long-term incentive plan for senior leadership, and discretionary plan for all employees. Executive officers and certain employees are eligible for cash, restricted stock units (RSUs), and/or performance stock units (PSUs) based on metrics such as EBITDA, EBITDA margin, and safety for annual awards, and return on invested capital (ROIC), earnings per share (EPS), and total stockholder return (TSR) for the January 1, 2026 to December 31, 2028 performance period. All equity awards will be issued under the Quanta Services, Inc. 2019 Omnibus Equity Incentive Plan, as amended.

• ·Awards governed by Exhibits 10.1 through 10.6, including term sheets and forms of PSU and RSU award agreements.
• ·Performance period for long-term incentives: January 1, 2026 through December 31, 2028.

04-03-2026

Allied Energy, Inc. dismissed its independent registered public accounting firm, Victor Mokuolu, CPA PLLC, on March 3, 2026, after notifying them of intent on February 24, 2026, and engaged J&S Associate PLT as the new auditor on the same date, with Board approval. There were no disagreements on accounting principles, financial disclosures, or auditing scope during FY2023, FY2024, or interim periods through March 3, 2026. However, the prior auditor's reports for FY2023 and FY2024 included an explanatory paragraph noting substantial doubt about the Company's ability to continue as a going concern.

• ·Company is an emerging growth company and has elected not to use the extended transition period for new accounting standards.
• ·Auditor's response letter dated March 4, 2026, filed as Exhibit 16.1.

04-03-2026

Omega Flex, Inc. reported FY 2025 net sales of $98.3M, down 3.3% YoY from $101.7M, with Q4 sales declining 6.5% to $25.2M from $27.0M, driven by lower unit volumes amid a suppressed housing market. Net income fell 17.7% to $14.8M for the year from $18.0M, and dropped 27.1% in Q4 to $3.4M from $4.7M, due to lower sales and higher product development expenses. EPS declined to $1.47 annually from $1.78 and to $0.34 in Q4 from $0.46.

• ·Decrease in net sales mainly due to lower sales unit volumes from suppressed market and decline in housing starts.
• ·Net income decline also attributed to increase in product development, certification, and consulting related expenses.
• ·Filing date: March 04, 2026, for periods ended December 31, 2025.

04-03-2026

Octave Specialty Group Inc reported total revenues of $251.2M for FY 2025, up 6.5% YoY from $235.8M, driven by strong Insurance Distribution segment growth with premiums placed nearly doubling to $951.8M (+93%) and commissions rising 56% to $143.4M. However, the company posted a widened net loss from continuing operations of $(95.8M) vs $(58.9M) in 2024, with Specialty Property & Casualty Insurance seeing gross premiums written decline 5.8% to $360.4M, net premiums written drop 17% to $73.9M, and combined ratio worsen to 105.2%. Operating cash flow turned negative at $(52.3M) from positive $0.8M.

• ·Adjusted EBITDA attributable to shareholders FY2025: $(7.5M) vs $2.2M FY2024
• ·Specialty P&C retention ratio declined to 20.5% from 23.2% YoY
• ·Insurance Distribution pretax loss $(20.5M) vs $(7.8M) YoY, despite revenue growth
• ·Corporate & Other pretax loss $(83.9M) vs $(64.3M) YoY
• ·Net cash flow FY2025: $21.4M vs $28.6M FY2024

04-03-2026

Viemed Healthcare reported record Q4 2025 net revenues of $76.2M, up 26% YoY, and full-year 2025 revenues of $270.3M, up 21% YoY, driven by organic growth and the Lehan's acquisition; net income attributable to Viemed rose 31% YoY to $5.6M in Q4 and 33% to $14.9M for the year, with Adjusted EBITDA reaching a record $61.4M annually. Patient counts showed strong growth in PAP therapy (+62% to 34,528) and sleep resupply (+49% to 36,561), though ventilator patients increased only 4% to 12,259; cash balances declined to $13.5M from $17.5M YoY amid robust free cash flow of $28.1M. The company issued 2026 guidance of $310-320M revenue and $65-69M Adjusted EBITDA, and authorized a new share repurchase program.

• ·Net cash provided by operating activities FY 2025: $51.9M (up from $39.1M YoY)
• ·Conference call scheduled for March 5, 2026 at 11:00 a.m. ET
• ·Total assets as of Dec 31, 2025: $199.2M (up from $177.1M YoY)
• ·2026 net capital expenditures guidance: 10% to 11.5% of net revenue
• ·Common shares issued/outstanding decreased to 38,019,082 from 39,132,897 YoY

04-03-2026

Red Violet, Inc. reported FY2025 revenue of $90.3M, up 20% YoY from $75.2M, with net income surging 88% to $13.2M, Adjusted EBITDA increasing 31% to $31.0M, and Adjusted EBITDA margin expanding to 34% from 31%. Q4 2025 revenue grew 20% YoY to $23.4M and net income rose 226% to $2.8M, but operating cash flow remained flat YoY at $6.7M while free cash flow declined 17% to $3.7M, and income from operations fell QoQ from $4.6M in Q3 to $1.6M.

• ·Total assets grew to $112.0M from $98.5M as of Dec 31, 2025.
• ·Cash and equivalents increased to $43.6M from $36.5M.
• ·Gross margin stable at 72% for FY2025 and Q4.
• ·Adjusted gross margin improved to 84% FY2025 from 81%.
• ·Accounts receivable net $10.7M (Dec 2025) vs $8.1M (Dec 2024).
• ·Intangible assets net $39.3M (Dec 2025) vs $36.0M (Dec 2024).

04-03-2026

On March 3, 2026, Tamboran Resources Corporation held a special shareholder meeting approving the issuance of 6,537,503 shares to Falcon Oil & Gas Ltd. and up to 147,508 shares to Falcon Australia minority holders (1.9% equity) to complete the acquisition of Falcon's subsidiaries via a plan of arrangement. All three proposals (Stock Issuance, ASX Capacity, and Adjournment) passed with overwhelming support, with FOR votes exceeding 99.9% of votes cast on the key proposals; however, only 57% of the 22,639,513 outstanding shares participated, representing a quorum of 12,923,245 shares.

• ·Proxy statement filed with SEC on January 28, 2026.
• ·Record date for meeting: January 23, 2026.
• ·ASX Capacity Proposal approved for Listing Rule 7.1 compliance.
• ·Adjournment Proposal received 12,905,738 FOR, 9,869 AGAINST, 7,638 ABSTAIN.

04-03-2026

Cooper-Standard Holdings Inc.'s subsidiary, Cooper-Standard Automotive Inc., issued $1.1B aggregate principal amount of 9.250% Senior Secured First Lien Notes due 2031 and entered into related security and intercreditor agreements. Proceeds, along with cash on hand, were used to fully redeem $616.9M of higher-rate 13.50% First Lien Notes due 2027 (at 102.250%), $391.8M of 5.625%/10.625% Third Lien Notes due 2027 (at 101.410%), and $42.6M of 5.625% Senior Notes due 2026 (at 100%). The company also amended its ABL Facility to adjust guarantors and covenants, refinancing shorter-term, higher-cost debt with lower-cost, longer-term obligations.

• ·Notes mature on March 1, 2031; interest payable semi-annually on May 15 and November 15, commencing November 15, 2026.
• ·Optional redemption after March 1, 2028 at par plus premiums; prior redemptions include make-whole premium or up to 35% from equity proceeds or 10% at 103%.
• ·Change of Control requires repurchase offer at 101% of principal.
• ·Indenture includes covenants limiting indebtedness, liens, dividends, investments, affiliates transactions, and asset sales.

04-03-2026

Stabilis Solutions reported Q4 2025 revenues of $13.3 million, down 23.3% YoY from $17.3 million due to the wind-down of multi-year marine bunkering and power-generation contracts, leading to a net loss of $0.3 million versus net income of $2.1 million in Q4 2024, and Adjusted EBITDA of $1.5 million compared to $4.0 million. Full-year 2025 revenues declined 7.0% YoY to $68.2 million from $73.3 million, with net loss of $1.4 million versus $4.6 million income and Adjusted EBITDA of $8.0 million down from $11.8 million. Despite current declines, the company highlighted a new multi-year take-or-pay LNG supply agreement worth ~$200 million starting early 2027 and a Final Investment Decision expected by end Q1 2026 for the Galveston LNG project.

• ·Q3 2025 revenues were $20.3 million (QoQ decline of 34.6% into Q4 2025)
• ·FY 2025 capex of $8.1 million on fixed assets
• ·Total assets $83.1 million as of Dec 31, 2025 (down from $85.6 million at Dec 31, 2024)
• ·18.6 million common shares outstanding as of Dec 31, 2025

04-03-2026

Kohl’s Corporation promoted Mari Steinmetz to Senior Executive Vice President, Chief People Officer, effective February 27, 2026, and designated her as an executive officer. She has served in the EVP role since March 2023, joined the company in 2010, and previously held progressive HR leadership positions including Senior Vice President of Benefits, Compensation, Talent Management, People Analytics, and HR Business Partners. Ms. Steinmetz brings more than 20 years of retail and human resources experience, including prior roles at Target.

• ·Ms. Steinmetz will continue to lead talent, culture, human resources, recruitment, associate development, relations, compensation, benefits, and organizational culture.
• ·Filed on March 4, 2026, reporting event of February 27, 2026.

04-03-2026

Ellington Credit Company (EARN) reported a Q3 FY26 GAAP net loss of $21.1 million ($0.56 per share), driven by $27.5 million in unrealized losses on investments (primarily CLO equity) and $2.0 million in credit hedge losses, despite net investment income of $7.8 million ($0.21 per share) and $19.1 million in recurring cash distributions ($0.51 per share). NAV per share declined to $5.19, with the CLO portfolio at $369.5 million fair value (down from amortized cost of $395.7 million). QoQ, total investment income fell 3% to $13.7 million and NII declined 9% to $7.8 million, while net income swung sharply from a $4.3 million profit to a loss.

• ·Monthly distributions declared at $0.08 per share from Oct 2025 to Mar 2026.
• ·Conference call scheduled for March 5, 2026 at 11:00 a.m. ET.
• ·Investor presentation posted on www.ellingtoncredit.com.

04-03-2026

NACCO Industries reported FY2025 total revenue of $277.2M, up 16.6% YoY from $237.7M, with Utility Coal Mining surging 28.5% to $88.2M and Contract Mining growing 17.1% to $140.0M, while Minerals and Royalties increased 8.9% to $37.6M. However, operating profit fell 38.4% to $22.0M from $35.7M, primarily due to higher unallocated items losses and a $7.8M pension settlement charge, resulting in net income declining 47.9% to $17.6M from $33.7M. Cash from operating activities improved sharply to $50.9M from $22.3M, though cash and equivalents decreased to $49.7M.

• ·Expenditures for PP&E and mineral interests: $53.3M in 2025 (down $2.1M YoY)
• ·Pension settlement charge: $7.8M in 2025
• ·Closed mine obligations: $24.7M at Dec 31, 2025 (down from $25.8M)
• ·Gain on settlement of excess funding liability: $3.6M in 2025

04-03-2026

Preformed Line Products (PLPC) reported Q4 2025 net sales of $173.1M, up 4% YoY from $167.1M, and full-year 2025 net sales of $669.3M, up 13% YoY from $593.7M, driven by energy and communications markets, with backlog surging 22% to $232.8M. However, Q4 net income declined 19% to $8.4M from $10.5M due to tariffs and LIFO inventory costs, and full-year net income fell 5% to $35.3M from $37.1M, impacted by a pension termination charge. Adjusted full-year diluted EPS rose 16% to $8.70, and the quarterly dividend increased 5% to $0.21 per share.

• ·Q4 gross profit declined to $51.6M from $55.6M YoY due to higher cost of products sold.
• ·Q4 operating income fell to $11.7M from $17.5M YoY.
• ·Cash and equivalents increased 46% to $83.4M as of Dec 31, 2025.
• ·Inventories rose to $148.7M from $129.9M year-end.
• ·Incremental sales from acquired JAP Telecom in Asia-Pacific.

04-03-2026

Unity Bancorp, Inc. reported strong FY2025 results with net income per diluted share up 39.7% to $5.67 from $4.06 in FY2024, driven by net interest income increasing 18.7% to $117.0 million and noninterest income surging 74.5% to $14.8 million. However, noninterest expenses rose $3.7 million to $52.4 million due to higher compensation, processing, and occupancy costs. Net income before provision for income taxes grew 38.8% to $75.5 million, with GAAP net income at $58.0 million versus $41.5 million prior year.

• ·Return on average assets improved to 2.17% from 1.68%.
• ·Return on average equity rose to 18.07% from 14.99%.
• ·Dividend payout ratio decreased to 10.23% from 12.81%.
• ·Adjusted net income (non-GAAP) increased to $51.8M from $41.5M after adjustments for securities gains and credit loss releases.

04-03-2026

04-03-2026

ENVIRI Corp filed DEFA14A additional proxy soliciting materials on March 04, 2026, related to the proposed sale of its Clean Earth business and the contemplated spin-off of New Enviri into a separate entity. The filing includes forward-looking statement cautions and urges shareholders to review upcoming definitive proxy statements, registration statements, and other SEC documents for transaction details before voting. It also discloses that the Company, directors, and executive officers may be participants in the proxy solicitation, with their interests detailed in forthcoming filings.

• ·2025 Annual Meeting proxy statement filed with SEC on March 12, 2025
• ·Equity Compensation Plan Information as of December 31, 2024
• ·Documents available at www.sec.gov and www.enviri.com

04-03-2026

Impact BioMedical Inc. amended its Merger and Share Exchange Agreement dated June 21, 2025, extending the termination date from March 31, 2026, to July 1, 2026, and providing for issuance of 53,000 PubCo ordinary shares (first batch) and 75,000 (second batch) to DSS, Inc., plus 22,000 to CEO Frank D. Heuszel, all deducted from the 169,560,000 shares (94.20% ownership) to be issued to the Dr Ashleys Shareholder at closing. Amendments to the Voting and Support Agreement updated supporting stockholders' ownership to 92,980,843 Impact shares (88.87% on fully diluted basis), and the Transition Arrangement Agreement outlined DSS funding obligations tied to the share issuances. No financial metrics or performance declines were reported.

• ·Merger termination End Date extended to July 1, 2026 (previously March 31, 2026).
• ·Impact required to seek board approval for certain loan agreements prior to Effective Time.
• ·DSS shares issuance subject to effectiveness of registration statement and full performance of funding obligations.

04-03-2026

Orthopediatrics Corp (KIDS) reported net revenue of $236.3M for FY 2025, up 15% YoY from $204.7M, with U.S. revenue at $186.4M (79% of total, +16% YoY) and international at $50.0M (21%, +15% YoY); product categories showed Trauma & Deformity up 15% to $166.3M (70%), Scoliosis up 20% to $66.0M (28%), but Sports medicine/other down 10% to $4.0M (2%). However, net loss widened 5% YoY to $39.6M amid higher sales & marketing (+13%), G&A (+17%), impairment (+153%), and restructuring (+53%) expenses, despite R&D down 18%; operating loss increased to $39.2M. Cash and restricted cash decreased $24.2M to $21.6M, with total assets at $508.6M but stockholders' equity down to $346.6M.

• ·Gross profit $172.7M FY2025 (+16% YoY from $148.6M).
• ·Operating expenses totaled $211.9M (+15% YoY).
• ·Long-term debt increased to $48.2M term loan and $48.5M convertible note.
• ·Accumulated deficit grew to $275.2M.
• ·Shares outstanding increased to 25.1M from 24.2M.

04-03-2026

AIAI Holdings Corp filed an S-1/A amendment on March 4, 2026, for a direct listing as an emerging growth company with no operating history, formed on July 19, 2024, and no established financial sources or AI application to Portfolio Companies yet. The filing extensively details risk factors such as dependence on acquiring additional Portfolio Companies, potential integration failures, limited public company experience of management, high key personnel turnover risk, and acquisition-related costs that could dilute shareholders or lead to losses. No financial metrics or performance data are provided, underscoring substantial uncertainties and high investment risks.

• ·Company qualifies as emerging growth company (EGC) with elected extended transition period for new accounting standards.
• ·No 'key person' insurance on employees.
• ·Substantially all Portfolio Company key personnel have at-will employment.

04-03-2026

Bowman Consulting Group Ltd. reported record FY 2025 financial results with gross contract revenue up 14.9% YoY to $490.0M, net service billing up 14.5% to $434.8M, and adjusted EBITDA up 22.5% to $72.9M with margin expansion of 110 bps to 16.8%; gross backlog also grew 20.1% to $479.1M. However, Q4 net income declined to $2.0M from $5.9M due to a prior one-time $5.4M tax benefit, adjusted EBITDA margin remained nearly flat at 17.3% vs 17.2%, and FY organic net service billing growth slightly decreased to 12.4% from 13.1%. The company acquired RPT Alliance, raised 2026 net revenue guidance to $495-510M from $465-480M, increased its credit facility to $250M from $210M, and announced CEO Gary Bowman's planned retirement in 2026.

• ·Acquired RPT Alliance on December 8, 2025, expanding power and utilities practice.
• ·Entered Third Amendment to Credit Agreement on March 3, 2026, increasing revolving credit facility to $250M from $210M.
• ·Repurchased 272,885 shares in Q4 2025 at avg $34.25/share; 683,448 shares in FY 2025 at avg $27.51/share; additional 159,177 shares post-year end at avg $34.11/share.
• ·Cash from operations FY 2025: $35.8M vs $24.3M prior year.
• ·Dec 31, 2025 revolving credit facility balance: $95.4M vs $37.0M prior year.
• ·Over 2,300 employees across 135 US locations.
• ·Conference call scheduled March 5, 2026 at 9:00 a.m. ET.

04-03-2026

Middleby Corp reported FY2025 net sales of $3.2B, up 1.6% YoY from $3.2B, with Food Processing segment growing 10.4% to $850.2M while Commercial Foodservice declined 1.2% to $2.4B. Net earnings from continuing operations decreased 12.8% to $367.3M (11.5% margin vs 13.4%), but overall net loss was $277.7M due to $645.0M discontinued operations loss from $704.4M impairments in Residential Kitchen Equipment Group. Stockholders' equity fell to $2.8B from $3.6B, impacted by $729.7M treasury stock repurchases.

• ·Cash and cash equivalents declined to $222.2M from $638.8M YoY.
• ·Long-term debt decreased to $2.1B from $2.4B.
• ·Goodwill balance $1.8B as of Jan 3, 2026.
• ·Impairment test performed as of Sep 27, 2025 for Residential Kitchen Equipment Group.
• ·Current assets held for sale - discontinued operations: $1.1B as of Jan 3, 2026.

04-03-2026

Consumer Portfolio Services, Inc. (CPS) announced the closing of a $50M securitization of residual interests on March 4, 2026, secured by an 80% interest in a CPS majority-owned affiliate (MOA) that holds residuals from four CPS securitizations issued between January 2025 and October 2025. The notes carry an 8.75% coupon, with monthly interest payments and principal allocations as needed to maintain a specified minimum collateral ratio. CPS stated this transaction is in the ordinary course of business, with no financial statements provided.

• ·MOA owns residuals in four CPS securitizations issued from January 2025 through October 2025.
• ·Over-collateralization defined as outstanding principal balance of receivables less notes.

04-03-2026

Riley Exploration Permian, Inc. (REPX) reported net oil and natural gas sales of $392M for the year ended December 31, 2025, down 4% YoY from $410M in 2024, driven by lower realized oil prices ($62.95/Bbl vs. $74.10) despite a 29% increase in total production to 10,660 MBoe (daily volumes up to 29,205 Boe/d from 22,546). Oil production rose 15% to 6,328 MBbls, but natural gas and NGL sales posted net losses of $3.3M and $3.0M respectively due to elevated GP&T costs ($57.8M total). Average operating costs per Boe improved slightly, with LOE at $8.21 vs. $8.66 YoY.

• ·Natural gas sales net loss widened to $(3.3M) in 2025 from $(1.4M) in 2024 due to higher GP&T costs.
• ·NGL sales turned to net loss of $(3.0M) in 2025 from $2.3M profit in 2024.
• ·Production and ad valorem taxes per Boe declined to $2.73 in 2025 from $3.57 in 2024.

04-03-2026

On February 26, 2026, Glen W. Herrick resigned immediately as director of MVB Financial Corp and MVB Bank, Inc., where he served as Chair of the Audit Committee and a member of the Finance Committee, citing concerns with the Company's corporate governance practices, executive compensation philosophy, and strategic focus. Cheryl Spielman, an existing Audit Committee member and qualified audit committee financial expert, was appointed as the new Chair of the Audit Committee. The resignation letter does not implicate any issues with financial statements, accounting, internal controls, or auditing.

• ·Resignation letter attached as Exhibit 17.1.
• ·Company provided disclosures to Mr. Herrick and will file any response letter from him as an amendment within two business days of receipt.
• ·Filing signed by Michael R. Sumbs on March 4, 2026.

04-03-2026

WesBanco, Inc.'s Board reduced its size from 19 to 15 directors effective after the April 2026 Annual Meeting, accepting voluntary retirements from Abigail M. Feinknopf, James W. Cornelsen, D. Bruce Knox, and Michael J. Crawford (the latter due to age policy), with no disagreements on company matters. Retiring directors received a one-time equity grant of restricted common stock valued at $250,000. To balance board classes, John L. Bookmyer and Joseph R. Robinson were reclassified and nominated for election at the 2026 Annual Meeting.

• ·Retirements and board size reduction effective at conclusion of 2026 Annual Meeting in April 2026.
• ·Bookmyer nominated for three-year term expiring 2029; Robinson for one-year term expiring 2027.
• ·Reclassifications of Bookmyer and Robinson solely for class balance; service deemed uninterrupted for committees and compensation.

04-03-2026

ClearSign Technologies Corporation held a special stockholder meeting on February 26, 2026, with a quorum of 35,968,485 shares present or by proxy, representing 67.09% of outstanding voting shares. Shareholders approved Proposal 1 to amend the certificate of incorporation for a potential reverse stock split (1-for-2 to 1-for-10) at board discretion to comply with Nasdaq rules (26,667,027 for; 9,224,242 against; 77,216 abstentions), and Proposal 2 to approve adjournments (27,887,899 for; 7,865,883 against; 214,703 abstentions), though both saw significant opposition votes exceeding 20%. The company announced its 2026 annual meeting for June 8, 2026 (record date April 13, 2026), with stockholder proposal deadlines of March 14, 2026.

• ·Special meeting record date: January 22, 2026.
• ·Definitive proxy statement filed with SEC on February 2, 2026.
• ·Annual meeting record date: April 13, 2026.
• ·Stockholder proposals under Rule 14a-8 and bylaws nominations due by close of business March 14, 2026.
• ·Common stock par value: $0.0001 per share.
• ·No broker non-votes on either proposal.

04-03-2026

NeOnc Technologies Holdings, Inc., through its subsidiary NeOnc Technologies, Inc., settled a long-standing dispute with Fox Infused, LLC over the termination of a 2022 Intellectual Property License and Supply Agreement by making a full payment of $737,920.77 (including $137,920.77 in interest) on February 27, 2026. The agreement, effective July 1, 2022, was terminated on April 25, 2023, leading to litigation in the Central District of California (dismissed) and subsequent arbitration. This payment fully resolves the matter, with no further obligations.

• ·Agreement terminated on April 25, 2023
• ·Fox Infused complaint filed June 6, 2023 (Civil Action No. 2:23-04431)
• ·Refiled in arbitration (Case No. 01-23-0002-5020)
• ·Settlement payment due within 5 business days of IPO closing or March 31, 2024

04-03-2026

On February 26, 2026, Chui Tin Mok, an executive director on the Board of Faraday Future Intelligent Electric Inc., notified the Board of his intent to resign upon confirmation of a successor to focus on business execution in the UAE and Middle East. He will continue serving as an executive officer and Head of FF Middle East. The resignation has no immediate impact as no successor is yet named.

• ·Trading symbols: FFAI (Class A common stock), FFAIW (redeemable warrants) on Nasdaq Stock Market LLC
• ·Company confirmed as emerging growth company
• ·Business address: 18455 S. Figueroa Street, Gardena, CA 90248
• ·Former name: Property Solutions Acquisition Corp. (changed March 4, 2020)

04-03-2026

IREN Limited entered into purchase agreements for over 50,000 NVIDIA B300 GPUs, expanding its total AI cloud fleet to 150,000 GPUs with phased deployments through H2 2026 across data centers in Mackenzie, British Columbia, and Childress, Texas. This expansion is projected to support over $3.7B in annualized AI Cloud run-rate revenue by end-2026, backed by $9.3B in secured funding over the past eight months and planned $3.5B additional capex in H2 2026. Figures are illustrative, not fully contracted, and subject to execution risks including timely delivery and contracting.

• ·Deployment phases through H2 2026 in air-cooled data centers at Mackenzie, British Columbia and Childress, Texas; existing capacity at Canal Flats.
• ·Payment terms structured post-shipment for working capital efficiency; procurement sequenced with commercial milestones and capital availability.

04-03-2026

AbbVie Inc. completed an underwritten public offering of $8B in senior notes on March 4, 2026, consisting of $750M floating rate notes due 2028 and fixed-rate notes including $1.5B 3.775% due 2028, $1.25B 4.125% due 2031, $1.25B 4.400% due 2033, $1.5B 4.750% due 2036, $1.25B 5.550% due 2056, and $500M 5.650% due 2066. The notes are unsecured, unsubordinated obligations ranking equally with existing debt, with optional redemption features including make-whole premiums before par call dates and at par thereafter. No period-over-period financial comparisons or performance metrics are disclosed.

• ·Floating Rate Notes and 2028 Notes mature March 3, 2028; other notes mature March 15 of their respective years.
• ·Optional redemption at make-whole price before par call dates (e.g., Feb 15, 2031 for 2031 Notes) and at 100% par thereafter.
• ·Indenture governed by Base Indenture dated November 8, 2012, supplemented by Supplemental Indenture No. 12 dated March 4, 2026.

04-03-2026

Proved reserves grew 14% YoY to 153.3M Boe as of December 31, 2025, driven by purchases of minerals in place (+14M Boe) and extensions/discoveries (+11.2M Boe), with oil up 12%, gas up 18%, and NGL up 19%. However, the standardized measure of discounted future net cash flows declined 9% YoY to $1.12B due to lower prices, including oil sales down 15% to $63.53/Bbl and total per Boe down 18% to $41.55/Boe, while gas prices remained negative at -$1.33/Mcf. Pre-tax PV-10 value stood at $1.32B, with top three customers (Phillips 66, Concord Energy, NGL Crude) comprising 89% of revenues.

• ·Phillips 66 represents 67% of revenues and 66% of accounts receivable.
• ·Texas reserves account for nearly 100% of total proved reserves (152.98M Boe).
• ·No purchases or sales of minerals in place from New Mexico.
• ·Future production costs as of Dec 31, 2025: $2.47B.
• ·Revisions to previous quantity estimates added 1.34M Boe net in 2025.